WO2006030032A1 - Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors - Google Patents
Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors Download PDFInfo
- Publication number
- WO2006030032A1 WO2006030032A1 PCT/EP2005/054636 EP2005054636W WO2006030032A1 WO 2006030032 A1 WO2006030032 A1 WO 2006030032A1 EP 2005054636 W EP2005054636 W EP 2005054636W WO 2006030032 A1 WO2006030032 A1 WO 2006030032A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- cycloalkyl
- alkynyl
- alkenyl
- alkylcycloalkyl
- Prior art date
Links
- 230000003281 allosteric effect Effects 0.000 title claims abstract description 36
- 150000005299 pyridinones Chemical class 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 352
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 claims abstract description 73
- 108010038421 metabotropic glutamate receptor 2 Proteins 0.000 claims abstract description 73
- 239000000203 mixture Substances 0.000 claims abstract description 48
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 33
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 27
- 229930195712 glutamate Natural products 0.000 claims abstract description 27
- 208000015114 central nervous system disease Diseases 0.000 claims abstract description 23
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 206010015037 epilepsy Diseases 0.000 claims abstract description 13
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 11
- 208000025966 Neurological disease Diseases 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 208000020016 psychiatric disease Diseases 0.000 claims abstract description 11
- 208000019695 Migraine disease Diseases 0.000 claims abstract description 10
- 206010027599 migraine Diseases 0.000 claims abstract description 10
- 230000000926 neurological effect Effects 0.000 claims abstract description 10
- 230000002265 prevention Effects 0.000 claims abstract description 10
- 230000004064 dysfunction Effects 0.000 claims abstract description 7
- 230000036506 anxiety Effects 0.000 claims abstract description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 237
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 183
- 125000000217 alkyl group Chemical group 0.000 claims description 126
- -1 -O-heteroaryl Chemical group 0.000 claims description 84
- 125000003118 aryl group Chemical group 0.000 claims description 70
- 239000001257 hydrogen Substances 0.000 claims description 67
- 229910052739 hydrogen Inorganic materials 0.000 claims description 67
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 58
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 51
- 125000001072 heteroaryl group Chemical group 0.000 claims description 51
- 125000003545 alkoxy group Chemical group 0.000 claims description 42
- 239000002253 acid Substances 0.000 claims description 40
- 150000003839 salts Chemical class 0.000 claims description 39
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 35
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 33
- 229910052736 halogen Inorganic materials 0.000 claims description 31
- 125000000623 heterocyclic group Chemical group 0.000 claims description 31
- 150000002431 hydrogen Chemical class 0.000 claims description 29
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 29
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 29
- 150000002367 halogens Chemical class 0.000 claims description 28
- 239000000556 agonist Substances 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 24
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 23
- 229910052757 nitrogen Inorganic materials 0.000 claims description 23
- 125000006618 5- to 10-membered aromatic heterocyclic group Chemical group 0.000 claims description 22
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 22
- 125000000304 alkynyl group Chemical group 0.000 claims description 21
- 229910052799 carbon Inorganic materials 0.000 claims description 19
- 125000005217 alkenylheteroaryl group Chemical group 0.000 claims description 18
- 125000005025 alkynylaryl group Chemical group 0.000 claims description 18
- 125000005024 alkenyl aryl group Chemical group 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 16
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 15
- 229940025084 amphetamine Drugs 0.000 claims description 15
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 claims description 13
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 claims description 13
- 125000000815 N-oxide group Chemical group 0.000 claims description 13
- 208000028017 Psychotic disease Diseases 0.000 claims description 13
- 125000004076 pyridyl group Chemical group 0.000 claims description 13
- 206010012289 Dementia Diseases 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 11
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 10
- 125000000335 thiazolyl group Chemical group 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 9
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 125000002883 imidazolyl group Chemical group 0.000 claims description 8
- 208000010877 cognitive disease Diseases 0.000 claims description 7
- 125000001041 indolyl group Chemical group 0.000 claims description 7
- 125000002757 morpholinyl group Chemical group 0.000 claims description 7
- 229940126027 positive allosteric modulator Drugs 0.000 claims description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 7
- 125000001544 thienyl group Chemical group 0.000 claims description 7
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 7
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 206010010904 Convulsion Diseases 0.000 claims description 5
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 5
- 208000019022 Mood disease Diseases 0.000 claims description 5
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 5
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 5
- 125000002541 furyl group Chemical group 0.000 claims description 5
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 5
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 230000003227 neuromodulating effect Effects 0.000 claims description 5
- 125000002971 oxazolyl group Chemical group 0.000 claims description 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 5
- 208000011117 substance-related disease Diseases 0.000 claims description 5
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 4
- 208000007848 Alcoholism Diseases 0.000 claims description 4
- 206010012218 Delirium Diseases 0.000 claims description 4
- 208000030814 Eating disease Diseases 0.000 claims description 4
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 4
- 208000003078 Generalized Epilepsy Diseases 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 230000006735 deficit Effects 0.000 claims description 4
- 235000014632 disordered eating Nutrition 0.000 claims description 4
- 230000002085 persistent effect Effects 0.000 claims description 4
- 208000022821 personality disease Diseases 0.000 claims description 4
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 4
- 208000005809 status epilepticus Diseases 0.000 claims description 4
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 4
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 3
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims description 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 3
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims description 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 3
- 208000020925 Bipolar disease Diseases 0.000 claims description 3
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 claims description 3
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 3
- 125000005103 alkyl silyl group Chemical group 0.000 claims description 3
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims description 3
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 3
- 125000005872 benzooxazolyl group Chemical group 0.000 claims description 3
- 229960003920 cocaine Drugs 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 206010013663 drug dependence Diseases 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 229960002715 nicotine Drugs 0.000 claims description 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 3
- 230000003287 optical effect Effects 0.000 claims description 3
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 3
- 125000004043 oxo group Chemical group O=* 0.000 claims description 3
- 208000019906 panic disease Diseases 0.000 claims description 3
- 125000005493 quinolyl group Chemical group 0.000 claims description 3
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 3
- 206010065040 AIDS dementia complex Diseases 0.000 claims description 2
- 208000008811 Agoraphobia Diseases 0.000 claims description 2
- 208000029197 Amphetamine-Related disease Diseases 0.000 claims description 2
- 206010002650 Anorexia nervosa and bulimia Diseases 0.000 claims description 2
- 208000022497 Cocaine-Related disease Diseases 0.000 claims description 2
- 206010012225 Delirium tremens Diseases 0.000 claims description 2
- 208000024254 Delusional disease Diseases 0.000 claims description 2
- 208000035444 Generalised non-convulsive epilepsy Diseases 0.000 claims description 2
- 208000034308 Grand mal convulsion Diseases 0.000 claims description 2
- 206010021750 Infantile Spasms Diseases 0.000 claims description 2
- 206010029350 Neurotoxicity Diseases 0.000 claims description 2
- 206010057852 Nicotine dependence Diseases 0.000 claims description 2
- 208000026251 Opioid-Related disease Diseases 0.000 claims description 2
- 208000037158 Partial Epilepsies Diseases 0.000 claims description 2
- 206010061334 Partial seizures Diseases 0.000 claims description 2
- 208000020186 Schizophreniform disease Diseases 0.000 claims description 2
- 206010041250 Social phobia Diseases 0.000 claims description 2
- 208000011962 Substance-induced mood disease Diseases 0.000 claims description 2
- 231100000395 Substance-induced mood disorder Toxicity 0.000 claims description 2
- 208000011963 Substance-induced psychotic disease Diseases 0.000 claims description 2
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims description 2
- 208000025569 Tobacco Use disease Diseases 0.000 claims description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 claims description 2
- 201000006791 West syndrome Diseases 0.000 claims description 2
- 206010001584 alcohol abuse Diseases 0.000 claims description 2
- 201000007930 alcohol dependence Diseases 0.000 claims description 2
- 208000025746 alcohol use disease Diseases 0.000 claims description 2
- 208000029650 alcohol withdrawal Diseases 0.000 claims description 2
- 208000006246 alcohol withdrawal delirium Diseases 0.000 claims description 2
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 201000006145 cocaine dependence Diseases 0.000 claims description 2
- 208000026725 cyclothymic disease Diseases 0.000 claims description 2
- 208000024732 dysthymic disease Diseases 0.000 claims description 2
- 201000007186 focal epilepsy Diseases 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 208000024714 major depressive disease Diseases 0.000 claims description 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 230000007135 neurotoxicity Effects 0.000 claims description 2
- 231100000228 neurotoxicity Toxicity 0.000 claims description 2
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 claims description 2
- 201000005040 opiate dependence Diseases 0.000 claims description 2
- 208000002851 paranoid schizophrenia Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 208000019899 phobic disease Diseases 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 208000022610 schizoaffective disease Diseases 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 238000003384 imaging method Methods 0.000 claims 1
- 239000000700 radioactive tracer Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 128
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 abstract description 18
- 201000010099 disease Diseases 0.000 abstract description 9
- 102000006239 metabotropic receptors Human genes 0.000 abstract description 5
- 108020004083 metabotropic receptors Proteins 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 244
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 161
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 104
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 99
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 86
- 238000006243 chemical reaction Methods 0.000 description 86
- 239000000377 silicon dioxide Substances 0.000 description 86
- 229910052681 coesite Inorganic materials 0.000 description 77
- 229910052906 cristobalite Inorganic materials 0.000 description 77
- 239000007787 solid Substances 0.000 description 77
- 229910052682 stishovite Inorganic materials 0.000 description 77
- 229910052905 tridymite Inorganic materials 0.000 description 77
- 239000012043 crude product Substances 0.000 description 74
- 239000000243 solution Substances 0.000 description 69
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 62
- 150000003254 radicals Chemical class 0.000 description 62
- 239000000741 silica gel Substances 0.000 description 57
- 229910002027 silica gel Inorganic materials 0.000 description 57
- 229960001866 silicon dioxide Drugs 0.000 description 57
- 238000005160 1H NMR spectroscopy Methods 0.000 description 56
- 238000003818 flash chromatography Methods 0.000 description 50
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 48
- 230000002829 reductive effect Effects 0.000 description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 48
- 229910001868 water Inorganic materials 0.000 description 46
- 239000011541 reaction mixture Substances 0.000 description 44
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 41
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
- 239000002904 solvent Substances 0.000 description 38
- 239000007832 Na2SO4 Substances 0.000 description 37
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 37
- 239000003480 eluent Substances 0.000 description 37
- 229910052938 sodium sulfate Inorganic materials 0.000 description 37
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 34
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 32
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 31
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 29
- 239000003921 oil Substances 0.000 description 27
- 235000019198 oils Nutrition 0.000 description 27
- 238000010898 silica gel chromatography Methods 0.000 description 27
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 25
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 239000012044 organic layer Substances 0.000 description 21
- 239000000725 suspension Substances 0.000 description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 17
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 17
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 16
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 16
- 239000012267 brine Substances 0.000 description 16
- 229910000027 potassium carbonate Inorganic materials 0.000 description 16
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 16
- 238000003786 synthesis reaction Methods 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 238000006161 Suzuki-Miyaura coupling reaction Methods 0.000 description 14
- 230000029936 alkylation Effects 0.000 description 14
- 238000005804 alkylation reaction Methods 0.000 description 14
- 230000006742 locomotor activity Effects 0.000 description 14
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 229920006395 saturated elastomer Polymers 0.000 description 13
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 12
- 239000008346 aqueous phase Substances 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 12
- 230000004913 activation Effects 0.000 description 11
- 229910052794 bromium Inorganic materials 0.000 description 11
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 238000010485 C−C bond formation reaction Methods 0.000 description 10
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 239000012230 colorless oil Substances 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 229910000104 sodium hydride Inorganic materials 0.000 description 10
- VOAAEKKFGLPLLU-UHFFFAOYSA-N (4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- 0 CN(c(c(**)c(*)c(*)c1*)c1C(C*)=C1*)C1=O Chemical compound CN(c(c(**)c(*)c(*)c1*)c1C(C*)=C1*)C1=O 0.000 description 9
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 229910052801 chlorine Inorganic materials 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 238000002425 crystallisation Methods 0.000 description 9
- 230000008025 crystallization Effects 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- CHDTWSPLGKBXPY-UHFFFAOYSA-N 5-(4-methoxyphenyl)-1h-pyridin-2-one Chemical compound C1=CC(OC)=CC=C1C1=CNC(=O)C=C1 CHDTWSPLGKBXPY-UHFFFAOYSA-N 0.000 description 8
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 8
- 231100000673 dose–response relationship Toxicity 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 230000003137 locomotive effect Effects 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- NDMZZQRNZFWMEZ-UHFFFAOYSA-N 5-bromo-1h-pyridin-2-one Chemical compound OC1=CC=C(Br)C=N1 NDMZZQRNZFWMEZ-UHFFFAOYSA-N 0.000 description 7
- XADICJHFELMBGX-UHFFFAOYSA-N 5-bromo-2-methoxypyridine Chemical class COC1=CC=C(Br)C=N1 XADICJHFELMBGX-UHFFFAOYSA-N 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 7
- 108091006027 G proteins Proteins 0.000 description 7
- 102000030782 GTP binding Human genes 0.000 description 7
- 108091000058 GTP-Binding Proteins 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- MATPZHBYOVDBLI-JJYYJPOSSA-N dcg-iv Chemical compound OC(=O)[C@@H](N)C1[C@@H](C(O)=O)[C@@H]1C(O)=O MATPZHBYOVDBLI-JJYYJPOSSA-N 0.000 description 7
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 7
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- KQNBRMUBPRGXSL-UHFFFAOYSA-N 1-(bromomethyl)-4-chlorobenzene Chemical compound ClC1=CC=C(CBr)C=C1 KQNBRMUBPRGXSL-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 6
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 6
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical class C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 description 6
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 125000002524 organometallic group Chemical group 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- VFCHIGGKTHAWDI-UHFFFAOYSA-N 5-chloro-2-oxidoisoquinolin-2-ium Chemical compound ClC1=CC=CC2=C[N+]([O-])=CC=C21 VFCHIGGKTHAWDI-UHFFFAOYSA-N 0.000 description 5
- YASVRZWVUGJELU-MDASVERJSA-N LY 379268 Chemical compound OC(=O)[C@]1(N)CO[C@H]2[C@H](C(O)=O)[C@@H]12 YASVRZWVUGJELU-MDASVERJSA-N 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000031709 bromination Effects 0.000 description 5
- 238000005893 bromination reaction Methods 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 5
- XKMLYUALXHKNFT-UHFFFAOYSA-N rGTP Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O XKMLYUALXHKNFT-UHFFFAOYSA-N 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 5
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 4
- IOBNSVLJEMUWET-UHFFFAOYSA-N 2-methoxy-5-(4-methoxyphenyl)-4-methylpyridine Chemical compound C1=CC(OC)=CC=C1C1=CN=C(OC)C=C1C IOBNSVLJEMUWET-UHFFFAOYSA-N 0.000 description 4
- IWTFOFMTUOBLHG-UHFFFAOYSA-N 2-methoxypyridine Chemical class COC1=CC=CC=N1 IWTFOFMTUOBLHG-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 235000019502 Orange oil Nutrition 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 4
- 238000006664 bond formation reaction Methods 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000001054 cortical effect Effects 0.000 description 4
- 239000010779 crude oil Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000010502 orange oil Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 125000000168 pyrrolyl group Chemical group 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 238000001665 trituration Methods 0.000 description 4
- DHADXDMPEUWEAS-UHFFFAOYSA-N (6-methoxypyridin-3-yl)boronic acid Chemical class COC1=CC=C(B(O)O)C=N1 DHADXDMPEUWEAS-UHFFFAOYSA-N 0.000 description 3
- YKTYUHMWNUVAAM-UHFFFAOYSA-N (6-methoxypyridin-3-yl)methanol Chemical compound COC1=CC=C(CO)C=N1 YKTYUHMWNUVAAM-UHFFFAOYSA-N 0.000 description 3
- RORNGIUYPAZGOJ-UHFFFAOYSA-N 1-[(4-chloro-3-fluorophenyl)methyl]-5-[2-(3-methoxyphenyl)ethyl]pyridin-2-one Chemical compound COC1=CC=CC(CCC2=CN(CC=3C=C(F)C(Cl)=CC=3)C(=O)C=C2)=C1 RORNGIUYPAZGOJ-UHFFFAOYSA-N 0.000 description 3
- IRXVQAIRZHDSIC-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-5-[(3-methoxyphenyl)methyl]pyridin-2-one Chemical compound COC1=CC=CC(CC2=CN(CC=3C=CC(Cl)=CC=3)C(=O)C=C2)=C1 IRXVQAIRZHDSIC-UHFFFAOYSA-N 0.000 description 3
- QXTBUMNULAPJDX-UHFFFAOYSA-N 2,3-dimethoxy-5-(4-methoxyphenyl)pyridine Chemical compound C1=CC(OC)=CC=C1C1=CN=C(OC)C(OC)=C1 QXTBUMNULAPJDX-UHFFFAOYSA-N 0.000 description 3
- CXSBYZYTCVDBAO-UHFFFAOYSA-N 2,4-dimethoxy-5-(4-methoxyphenyl)pyridine Chemical compound C1=CC(OC)=CC=C1C1=CN=C(OC)C=C1OC CXSBYZYTCVDBAO-UHFFFAOYSA-N 0.000 description 3
- CSJLJSGWKXPGRN-UHFFFAOYSA-N 2,4-dimethoxypyridine Chemical compound COC1=CC=NC(OC)=C1 CSJLJSGWKXPGRN-UHFFFAOYSA-N 0.000 description 3
- LMKMXQCFRDREQJ-UHFFFAOYSA-N 2-[2-methoxy-5-(4-methoxyphenyl)pyridin-4-yl]ethanol Chemical compound C1=CC(OC)=CC=C1C1=CN=C(OC)C=C1CCO LMKMXQCFRDREQJ-UHFFFAOYSA-N 0.000 description 3
- BZFSEQHAPTUYQK-UHFFFAOYSA-N 2-methoxy-4-(methoxymethyl)-5-(4-methoxyphenyl)pyridine Chemical compound COCC1=CC(OC)=NC=C1C1=CC=C(OC)C=C1 BZFSEQHAPTUYQK-UHFFFAOYSA-N 0.000 description 3
- IYFYTGGTCQJIJI-UHFFFAOYSA-N 2-methoxy-5-(phenoxymethyl)pyridine Chemical compound C1=NC(OC)=CC=C1COC1=CC=CC=C1 IYFYTGGTCQJIJI-UHFFFAOYSA-N 0.000 description 3
- DQBKTFMGGVATPY-UHFFFAOYSA-N 2-methoxy-5-[(4-methoxyphenyl)methoxy]pyridine Chemical compound C1=CC(OC)=CC=C1COC1=CC=C(OC)N=C1 DQBKTFMGGVATPY-UHFFFAOYSA-N 0.000 description 3
- GAJOVOCBARBIMY-UHFFFAOYSA-N 2-methoxy-5-[2-(3-methoxyphenyl)ethyl]pyridine Chemical compound COC1=CC=CC(CCC=2C=NC(OC)=CC=2)=C1 GAJOVOCBARBIMY-UHFFFAOYSA-N 0.000 description 3
- AUWVFNWUQAPELP-UHFFFAOYSA-N 4-(bromomethyl)-2-methoxy-5-(4-methoxyphenyl)pyridine Chemical compound C1=CC(OC)=CC=C1C1=CN=C(OC)C=C1CBr AUWVFNWUQAPELP-UHFFFAOYSA-N 0.000 description 3
- OQFDKWAYWIQAPK-UHFFFAOYSA-N 4-[2-(4-methoxyphenyl)ethyl]-2-oxidoisoquinolin-2-ium Chemical compound C1=CC(OC)=CC=C1CCC1=C[N+]([O-])=CC2=CC=CC=C12 OQFDKWAYWIQAPK-UHFFFAOYSA-N 0.000 description 3
- SEAQXYNIBNWEED-UHFFFAOYSA-N 4-[2-(4-methoxyphenyl)ethyl]isoquinoline Chemical compound C1=CC(OC)=CC=C1CCC1=CN=CC2=CC=CC=C12 SEAQXYNIBNWEED-UHFFFAOYSA-N 0.000 description 3
- VEVYBBKKLCPSLE-UHFFFAOYSA-N 4-[2-(4-methoxyphenyl)ethynyl]isoquinoline Chemical compound C1=CC(OC)=CC=C1C#CC1=CN=CC2=CC=CC=C12 VEVYBBKKLCPSLE-UHFFFAOYSA-N 0.000 description 3
- YOGUFEHWJJEPLF-UHFFFAOYSA-N 5-(4-fluorophenoxy)-2-methoxypyridine Chemical compound C1=NC(OC)=CC=C1OC1=CC=C(F)C=C1 YOGUFEHWJJEPLF-UHFFFAOYSA-N 0.000 description 3
- UUHHWLVYHXMAHT-UHFFFAOYSA-N 5-(4-methoxyphenyl)-1-(2-phenoxyethyl)pyridin-2-one Chemical compound C1=CC(OC)=CC=C1C1=CN(CCOC=2C=CC=CC=2)C(=O)C=C1 UUHHWLVYHXMAHT-UHFFFAOYSA-N 0.000 description 3
- BMINAQYNXZAXDK-UHFFFAOYSA-N 5-(4-methoxyphenyl)-1-[[6-(2-trimethylsilylethynyl)pyridin-3-yl]methyl]pyridin-2-one Chemical compound C1=CC(OC)=CC=C1C1=CN(CC=2C=NC(=CC=2)C#C[Si](C)(C)C)C(=O)C=C1 BMINAQYNXZAXDK-UHFFFAOYSA-N 0.000 description 3
- LYNXMVNNECXZDS-UHFFFAOYSA-N 5-[2-(4-methoxyphenyl)ethoxy]-2-oxidoisoquinolin-2-ium Chemical compound C1=CC(OC)=CC=C1CCOC1=CC=CC2=C[N+]([O-])=CC=C12 LYNXMVNNECXZDS-UHFFFAOYSA-N 0.000 description 3
- MAPYGUVDTWKHDR-UHFFFAOYSA-N 5-bromo-1-(3-methylbutyl)pyridin-2-one Chemical compound CC(C)CCN1C=C(Br)C=CC1=O MAPYGUVDTWKHDR-UHFFFAOYSA-N 0.000 description 3
- VSXDRIVAPWWONE-UHFFFAOYSA-N 5-bromo-2,3-dimethoxypyridine Chemical compound COC1=CC(Br)=CN=C1OC VSXDRIVAPWWONE-UHFFFAOYSA-N 0.000 description 3
- IRLDCGSNDXFFQH-UHFFFAOYSA-N 5-bromo-2,4-dimethoxypyridine Chemical compound COC1=CC(OC)=C(Br)C=N1 IRLDCGSNDXFFQH-UHFFFAOYSA-N 0.000 description 3
- 229910015845 BBr3 Inorganic materials 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 3
- QGWNDRXFNXRZMB-UUOKFMHZSA-K GDP(3-) Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O QGWNDRXFNXRZMB-UUOKFMHZSA-K 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229910010084 LiAlH4 Inorganic materials 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229910002666 PdCl2 Inorganic materials 0.000 description 3
- YNHIGQDRGKUECZ-UHFFFAOYSA-L PdCl2(PPh3)2 Substances [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- ZHHJBHHSAWWTOJ-UHFFFAOYSA-N [3-(methanesulfonamido)-4-methoxyphenyl]boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1NS(C)(=O)=O ZHHJBHHSAWWTOJ-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 150000001350 alkyl halides Chemical class 0.000 description 3
- 238000004873 anchoring Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- QGWNDRXFNXRZMB-UHFFFAOYSA-N guanidine diphosphate Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O QGWNDRXFNXRZMB-UHFFFAOYSA-N 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 230000035863 hyperlocomotion Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- KVALHYJFKPSITB-UHFFFAOYSA-N n-(4-fluorophenyl)-6-methoxy-n-methylpyridin-3-amine Chemical compound C1=NC(OC)=CC=C1N(C)C1=CC=C(F)C=C1 KVALHYJFKPSITB-UHFFFAOYSA-N 0.000 description 3
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 125000002098 pyridazinyl group Chemical group 0.000 description 3
- 150000003222 pyridines Chemical class 0.000 description 3
- 238000006268 reductive amination reaction Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 125000001425 triazolyl group Chemical group 0.000 description 3
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 3
- GEZMEIHVFSWOCA-UHFFFAOYSA-N (4-fluorophenyl)methanol Chemical compound OCC1=CC=C(F)C=C1 GEZMEIHVFSWOCA-UHFFFAOYSA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 2
- IBMDAWVWTJJHBU-UHFFFAOYSA-N 1-(cyclohexylmethyl)-5-(4-methoxyphenyl)pyridin-2-one Chemical compound C1=CC(OC)=CC=C1C1=CN(CC2CCCCC2)C(=O)C=C1 IBMDAWVWTJJHBU-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- VDWWVVMTLICDEN-UHFFFAOYSA-N 1-[(4-chloro-2-fluorophenyl)methyl]-5-(3-phenylpropyl)pyridin-2-one Chemical compound FC1=CC(Cl)=CC=C1CN1C(=O)C=CC(CCCC=2C=CC=CC=2)=C1 VDWWVVMTLICDEN-UHFFFAOYSA-N 0.000 description 2
- VLTLVMNNIVBONY-UHFFFAOYSA-N 1-[(4-chloro-2-fluorophenyl)methyl]-5-(4-methoxyphenyl)pyridin-2-one Chemical compound C1=CC(OC)=CC=C1C1=CN(CC=2C(=CC(Cl)=CC=2)F)C(=O)C=C1 VLTLVMNNIVBONY-UHFFFAOYSA-N 0.000 description 2
- HTQMPNJNKDEDLR-UHFFFAOYSA-N 1-[(4-chloro-2-fluorophenyl)methyl]-5-[4-(2h-tetrazol-5-ylmethoxy)phenyl]pyridin-2-one Chemical compound FC1=CC(Cl)=CC=C1CN1C(=O)C=CC(C=2C=CC(OCC3=NNN=N3)=CC=2)=C1 HTQMPNJNKDEDLR-UHFFFAOYSA-N 0.000 description 2
- XZRWHZWVLLBYAR-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-5-(4-fluorophenoxy)pyridin-2-one Chemical compound C1=CC(F)=CC=C1OC1=CN(CC=2C=CC(Cl)=CC=2)C(=O)C=C1 XZRWHZWVLLBYAR-UHFFFAOYSA-N 0.000 description 2
- POUXJLWOGDXQDO-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-5-[4-(2h-tetrazol-5-ylmethyl)phenyl]pyridin-2-one Chemical compound C1=CC(Cl)=CC=C1CN1C(=O)C=CC(C=2C=CC(CC3=NNN=N3)=CC=2)=C1 POUXJLWOGDXQDO-UHFFFAOYSA-N 0.000 description 2
- HDNBJAQMYSZDNH-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-5-[hydroxy-(3-methoxyphenyl)methyl]pyridin-2-one Chemical compound COC1=CC=CC(C(O)C2=CN(CC=3C=CC(Cl)=CC=3)C(=O)C=C2)=C1 HDNBJAQMYSZDNH-UHFFFAOYSA-N 0.000 description 2
- NIJPXGYCFXEMCD-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-5-cyclohexylpyridin-2-one Chemical compound C1=CC(Cl)=CC=C1CN1C(=O)C=CC(C2CCCCC2)=C1 NIJPXGYCFXEMCD-UHFFFAOYSA-N 0.000 description 2
- YUVPILCEQWUWFU-UHFFFAOYSA-N 1-[[4-(methoxymethyl)phenyl]methyl]-5-(4-methoxyphenyl)pyridin-2-one Chemical compound C1=CC(COC)=CC=C1CN1C(=O)C=CC(C=2C=CC(OC)=CC=2)=C1 YUVPILCEQWUWFU-UHFFFAOYSA-N 0.000 description 2
- JQZAEUFPPSRDOP-UHFFFAOYSA-N 1-chloro-4-(chloromethyl)benzene Chemical compound ClCC1=CC=C(Cl)C=C1 JQZAEUFPPSRDOP-UHFFFAOYSA-N 0.000 description 2
- ZEZJPIDPVXJEME-UHFFFAOYSA-N 2,4-Dihydroxypyridine Chemical compound OC=1C=CNC(=O)C=1 ZEZJPIDPVXJEME-UHFFFAOYSA-N 0.000 description 2
- ISAQTLDBJIJYTF-UHFFFAOYSA-N 2-(6-methoxypyridin-3-yl)-1,3-benzothiazole Chemical compound C1=NC(OC)=CC=C1C1=NC2=CC=CC=C2S1 ISAQTLDBJIJYTF-UHFFFAOYSA-N 0.000 description 2
- LBKCHCHTSRLQMS-UHFFFAOYSA-N 2-[(4-fluorophenyl)methyl]isoquinolin-1-one Chemical compound C1=CC(F)=CC=C1CN1C(=O)C2=CC=CC=C2C=C1 LBKCHCHTSRLQMS-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- KWNJGAJBZKLZTJ-UHFFFAOYSA-N 2-[4-[1-[(4-chloro-2-fluorophenyl)methyl]-6-oxopyridin-3-yl]phenoxy]acetonitrile Chemical compound FC1=CC(Cl)=CC=C1CN1C(=O)C=CC(C=2C=CC(OCC#N)=CC=2)=C1 KWNJGAJBZKLZTJ-UHFFFAOYSA-N 0.000 description 2
- 150000005749 2-halopyridines Chemical class 0.000 description 2
- PCDUJOCJGUNGFI-UHFFFAOYSA-N 2-methoxy-5-(3-phenylpropyl)pyridine Chemical compound C1=NC(OC)=CC=C1CCCC1=CC=CC=C1 PCDUJOCJGUNGFI-UHFFFAOYSA-N 0.000 description 2
- JJFLWZAWIYFMFM-UHFFFAOYSA-N 2-methoxy-5-(4-methoxyphenyl)pyridine Chemical compound C1=CC(OC)=CC=C1C1=CC=C(OC)N=C1 JJFLWZAWIYFMFM-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- CNUYBEIHDWMLSD-UHFFFAOYSA-N 4-(bromomethyl)-1-chloro-2-fluorobenzene Chemical compound FC1=CC(CBr)=CC=C1Cl CNUYBEIHDWMLSD-UHFFFAOYSA-N 0.000 description 2
- MSHFRERJPWKJFX-UHFFFAOYSA-N 4-Methoxybenzyl alcohol Chemical compound COC1=CC=C(CO)C=C1 MSHFRERJPWKJFX-UHFFFAOYSA-N 0.000 description 2
- NCSRXJHBTSOGDA-UHFFFAOYSA-N 5-(4-methoxyphenyl)-1-[[6-(trifluoromethyl)pyridin-3-yl]methyl]pyridin-2-one;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1C1=CN(CC=2C=NC(=CC=2)C(F)(F)F)C(=O)C=C1 NCSRXJHBTSOGDA-UHFFFAOYSA-N 0.000 description 2
- QYBDDDMIRFQGDG-UHFFFAOYSA-N 5-(cyclohexen-1-yl)-2-methoxypyridine Chemical compound C1=NC(OC)=CC=C1C1=CCCCC1 QYBDDDMIRFQGDG-UHFFFAOYSA-N 0.000 description 2
- RSWCTZNXSACFAL-UHFFFAOYSA-N 5-[2-(4-methoxyphenyl)ethoxy]-2-propylisoquinolin-1-one Chemical compound C1=CC=C2C(=O)N(CCC)C=CC2=C1OCCC1=CC=C(OC)C=C1 RSWCTZNXSACFAL-UHFFFAOYSA-N 0.000 description 2
- KNULMJDSQCYXQL-UHFFFAOYSA-N 5-cyclohexyl-2-methoxypyridine Chemical compound C1=NC(OC)=CC=C1C1CCCCC1 KNULMJDSQCYXQL-UHFFFAOYSA-N 0.000 description 2
- CTAIEPPAOULMFY-UHFFFAOYSA-N 6-methoxypyridine-3-carbaldehyde Chemical compound COC1=CC=C(C=O)C=N1 CTAIEPPAOULMFY-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 description 2
- 101100058513 Caenorhabditis elegans glo-2 gene Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- 239000007818 Grignard reagent Substances 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102100038354 Metabotropic glutamate receptor 4 Human genes 0.000 description 2
- 102100038294 Metabotropic glutamate receptor 7 Human genes 0.000 description 2
- 102100037636 Metabotropic glutamate receptor 8 Human genes 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 238000006751 Mitsunobu reaction Methods 0.000 description 2
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 2
- AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methylaniline Chemical compound CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 238000006959 Williamson synthesis reaction Methods 0.000 description 2
- UBVOLHQIEQVXGM-UHFFFAOYSA-N [4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]boronic acid Chemical compound CC(C)(C)OC(=O)NC1=CC=C(B(O)O)C=C1 UBVOLHQIEQVXGM-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 150000001723 carbon free-radicals Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 150000004795 grignard reagents Chemical class 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 230000004068 intracellular signaling Effects 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108010038422 metabotropic glutamate receptor 4 Proteins 0.000 description 2
- 108010038449 metabotropic glutamate receptor 7 Proteins 0.000 description 2
- 108010038448 metabotropic glutamate receptor 8 Proteins 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 229950010883 phencyclidine Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000004928 piperidonyl group Chemical group 0.000 description 2
- 125000005936 piperidyl group Chemical group 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- GUUBJKMBDULZTE-UHFFFAOYSA-M potassium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[K+].OCCN1CCN(CCS(O)(=O)=O)CC1 GUUBJKMBDULZTE-UHFFFAOYSA-M 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 125000002755 pyrazolinyl group Chemical group 0.000 description 2
- 125000001422 pyrrolinyl group Chemical group 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000006894 reductive elimination reaction Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- XOFLBQFBSOEHOG-UUOKFMHZSA-N γS-GTP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O XOFLBQFBSOEHOG-UUOKFMHZSA-N 0.000 description 2
- QMYCMNKKHXJWLC-UHFFFAOYSA-N (3-amino-4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1N QMYCMNKKHXJWLC-UHFFFAOYSA-N 0.000 description 1
- OBQRODBYVNIZJU-UHFFFAOYSA-N (4-acetylphenyl)boronic acid Chemical compound CC(=O)C1=CC=C(B(O)O)C=C1 OBQRODBYVNIZJU-UHFFFAOYSA-N 0.000 description 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- DYFBCVMPCWGVMV-UHFFFAOYSA-N 1,2-dihydropyridine-3-carbonitrile Chemical compound N#CC1=CC=CNC1 DYFBCVMPCWGVMV-UHFFFAOYSA-N 0.000 description 1
- HFSPLVZIZIJRHK-UHFFFAOYSA-N 1-(2-methylbutyl)-2-oxo-4-phenylpyridine-3-carbonitrile Chemical compound O=C1N(CC(C)CC)C=CC(C=2C=CC=CC=2)=C1C#N HFSPLVZIZIJRHK-UHFFFAOYSA-N 0.000 description 1
- WYZZZFGQOHXMSO-UHFFFAOYSA-N 1-(2-methylpropyl)-2-oxo-4-thiophen-2-ylpyridine-3-carbonitrile Chemical compound O=C1N(CC(C)C)C=CC(C=2SC=CC=2)=C1C#N WYZZZFGQOHXMSO-UHFFFAOYSA-N 0.000 description 1
- ZPNLAQVYPIAHTO-UHFFFAOYSA-N 1-(3-chlorophenyl)-n-methylmethanamine Chemical compound CNCC1=CC=CC(Cl)=C1 ZPNLAQVYPIAHTO-UHFFFAOYSA-N 0.000 description 1
- JSHCAYXRWHQQOX-UHFFFAOYSA-N 1-(3-methylbutyl)-2-oxo-4-phenylpyridine-3-carbonitrile Chemical compound O=C1N(CCC(C)C)C=CC(C=2C=CC=CC=2)=C1C#N JSHCAYXRWHQQOX-UHFFFAOYSA-N 0.000 description 1
- QJOJNEAXCANYRO-UHFFFAOYSA-N 1-(3-methylbutyl)-2-oxo-4-thiophen-2-ylpyridine-3-carbonitrile Chemical compound O=C1N(CCC(C)C)C=CC(C=2SC=CC=2)=C1C#N QJOJNEAXCANYRO-UHFFFAOYSA-N 0.000 description 1
- FFWQLZFIMNTUCZ-UHFFFAOYSA-N 1-(bromomethyl)-2-fluorobenzene Chemical compound FC1=CC=CC=C1CBr FFWQLZFIMNTUCZ-UHFFFAOYSA-N 0.000 description 1
- SCBZBMXPJYMXRC-UHFFFAOYSA-N 1-(bromomethyl)-3-fluorobenzene Chemical compound FC1=CC=CC(CBr)=C1 SCBZBMXPJYMXRC-UHFFFAOYSA-N 0.000 description 1
- UFCSSWZQROEFBZ-UHFFFAOYSA-N 1-(bromomethyl)-4-chloro-2-fluorobenzene Chemical compound FC1=CC(Cl)=CC=C1CBr UFCSSWZQROEFBZ-UHFFFAOYSA-N 0.000 description 1
- NVFVONVTGUPMQF-UHFFFAOYSA-N 1-(cyclohexylmethyl)-2-oxo-4-thiophen-2-ylpyridine-3-carbonitrile Chemical compound O=C1C(C#N)=C(C=2SC=CC=2)C=CN1CC1CCCCC1 NVFVONVTGUPMQF-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- OECFEDKXGQNJIM-UHFFFAOYSA-N 1-[(2-methylphenyl)methyl]-2-oxo-4-thiophen-2-ylpyridine-3-carbonitrile Chemical compound CC1=CC=CC=C1CN1C(=O)C(C#N)=C(C=2SC=CC=2)C=C1 OECFEDKXGQNJIM-UHFFFAOYSA-N 0.000 description 1
- YPNWWECGLFCKMI-UHFFFAOYSA-N 1-[(3,4-difluorophenyl)methyl]-5-(phenoxymethyl)pyridin-2-one Chemical compound C1=C(F)C(F)=CC=C1CN1C(=O)C=CC(COC=2C=CC=CC=2)=C1 YPNWWECGLFCKMI-UHFFFAOYSA-N 0.000 description 1
- LMBXMEQTPRNSBB-UHFFFAOYSA-N 1-[(3-chlorophenyl)methyl]-5-(4-fluorophenyl)pyridin-2-one Chemical compound C1=CC(F)=CC=C1C1=CN(CC=2C=C(Cl)C=CC=2)C(=O)C=C1 LMBXMEQTPRNSBB-UHFFFAOYSA-N 0.000 description 1
- CMWJEBKQNANDFC-UHFFFAOYSA-N 1-[(3-chlorophenyl)methyl]-5-phenylpyridin-2-one Chemical compound ClC1=CC=CC(CN2C(C=CC(=C2)C=2C=CC=CC=2)=O)=C1 CMWJEBKQNANDFC-UHFFFAOYSA-N 0.000 description 1
- YNKMIRUPOPRESA-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]-4-(2-phenylethoxy)pyridin-2-one Chemical compound FC1=CC=CC(CN2C(C=C(OCCC=3C=CC=CC=3)C=C2)=O)=C1 YNKMIRUPOPRESA-UHFFFAOYSA-N 0.000 description 1
- UCFOQQLYAWQKNF-UHFFFAOYSA-N 1-[(4-chloro-2-fluorophenyl)methyl]-5-(4-hydroxyphenyl)pyridin-2-one Chemical compound C1=CC(O)=CC=C1C1=CN(CC=2C(=CC(Cl)=CC=2)F)C(=O)C=C1 UCFOQQLYAWQKNF-UHFFFAOYSA-N 0.000 description 1
- JEIAGZWDYXFWGC-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-2-oxo-4-thiophen-2-ylpyridine-3-carbonitrile Chemical compound C1=CC(Cl)=CC=C1CN1C(=O)C(C#N)=C(C=2SC=CC=2)C=C1 JEIAGZWDYXFWGC-UHFFFAOYSA-N 0.000 description 1
- WDCMBMVZPURTNT-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-3-(hydroxymethyl)-5-(4-methoxyphenyl)pyridin-2-one Chemical compound C1=CC(OC)=CC=C1C1=CN(CC=2C=CC(Cl)=CC=2)C(=O)C(CO)=C1 WDCMBMVZPURTNT-UHFFFAOYSA-N 0.000 description 1
- CFCUEYBKVMGHFJ-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-4-(2-methoxyethyl)-5-(4-methoxyphenyl)pyridin-2-one Chemical compound C1=C(C=2C=CC(OC)=CC=2)C(CCOC)=CC(=O)N1CC1=CC=C(Cl)C=C1 CFCUEYBKVMGHFJ-UHFFFAOYSA-N 0.000 description 1
- BRDWRZXVCDWHKT-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-5-(3-methoxybenzoyl)pyridin-2-one Chemical compound COC1=CC=CC(C(=O)C2=CN(CC=3C=CC(Cl)=CC=3)C(=O)C=C2)=C1 BRDWRZXVCDWHKT-UHFFFAOYSA-N 0.000 description 1
- HUWIXJBQIMXASF-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-5-(4-fluoro-n-methylanilino)pyridin-2-one Chemical compound C1=CC(=O)N(CC=2C=CC(Cl)=CC=2)C=C1N(C)C1=CC=C(F)C=C1 HUWIXJBQIMXASF-UHFFFAOYSA-N 0.000 description 1
- YPUGQVARSFDNAD-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-5-(4-methoxyphenyl)pyrazin-2-one Chemical compound C1=CC(OC)=CC=C1C(N=CC1=O)=CN1CC1=CC=C(Cl)C=C1 YPUGQVARSFDNAD-UHFFFAOYSA-N 0.000 description 1
- WDWXPXZWGUFWNZ-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-5-[(4-methoxyphenoxy)methyl]pyridin-2-one Chemical compound C1=CC(OC)=CC=C1OCC1=CN(CC=2C=CC(Cl)=CC=2)C(=O)C=C1 WDWXPXZWGUFWNZ-UHFFFAOYSA-N 0.000 description 1
- JHLYBVORKMGGTP-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-5-[4-(2-hydroxypropan-2-yl)phenyl]pyridin-2-one Chemical compound C1=CC(C(C)(O)C)=CC=C1C1=CN(CC=2C=CC(Cl)=CC=2)C(=O)C=C1 JHLYBVORKMGGTP-UHFFFAOYSA-N 0.000 description 1
- SKEQMISRMHODQY-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-5-[4-(3-hydroxypropyl)phenyl]pyridin-2-one Chemical compound C1=CC(CCCO)=CC=C1C1=CN(CC=2C=CC(Cl)=CC=2)C(=O)C=C1 SKEQMISRMHODQY-UHFFFAOYSA-N 0.000 description 1
- QACDAMSBMACTNI-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-5-[4-(ethoxymethyl)phenyl]pyridin-2-one Chemical compound C1=CC(COCC)=CC=C1C1=CN(CC=2C=CC(Cl)=CC=2)C(=O)C=C1 QACDAMSBMACTNI-UHFFFAOYSA-N 0.000 description 1
- AJVRWYQRQYCTLE-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-5-[4-(hydroxymethyl)phenyl]pyridin-2-one Chemical compound C1=CC(CO)=CC=C1C1=CN(CC=2C=CC(Cl)=CC=2)C(=O)C=C1 AJVRWYQRQYCTLE-UHFFFAOYSA-N 0.000 description 1
- ZIBMWVYUBRZTLI-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]quinolin-2-one Chemical compound C1=CC(Cl)=CC=C1CN1C(=O)C=CC2=CC=CC=C21 ZIBMWVYUBRZTLI-UHFFFAOYSA-N 0.000 description 1
- MVZQBGUKZVQQIX-UHFFFAOYSA-N 1-[(4-methoxyphenyl)methyl]-2-oxo-4-phenylpyridine-3-carbonitrile Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C(C#N)=C(C=2C=CC=CC=2)C=C1 MVZQBGUKZVQQIX-UHFFFAOYSA-N 0.000 description 1
- QNFWQBCDRZLBDS-UHFFFAOYSA-N 1-[(4-methylphenyl)methyl]-2-oxo-4-phenylpyridine-3-carbonitrile Chemical compound C1=CC(C)=CC=C1CN1C(=O)C(C#N)=C(C=2C=CC=CC=2)C=C1 QNFWQBCDRZLBDS-UHFFFAOYSA-N 0.000 description 1
- LSBIVSBSZXINAJ-UHFFFAOYSA-N 1-[(4-methylphenyl)methyl]-2-oxo-4-thiophen-2-ylpyridine-3-carbonitrile Chemical compound C1=CC(C)=CC=C1CN1C(=O)C(C#N)=C(C=2SC=CC=2)C=C1 LSBIVSBSZXINAJ-UHFFFAOYSA-N 0.000 description 1
- VKGJCJMYWXONNH-UHFFFAOYSA-N 1-[2-[4-[1-[(4-chloro-2-fluorophenyl)methyl]-2H-pyridin-5-yl]phenoxy]ethyl]pyrrolidin-2-one Chemical compound ClC1=CC(=C(CN2CC=CC(=C2)C2=CC=C(C=C2)OCCN2C(CCC2)=O)C=C1)F VKGJCJMYWXONNH-UHFFFAOYSA-N 0.000 description 1
- YXZFFTJAHVMMLF-UHFFFAOYSA-N 1-bromo-3-methylbutane Chemical compound CC(C)CCBr YXZFFTJAHVMMLF-UHFFFAOYSA-N 0.000 description 1
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 1
- SIPJKTMDINXYJA-UHFFFAOYSA-N 1-butyl-2-oxo-4-thiophen-2-ylpyridine-3-carbonitrile Chemical compound O=C1N(CCCC)C=CC(C=2SC=CC=2)=C1C#N SIPJKTMDINXYJA-UHFFFAOYSA-N 0.000 description 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- QHUHPERZCBUMRK-UHFFFAOYSA-N 2,3-dimethoxypyridine Chemical compound COC1=CC=CN=C1OC QHUHPERZCBUMRK-UHFFFAOYSA-N 0.000 description 1
- YFTHTJAPODJVSL-UHFFFAOYSA-N 2-(1-benzothiophen-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(SC=C2)C2=C1 YFTHTJAPODJVSL-UHFFFAOYSA-N 0.000 description 1
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 1
- VGNLBKZLLKZPAS-UHFFFAOYSA-N 2-[4-[1-[(4-chloro-2-fluorophenyl)methyl]-6-oxopyridin-3-yl]phenoxy]-n-methylacetamide Chemical compound C1=CC(OCC(=O)NC)=CC=C1C1=CN(CC=2C(=CC(Cl)=CC=2)F)C(=O)C=C1 VGNLBKZLLKZPAS-UHFFFAOYSA-N 0.000 description 1
- RUWXXCVQIRFTLV-UHFFFAOYSA-N 2-[4-[1-[(4-chlorophenyl)methyl]-6-oxopyridin-3-yl]phenyl]-n-methylacetamide Chemical compound C1=CC(CC(=O)NC)=CC=C1C1=CN(CC=2C=CC(Cl)=CC=2)C(=O)C=C1 RUWXXCVQIRFTLV-UHFFFAOYSA-N 0.000 description 1
- GTCHZRRBCGBMAS-UHFFFAOYSA-N 2-[4-[1-[(4-chlorophenyl)methyl]-6-oxopyridin-3-yl]phenyl]acetonitrile Chemical compound C1=CC(Cl)=CC=C1CN1C(=O)C=CC(C=2C=CC(CC#N)=CC=2)=C1 GTCHZRRBCGBMAS-UHFFFAOYSA-N 0.000 description 1
- ULDFRPKVIZMKJG-UHFFFAOYSA-N 2-amino-4-fluorophenol Chemical compound NC1=CC(F)=CC=C1O ULDFRPKVIZMKJG-UHFFFAOYSA-N 0.000 description 1
- DRLMMVPCYXFPEP-UHFFFAOYSA-N 2-bromo-1,3-benzothiazole Chemical compound C1=CC=C2SC(Br)=NC2=C1 DRLMMVPCYXFPEP-UHFFFAOYSA-N 0.000 description 1
- REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 description 1
- WGFCNCNTGOFBBF-UHFFFAOYSA-N 2-bromopyrazine Chemical compound BrC1=CN=CC=N1 WGFCNCNTGOFBBF-UHFFFAOYSA-N 0.000 description 1
- PMTPFBWHUOWTNN-UHFFFAOYSA-N 2-chloro-4-methoxypyridine Chemical compound COC1=CC=NC(Cl)=C1 PMTPFBWHUOWTNN-UHFFFAOYSA-N 0.000 description 1
- SKCNYHLTRZIINA-UHFFFAOYSA-N 2-chloro-5-(chloromethyl)pyridine Chemical compound ClCC1=CC=C(Cl)N=C1 SKCNYHLTRZIINA-UHFFFAOYSA-N 0.000 description 1
- WQMAANNAZKNUDL-UHFFFAOYSA-N 2-dimethylaminoethyl chloride Chemical compound CN(C)CCCl WQMAANNAZKNUDL-UHFFFAOYSA-N 0.000 description 1
- CCZWSTFVHJPCEM-UHFFFAOYSA-N 2-iodopyridine Chemical compound IC1=CC=CC=N1 CCZWSTFVHJPCEM-UHFFFAOYSA-N 0.000 description 1
- WPUYXJZBWYVMDU-UHFFFAOYSA-N 2-oxo-1-(3-phenylprop-2-enyl)-4-thiophen-2-ylpyridine-3-carbonitrile Chemical compound O=C1C(C#N)=C(C=2SC=CC=2)C=CN1CC=CC1=CC=CC=C1 WPUYXJZBWYVMDU-UHFFFAOYSA-N 0.000 description 1
- DNRHRGTUBGDLQO-UHFFFAOYSA-N 2-oxo-1-pentan-2-yl-4-thiophen-2-ylpyridine-3-carbonitrile Chemical compound O=C1N(C(C)CCC)C=CC(C=2SC=CC=2)=C1C#N DNRHRGTUBGDLQO-UHFFFAOYSA-N 0.000 description 1
- FTASVXKOOIEHIY-UHFFFAOYSA-N 2-oxo-1-propyl-4-thiophen-2-ylpyridine-3-carbonitrile Chemical compound O=C1N(CCC)C=CC(C=2SC=CC=2)=C1C#N FTASVXKOOIEHIY-UHFFFAOYSA-N 0.000 description 1
- FRWQCAWIJWUOCH-UHFFFAOYSA-N 2-oxo-4-thiophen-2-yl-1-[[6-(trifluoromethyl)pyridin-3-yl]methyl]pyridine-3-carbonitrile Chemical compound C1=NC(C(F)(F)F)=CC=C1CN1C(=O)C(C#N)=C(C=2SC=CC=2)C=C1 FRWQCAWIJWUOCH-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- RGXJWZZBHUMAIP-UHFFFAOYSA-N 3-[4-[1-[(4-chlorophenyl)methyl]-6-oxopyridin-3-yl]phenyl]-n,n-dimethylpropanamide Chemical compound C1=CC(CCC(=O)N(C)C)=CC=C1C1=CN(CC=2C=CC(Cl)=CC=2)C(=O)C=C1 RGXJWZZBHUMAIP-UHFFFAOYSA-N 0.000 description 1
- VWXKNBLZXNUZJO-UHFFFAOYSA-N 3-[4-[1-[(4-chlorophenyl)methyl]-6-oxopyridin-3-yl]phenyl]-n-methylpropanamide Chemical compound C1=CC(CCC(=O)NC)=CC=C1C1=CN(CC=2C=CC(Cl)=CC=2)C(=O)C=C1 VWXKNBLZXNUZJO-UHFFFAOYSA-N 0.000 description 1
- HUCBGTOFZLPKDN-UHFFFAOYSA-N 3-[4-[1-[(4-chlorophenyl)methyl]-6-oxopyridin-3-yl]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1C1=CN(CC=2C=CC(Cl)=CC=2)C(=O)C=C1 HUCBGTOFZLPKDN-UHFFFAOYSA-N 0.000 description 1
- 150000005763 3-bromopyridine Chemical class 0.000 description 1
- CLRPXACRDTXENY-UHFFFAOYSA-N 3-ethynylpyridine Chemical compound C#CC1=CC=CN=C1 CLRPXACRDTXENY-UHFFFAOYSA-N 0.000 description 1
- XDELKSRGBLWMBA-UHFFFAOYSA-N 3-iodopyridine Chemical class IC1=CC=CN=C1 XDELKSRGBLWMBA-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- QREKZSDOFWHPKW-UHFFFAOYSA-N 4-(1,3-benzodioxol-5-yl)-1-(3-methylbutyl)-2-oxopyridine-3-carbonitrile Chemical compound O=C1N(CCC(C)C)C=CC(C=2C=C3OCOC3=CC=2)=C1C#N QREKZSDOFWHPKW-UHFFFAOYSA-N 0.000 description 1
- JJIFTOPVKWDHJI-UHFFFAOYSA-N 4-(bromomethyl)-1,2-difluorobenzene Chemical compound FC1=CC=C(CBr)C=C1F JJIFTOPVKWDHJI-UHFFFAOYSA-N 0.000 description 1
- WRQSCJDQFNXZMR-UHFFFAOYSA-N 4-(furan-2-yl)-1-(3-methylbutyl)-2-oxopyridine-3-carbonitrile Chemical compound O=C1N(CCC(C)C)C=CC(C=2OC=CC=2)=C1C#N WRQSCJDQFNXZMR-UHFFFAOYSA-N 0.000 description 1
- GJJCQBRPUFGGCU-UHFFFAOYSA-N 4-(furan-2-yl)-1-[(4-methylphenyl)methyl]-2-oxopyridine-3-carbonitrile Chemical compound C1=CC(C)=CC=C1CN1C(=O)C(C#N)=C(C=2OC=CC=2)C=C1 GJJCQBRPUFGGCU-UHFFFAOYSA-N 0.000 description 1
- YXCDWFNEYWEVPQ-UHFFFAOYSA-N 4-(furan-2-yl)-2-oxo-1-(3-phenylpropyl)pyridine-3-carbonitrile Chemical compound O=C1C(C#N)=C(C=2OC=CC=2)C=CN1CCCC1=CC=CC=C1 YXCDWFNEYWEVPQ-UHFFFAOYSA-N 0.000 description 1
- XWCKVCYYSMGDOK-UHFFFAOYSA-N 4-[1-(3-methylbutyl)-6-oxopyridin-3-yl]benzonitrile Chemical compound C1=CC(=O)N(CCC(C)C)C=C1C1=CC=C(C#N)C=C1 XWCKVCYYSMGDOK-UHFFFAOYSA-N 0.000 description 1
- KGGXBJQRINOVST-UHFFFAOYSA-N 4-[1-[(3,4-difluorophenyl)methyl]-6-oxopyridin-3-yl]benzonitrile Chemical compound C1=C(F)C(F)=CC=C1CN1C(=O)C=CC(C=2C=CC(=CC=2)C#N)=C1 KGGXBJQRINOVST-UHFFFAOYSA-N 0.000 description 1
- WRAXKWAYGNHLEH-UHFFFAOYSA-N 4-[1-[(4-chlorophenyl)methyl]-6-oxopyridin-3-yl]-n,n-dimethylbenzamide Chemical compound C1=CC(C(=O)N(C)C)=CC=C1C1=CN(CC=2C=CC(Cl)=CC=2)C(=O)C=C1 WRAXKWAYGNHLEH-UHFFFAOYSA-N 0.000 description 1
- ALQWYZPNGMXOFL-UHFFFAOYSA-N 4-[1-[(4-methoxyphenyl)methyl]-6-oxopyridin-3-yl]benzonitrile Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C=CC(C=2C=CC(=CC=2)C#N)=C1 ALQWYZPNGMXOFL-UHFFFAOYSA-N 0.000 description 1
- YZUBYYVUESQFDE-UHFFFAOYSA-N 4-[[5-(4-methoxyphenyl)-2-oxopyridin-1-yl]methyl]benzonitrile Chemical compound C1=CC(OC)=CC=C1C1=CN(CC=2C=CC(=CC=2)C#N)C(=O)C=C1 YZUBYYVUESQFDE-UHFFFAOYSA-N 0.000 description 1
- YFTGMMXMLPTTAY-UHFFFAOYSA-N 4-bromo-2-methoxypyridine Chemical compound COC1=CC(Br)=CC=N1 YFTGMMXMLPTTAY-UHFFFAOYSA-N 0.000 description 1
- SCRBSGZBTHKAHU-UHFFFAOYSA-N 4-bromoisoquinoline Chemical compound C1=CC=C2C(Br)=CN=CC2=C1 SCRBSGZBTHKAHU-UHFFFAOYSA-N 0.000 description 1
- HFGHRUCCKVYFKL-UHFFFAOYSA-N 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5h-pyrimido[5,4-b]indole Chemical compound C1=C2NC=3C(OCC)=NC(N4CCNCC4)=NC=3C2=CC=C1C1=CC=NC=C1 HFGHRUCCKVYFKL-UHFFFAOYSA-N 0.000 description 1
- VLWRKVBQUANIGI-UHFFFAOYSA-N 4-fluoro-n-methylaniline Chemical compound CNC1=CC=C(F)C=C1 VLWRKVBQUANIGI-UHFFFAOYSA-N 0.000 description 1
- 150000005751 4-halopyridines Chemical class 0.000 description 1
- MRRFWZIZEDKWCI-UHFFFAOYSA-N 5-(1,3-benzothiazol-2-yl)-1-[(4-chloro-3-fluorophenyl)methyl]pyridin-2-one Chemical compound C1=C(Cl)C(F)=CC(CN2C(C=CC(=C2)C=2SC3=CC=CC=C3N=2)=O)=C1 MRRFWZIZEDKWCI-UHFFFAOYSA-N 0.000 description 1
- CQXSHYFQZBZQOB-UHFFFAOYSA-N 5-(4-chlorophenyl)-1-[[3-(trifluoromethyl)phenyl]methyl]pyridin-2-one Chemical compound FC(F)(F)C1=CC=CC(CN2C(C=CC(=C2)C=2C=CC(Cl)=CC=2)=O)=C1 CQXSHYFQZBZQOB-UHFFFAOYSA-N 0.000 description 1
- PRPAYPBERKUDKO-UHFFFAOYSA-N 5-(chloromethyl)-2-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(CCl)C=N1 PRPAYPBERKUDKO-UHFFFAOYSA-N 0.000 description 1
- WXNXXPCWWCTGMJ-UHFFFAOYSA-N 5-[2-(4-hydroxyphenyl)ethylamino]-2-propylisoquinolin-1-one Chemical compound C1=CC=C2C(=O)N(CCC)C=CC2=C1NCCC1=CC=C(O)C=C1 WXNXXPCWWCTGMJ-UHFFFAOYSA-N 0.000 description 1
- HROSUXHYIBBZHF-UHFFFAOYSA-N 5-[4-(bromomethyl)phenyl]-1-[(4-chlorophenyl)methyl]pyridin-2-one Chemical compound C1=CC(Cl)=CC=C1CN1C(=O)C=CC(C=2C=CC(CBr)=CC=2)=C1 HROSUXHYIBBZHF-UHFFFAOYSA-N 0.000 description 1
- DKKVHXSZAVLHAW-UHFFFAOYSA-N 5-bromo-1-[(4-chlorophenyl)methyl]pyrazin-2-one Chemical compound C1=CC(Cl)=CC=C1CN1C(=O)C=NC(Br)=C1 DKKVHXSZAVLHAW-UHFFFAOYSA-N 0.000 description 1
- RDSIMGKJEYNNLF-UHFFFAOYSA-N 5-bromo-1-benzothiophene Chemical compound BrC1=CC=C2SC=CC2=C1 RDSIMGKJEYNNLF-UHFFFAOYSA-N 0.000 description 1
- ITTXBHQAWOFJAI-UHFFFAOYSA-N 5-bromo-1h-pyrazin-2-one Chemical compound BrC1=CNC(=O)C=N1 ITTXBHQAWOFJAI-UHFFFAOYSA-N 0.000 description 1
- HTBPXLJKMNBQMS-UHFFFAOYSA-N 5-bromo-2-methoxy-4-methylpyridine Chemical compound COC1=CC(C)=C(Br)C=N1 HTBPXLJKMNBQMS-UHFFFAOYSA-N 0.000 description 1
- PJHSMEMFNSINJE-UHFFFAOYSA-N 5-chloroisoquinoline Chemical compound N1=CC=C2C(Cl)=CC=CC2=C1 PJHSMEMFNSINJE-UHFFFAOYSA-N 0.000 description 1
- URWNQEHUDPYHIW-UHFFFAOYSA-N 6-chloro-1-(3-methylbutyl)-3,7-dihydroquinolin-2-one Chemical compound ClC1=CC2=CCC(N(C2=CC1)CCC(C)C)=O URWNQEHUDPYHIW-UHFFFAOYSA-N 0.000 description 1
- LKBKDKVMHWPZDB-UHFFFAOYSA-N 6-methoxypyridin-3-ol Chemical compound COC1=CC=C(O)C=N1 LKBKDKVMHWPZDB-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102000003678 AMPA Receptors Human genes 0.000 description 1
- 108090000078 AMPA Receptors Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 238000007125 Buchwald synthesis reaction Methods 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 101100472050 Caenorhabditis elegans rpl-2 gene Proteins 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000027691 Conduct disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000034353 G alpha subunit Human genes 0.000 description 1
- 108091006099 G alpha subunit Proteins 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 208000004404 Intractable Pain Diseases 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108010008812 Ionotropic Glutamate Receptors Proteins 0.000 description 1
- 102000000079 Kainic Acid Receptors Human genes 0.000 description 1
- 108010069902 Kainic Acid Receptors Proteins 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 description 1
- 102100038352 Metabotropic glutamate receptor 3 Human genes 0.000 description 1
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 description 1
- 102100038300 Metabotropic glutamate receptor 6 Human genes 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 description 1
- YMQHUBJVLUNOFA-UHFFFAOYSA-N O=C(C=C1)N(Cc(ccc(Cl)c2)c2F)C=C1c1ccc2[s]ccc2c1 Chemical compound O=C(C=C1)N(Cc(ccc(Cl)c2)c2F)C=C1c1ccc2[s]ccc2c1 YMQHUBJVLUNOFA-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 108010002724 Pheromone Receptors Proteins 0.000 description 1
- 101001071458 Rattus norvegicus Metabotropic glutamate receptor 2 Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 238000006619 Stille reaction Methods 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 102100038344 Vomeronasal type-1 receptor 2 Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- RPRMOEFOTPSWBO-UHFFFAOYSA-N [2-(methanesulfonamido)phenyl]boronic acid Chemical compound CS(=O)(=O)NC1=CC=CC=C1B(O)O RPRMOEFOTPSWBO-UHFFFAOYSA-N 0.000 description 1
- KCRVWMBFIDPDIF-UHFFFAOYSA-N [4-(3-hydroxypropyl)phenyl]boronic acid Chemical compound OCCCC1=CC=C(B(O)O)C=C1 KCRVWMBFIDPDIF-UHFFFAOYSA-N 0.000 description 1
- RDHSYXFAOVTAEH-UHFFFAOYSA-N [4-(bromomethyl)phenyl]methanol Chemical compound OCC1=CC=C(CBr)C=C1 RDHSYXFAOVTAEH-UHFFFAOYSA-N 0.000 description 1
- YKVMTTIYBSVPEQ-UHFFFAOYSA-N [4-(cyanomethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(CC#N)C=C1 YKVMTTIYBSVPEQ-UHFFFAOYSA-N 0.000 description 1
- PZRPBPMLSSNFOM-UHFFFAOYSA-N [4-(hydroxymethyl)phenyl]boronic acid Chemical compound OCC1=CC=C(B(O)O)C=C1 PZRPBPMLSSNFOM-UHFFFAOYSA-N 0.000 description 1
- MLBHKDLSKWBLCL-UHFFFAOYSA-M [Br-].COC1=CC=CC(C[Mg+])=C1 Chemical compound [Br-].COC1=CC=CC(C[Mg+])=C1 MLBHKDLSKWBLCL-UHFFFAOYSA-M 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000005233 alkylalcohol group Chemical group 0.000 description 1
- 229940125516 allosteric modulator Drugs 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 101150024767 arnT gene Proteins 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- UUWSLBWDFJMSFP-UHFFFAOYSA-N bromomethylcyclohexane Chemical compound BrCC1CCCCC1 UUWSLBWDFJMSFP-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 235000019993 champagne Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003426 co-catalyst Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- JGFBRKRYDCGYKD-UHFFFAOYSA-N dibutyl(oxo)tin Chemical compound CCCC[Sn](=O)CCCC JGFBRKRYDCGYKD-UHFFFAOYSA-N 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 125000006001 difluoroethyl group Chemical group 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- VSAWIUDKFATBRT-UHFFFAOYSA-N ethyl 2-[4-[1-[(4-chlorophenyl)methyl]-6-oxopyridin-3-yl]phenoxy]acetate Chemical compound C1=CC(OCC(=O)OCC)=CC=C1C1=CN(CC=2C=CC(Cl)=CC=2)C(=O)C=C1 VSAWIUDKFATBRT-UHFFFAOYSA-N 0.000 description 1
- GJZUBLBLZXDGTC-UHFFFAOYSA-N ethyl 2-[5-(4-methoxyphenyl)-2-oxopyridin-1-yl]acetate Chemical compound C1=CC(=O)N(CC(=O)OCC)C=C1C1=CC=C(OC)C=C1 GJZUBLBLZXDGTC-UHFFFAOYSA-N 0.000 description 1
- IVBFVOMWNYISSA-UHFFFAOYSA-N ethyl 4-(1-benzyl-6-oxopyridin-3-yl)benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1C1=CN(CC=2C=CC=CC=2)C(=O)C=C1 IVBFVOMWNYISSA-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000006005 fluoroethoxy group Chemical group 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 125000006289 hydroxybenzyl group Chemical group 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- CSNXUYRHPXGSJD-UHFFFAOYSA-N isoquinolin-5-ol Chemical compound N1=CC=C2C(O)=CC=CC2=C1 CSNXUYRHPXGSJD-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 108010038445 metabotropic glutamate receptor 3 Proteins 0.000 description 1
- 108010038450 metabotropic glutamate receptor 6 Proteins 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- JUOWJOXVQJAFRQ-UHFFFAOYSA-N methyl 2-[4-[1-[(4-chloro-2-fluorophenyl)methyl]-6-oxopyridin-3-yl]phenoxy]acetate Chemical compound C1=CC(OCC(=O)OC)=CC=C1C1=CN(CC=2C(=CC(Cl)=CC=2)F)C(=O)C=C1 JUOWJOXVQJAFRQ-UHFFFAOYSA-N 0.000 description 1
- ZHKLSJLRBMODER-UHFFFAOYSA-N methyl 2-[4-[1-[(4-chlorophenyl)methyl]-6-oxopyridin-3-yl]phenyl]acetate Chemical compound C1=CC(CC(=O)OC)=CC=C1C1=CN(CC=2C=CC(Cl)=CC=2)C(=O)C=C1 ZHKLSJLRBMODER-UHFFFAOYSA-N 0.000 description 1
- AAMGWALXPFDUKZ-UHFFFAOYSA-N methyl 3-[3-[1-[(4-chlorophenyl)methyl]-6-oxopyridin-3-yl]phenyl]propanoate Chemical compound COC(=O)CCC1=CC=CC(C2=CN(CC=3C=CC(Cl)=CC=3)C(=O)C=C2)=C1 AAMGWALXPFDUKZ-UHFFFAOYSA-N 0.000 description 1
- XRHZLIHEGGBHTE-UHFFFAOYSA-N methyl 4-[1-[(4-chlorophenyl)methyl]-6-oxopyridin-3-yl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C1=CN(CC=2C=CC(Cl)=CC=2)C(=O)C=C1 XRHZLIHEGGBHTE-UHFFFAOYSA-N 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- IXRNQIKIVWWFBH-UHFFFAOYSA-N n-(1-phenylethenyl)acetamide Chemical compound CC(=O)NC(=C)C1=CC=CC=C1 IXRNQIKIVWWFBH-UHFFFAOYSA-N 0.000 description 1
- MFTZXLSIKVIMSL-UHFFFAOYSA-N n-[3-[1-(3-methylbutyl)-6-oxopyridin-3-yl]phenyl]methanesulfonamide Chemical compound C1=CC(=O)N(CCC(C)C)C=C1C1=CC=CC(NS(C)(=O)=O)=C1 MFTZXLSIKVIMSL-UHFFFAOYSA-N 0.000 description 1
- PXVJZDGRDODTFS-UHFFFAOYSA-N n-[3-[1-[(4-chloro-2-fluorophenyl)methyl]-6-oxopyridin-3-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C2=CN(CC=3C(=CC(Cl)=CC=3)F)C(=O)C=C2)=C1 PXVJZDGRDODTFS-UHFFFAOYSA-N 0.000 description 1
- NRZFRYYTNOCHEI-UHFFFAOYSA-N n-[3-[1-[(4-chlorophenyl)methyl]-6-oxopyridin-3-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(C2=CN(CC=3C=CC(Cl)=CC=3)C(=O)C=C2)=C1 NRZFRYYTNOCHEI-UHFFFAOYSA-N 0.000 description 1
- YRRURTBQNODDSY-UHFFFAOYSA-N n-[3-[4-[1-[(4-chloro-2-fluorophenyl)methyl]-6-oxopyridin-3-yl]phenoxy]propyl]acetamide Chemical compound C1=CC(OCCCNC(=O)C)=CC=C1C1=CN(CC=2C(=CC(Cl)=CC=2)F)C(=O)C=C1 YRRURTBQNODDSY-UHFFFAOYSA-N 0.000 description 1
- RZNGGTWWHUQICV-UHFFFAOYSA-N n-[3-[4-[1-[(4-chloro-2-fluorophenyl)methyl]-6-oxopyridin-3-yl]phenoxy]propyl]methanesulfonamide Chemical compound C1=CC(OCCCNS(=O)(=O)C)=CC=C1C1=CN(CC=2C(=CC(Cl)=CC=2)F)C(=O)C=C1 RZNGGTWWHUQICV-UHFFFAOYSA-N 0.000 description 1
- IULINCBVKHETLO-UHFFFAOYSA-N n-[3-[5-chloro-1-(3-methylbutyl)-6-oxopyridin-3-yl]phenyl]methanesulfonamide Chemical compound C1=C(Cl)C(=O)N(CCC(C)C)C=C1C1=CC=CC(NS(C)(=O)=O)=C1 IULINCBVKHETLO-UHFFFAOYSA-N 0.000 description 1
- QFYRXXCZDKIGNO-UHFFFAOYSA-N n-[3-[5-chloro-1-[(4-chlorophenyl)methyl]-6-oxopyridin-3-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C2=CN(CC=3C=CC(Cl)=CC=3)C(=O)C(Cl)=C2)=C1 QFYRXXCZDKIGNO-UHFFFAOYSA-N 0.000 description 1
- YLELWWFUQVQRTG-UHFFFAOYSA-N n-[5-[1-[(4-chlorophenyl)methyl]-6-oxopyridin-3-yl]-2-methoxyphenyl]methanesulfonamide Chemical compound C1=C(NS(C)(=O)=O)C(OC)=CC=C1C1=CN(CC=2C=CC(Cl)=CC=2)C(=O)C=C1 YLELWWFUQVQRTG-UHFFFAOYSA-N 0.000 description 1
- XKDDVEUGVHVEDP-UHFFFAOYSA-N n-acetyl-n-[2-[4-[1-[(4-chloro-2-fluorophenyl)methyl]-6-oxopyridin-3-yl]phenoxy]ethyl]acetamide Chemical compound C1=CC(OCCN(C(=O)C)C(C)=O)=CC=C1C1=CN(CC=2C(=CC(Cl)=CC=2)F)C(=O)C=C1 XKDDVEUGVHVEDP-UHFFFAOYSA-N 0.000 description 1
- DETQGIUNLFCXQU-UHFFFAOYSA-N n-acetyl-n-[3-[4-[1-[(4-chloro-2-fluorophenyl)methyl]-6-oxopyridin-3-yl]phenoxy]propyl]acetamide Chemical compound C1=CC(OCCCN(C(=O)C)C(C)=O)=CC=C1C1=CN(CC=2C(=CC(Cl)=CC=2)F)C(=O)C=C1 DETQGIUNLFCXQU-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 210000001009 nucleus accumben Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000007122 ortho-metalation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 208000033300 perinatal asphyxia Diseases 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002427 pheromone receptor Substances 0.000 description 1
- 125000002265 phtalazinyl group Chemical group 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000006977 prepulse inhibition Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000001944 prunus armeniaca kernel oil Substances 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- YNRCVVBNEPJYOF-UHFFFAOYSA-N pyridin-2-ylmethanesulfonamide Chemical class NS(=O)(=O)CC1=CC=CC=N1 YNRCVVBNEPJYOF-UHFFFAOYSA-N 0.000 description 1
- WIRTYVGMQVIVDM-UHFFFAOYSA-N pyridine-3-carbonitrile Chemical compound N#CC1=C=NC=C[CH]1 WIRTYVGMQVIVDM-UHFFFAOYSA-N 0.000 description 1
- 125000005494 pyridonyl group Chemical group 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 230000021317 sensory perception Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000024587 synaptic transmission, glutamatergic Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- GPTXCAZYUMDUMN-UHFFFAOYSA-N tert-butyl n-(2-hydroxyethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCO GPTXCAZYUMDUMN-UHFFFAOYSA-N 0.000 description 1
- OWNCKXNSAMVFMH-UHFFFAOYSA-N tert-butyl n-[2-[4-[1-[(4-chloro-2-fluorophenyl)methyl]-6-oxopyridin-3-yl]phenoxy]ethyl]carbamate Chemical compound C1=CC(OCCNC(=O)OC(C)(C)C)=CC=C1C1=CN(CC=2C(=CC(Cl)=CC=2)F)C(=O)C=C1 OWNCKXNSAMVFMH-UHFFFAOYSA-N 0.000 description 1
- ZIANIYJFJBOJPU-UHFFFAOYSA-N tert-butyl n-[[4-[1-[(4-chloro-2-fluorophenyl)methyl]-6-oxopyridin-3-yl]phenyl]methyl]carbamate Chemical compound C1=CC(CNC(=O)OC(C)(C)C)=CC=C1C1=CN(CC=2C(=CC(Cl)=CC=2)F)C(=O)C=C1 ZIANIYJFJBOJPU-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 230000000542 thalamic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 235000019505 tobacco product Nutrition 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000003936 working memory Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/18—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
Definitions
- the present invention relates to novel compounds, in particular novel pyridinone- derivatives that are positive allosteric modulators of metabotropic receptors - subtype 2 ("mGluR2") which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved.
- mGluR2 metabotropic receptors - subtype 2
- the invention is also directed to the pharmaceutical compositions, the processes to prepare such compounds and compositions and the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
- Glutamate is the major amino-acid transmitter in the mammalian central nervous system (CNS). Glutamate plays a major role in numerous physiological functions, such as learning and memory but also sensory perception, development of synaptic plasticity, motor control, respiration, and regulation of cardiovascular function. Furthermore, glutamate is at the centre of several different neurological and psychiatric diseases, where there is an imbalance in glutamatergic neurotransmission.
- Glutamate mediates synaptic neurotransmission through the activation of ionotropic glutamate receptors channels (iGluRs), the NMDA, AMPA and kainate receptors which are responsible for fast excitatory transmission (Nakanishi et al., (1998) Brain Res Brain Res Rev., 26:230-235).
- glutamate activates metabotropic glutamate receptors (mGluRs) which have a more modulatory role that contributes to the fine-tuning of synaptic efficacy.
- the mGluRs are seven-transmembrane G protein-coupled receptors (GPCRs) belonging to family 3 of GPCRs along with the calcium- sensing, GABAb, and pheromone receptors. Glutamate activates the mGluRs through binding to the large extracellular amino- terminal domain of the receptor, herein called the orthosteric binding site. This binding induces a conformational change in the receptor which results in the activation of the G-protein and intracellular signalling pathways.
- GPCRs G protein-coupled receptors
- group I comprising mGluRl and mGluR5; group II comprising mGluR2 and mGluR3; group III comprising mGluR4, mGluR ⁇ , mGluR7, and mGluR8) according to sequence homology, pharmacological profile, and nature of intracellular signalling cascades activated (Schoepp et al. (1999) Neuropharmacology, 38:1431-76).
- mGluR2 subtype is negatively coupled to adenylate cyclase via activation of G ⁇ i-protein, and its activation leads to inhibition of glutamate release in the synapse (Cartmell & Schoepp (2000) J Neurochem 75:889-907).
- mGluR2 receptors are abundant mainly throughout cortex, thalamic regions, accessory olfactory bulb, hippocampus, amygdala, caudate-putamen and nucleus accumbens (Ohishi et al. (1998) Neurosci Res 30:65-82).
- Activating mGluR2 was shown in clinical trials to be efficacious to treat anxiety disorders (Levine et al. (2002) Neuropharmacology 43: 294 ; Holden (2003) Science 300:1866-68; Grillon et al. (2003) Psychopharmacology 168:446-54 ; Kellner et al. (2005) Psychopharmacology 179: 310-15).
- activating mGluR2 in various animal models was shown to be efficacious, thus representing a potential novel therapeutic approach for the treatment of schizophrenia (reviewed in Schoepp & Marek (2002) Curr Drug Targets. 1:215-25), epilepsy (reviewed in Moldrich et al. (2003) Eur J Pharmacol.
- WO2004092135 NPS & Astra Zeneca
- WO04018386 Merck
- WO0156990 Eli Lilly
- phenyl sulfonamid, acetophenone and pyridylmethyl sulfonamide derivatives as mGluR2 positive allosteric modulators.
- none of the specifically disclosed compounds are structurally related to the compounds of the invention. It was demonstrated that such molecules do not activate the receptor by themselves (Johnson MP et al. (2003) J Med Chem. 46:3189-92; Schaffhauser et al. (2003) MoI Pharmacol. 64:798-810).
- Allosteric modulators of mGluR2 have the same effects in anxiety and psychosis models as those obtained with orthosteric agonists. Allosteric modulators of mGluR2 were shown to be active in fear-potentiated startle (Johnson et al. (2003) J Med Chem. 46:3189-92; Johnson et al. (2005) Psychopharmacology 179:271-83), and in stress-induced hyperthermia (Johnson et al. (2005) Psychopharmacology 179:271-83) models of anxiety. Furthermore, such compounds were shown to be active in reversal of ketamine- (Govek et al.
- Positive allosteric modulators enable potentiation of the glutamate response, but they have also been shown to potentiate the response to orthosteric mGluR2 agonists such as
- the invention relates to compounds having metabotropic glutamate receptor 2 modulator activity.
- the present invention provides a compound according to Formula (I),
- R 1 is not hydrogen and is an optionally substituted radical selected from the group of - (C 1 -C(OaIkVl, -(C 2 -C 6 )alkynyl, -(C 2 -C 6 )alkenyl, -(C 3 -C 7 )cycloalkyl, -(C 3 -C 8 )cyclo- alkenyl, -(C 1 -C 6 )alkylhalo, -(Ci-C ⁇ alkylcyano and a radical -V 1 -T 1 -M 1 ;
- -OC(O)NR 10 R 11 , -OR 10 and an optionally substituted radical selected from the group of -(C 1 -C 6 )alkyl, -(C 1 -C 6 )alkylhalo, -(C 2 -C 6 )alkynyl, -(C 2 -C 6 )alkenyl, -(C 3 -C 7 )- cycloalkyl, -(C 3 -C 8 )cycloalkenyl, -(C 1 -C 6 )alkylcyano, -(C 1 -C 6 )alkylaryl, -(C 1 -C 6 )- alkylheteroaryl, aryl, heteroaryl and a radical -V 2 -T 2 -M 2 ;
- R 2 and R 3 or (R 4 and R 5 ) taken together may form an optionally substituted 3 to 10 membered ring selected from the group of aryl, heteroaryl, heterocyclic and cycloalkyl;
- R 7 , R 8 and R 9 may be taken together to form an optionally substituted 3 to 10 membered non-aromatic heterocyclic ring or an optionally substituted 5 to 10 membered aromatic heterocyclic ring;
- R 10 , R 11 , R 12 and R 13 may be taken together to form an optionally substituted 3 to 10 membered non-aromatic heterocyclic ring or an optionally substituted 5 to 10 membered aromatic heterocyclic ring;
- R 14 , R 15 , R 16 and R 17 may be taken together to form an optionally substituted 3 to 10 membered non-aromatic heterocyclic ring or an optionally substituted 5 to 10 membered aromatic heterocyclic ring.
- the invention concerns a compound according to Formula (II)
- Z 1 , Z 2 , Z 3 and Z 4 are each independently, selected from the group of a covalent bond, C, S, N and O, representing a 5 or 6 membered heteroaryl or aryl ring which may further be substituted by 1 to 4 radicals A n ;
- a n radicals are each independently selected from the group of hydrogen, halogen, -CN, -OH, -NO2, -CF 3 , -SH, -NH2, and an optionally substituted radical selected from the group of -(C 1 -C 6 )alkyl, -(C 1 -C 6 )alkylhalo, -(C 2 -C 6 )alkynyl, -(C 2 -C 6 )alkenyl, -(C 3 -C 7 )- cycloalkyl, -(C 1 -C 6 )alkylcyano, -O-(C 1 -C 6 )alkyl, -O-(C
- R 18 , R 19 , R 20 and R 21 are each independently hydrogen or an optionally substituted radical selected from the group of -(C 1 -C 6 )alkylhalo, -(C 1 -C 6 )alkyl, -(C 1 -C 6 )alkylcyano, -(C 2 -C 6 )alkynyl, -(C 2 -C 6 )alkenyl, -(C 3 -C 7 )cycloalkyl, -(C 4 -Ci 0 )alkylcycloalkyl, heteroaryl, -(C 1 -C 6 )alkylheteroaryl, aryl, -(C 1 -C 6 )alkylaryl, -(C 2 -C 6 )alkynyl-(C 3 -C 7 )- cycloalkyl, -(C 2 -C 6 )alkynyl-heteroaryl, -(
- R 18 , R 19 , R 20 and R 21 may be taken together to form an optionally substituted 3 to 10 membered non-aromatic heterocyclic ring or an optionally substituted 5 to 10 membered aromatic heterocyclic ring.
- Preferred structures according to Formula (II) are indicated in Figure A below.
- Z 5 , Z 6 , Z 7 , Z 8 and Z 9 are each independently selected from the group of a covalent bond, C, S, N and O, representing a 5 or 6 membered heteroaryl or aryl ring which may optionally be substituted by 1 to 5 radicals B m ;
- B m radicals are each independently selected from the group of hydrogen, halogen, -CN, -OH, -NO2, -CF 3 , -SH, -NH2, and an optionally substituted radical selected from the group of -(C 1 -C 6 )alkyl, -(C 1 -C 6 )alkylhalo, -(C 2 -C 6 )alkynyl, -(C 2 -C 6 )alkenyl, -(C 3 -C 7 )- cycloalkyl, -(C 1 -C 6 )alkylcyano, -O-(C 1 -C 6 )alkyl, -O-(C 1 -C 6 )alkylhalo, -O-(C 1 -C 6 )- alkylcyano, -O-(C 3 -C 6 )alkynyl, -O-(C 3 -C 7 )cycloalkyl, -
- R 22 , R 23 , R 24 and R 25 are each independently selected from hydrogen or an optionally substituted radical selected from the group of -(C 1 -C 6 )alkylhalo, -(C 1 -C 6 )alkyl, -(C 1 - C 6 )alkylcyano, -(C 2 -C 6 )alkynyl, -(C 2 -C 6 )alkenyl, -(C 3 -C 7 )cycloalkyl, -(C 4 -C 10 )- alkylcycloalkyl, heteroaryl, -(C 1 -C 6 )alkylheteroaryl, aryl, -(C 1 -C 6 )alkylaryl, -(C 2 -C 6 )- alkynyl-(C 3 -C 7 )cycloalkyl, -(C 2 -C 6 )alkynyl-heteroaryl, -(
- R 22 , R 23 , R 24 and R 25 may be taken together to form an optionally substituted 3 to 10 membered non-aromatic heterocyclic ring or an optionally substituted 5 to 10 membered aromatic heterocyclic ring.
- the invention provides a compound of Formula (II-b),
- R 2 is selected from the group of hydrogen, halogen, -CN, -CF 3 , and an optionally substituted radical selected from the group of -(C 1 -C 6 )alkyl, -(C 2 -C 6 )alkenyl, -(C 2 -C 6 )- alkynyl, -(C 1 -C 6 )alkylhalo, -(C 3 -C 7 )cycloalkyl, -(C 1 -C 6 )alkylcyano, -O-(C 1 -C 6 )alkyl, -O-(C 1 -C 6 )alkylhalo, -O-(C 1 -C 6 )alkylcyano, -O-(C 3 -C 6 )alkynyl, -O-(C 3 -C 7 )cycloalkyl, -O-(C 2 -C 6 )alkyl-OR 26 , -O-
- R 26 and R 27 are each independently hydrogen or an optionally substituted radical selected from the group of -(C 1 -C 6 )alkylhalo, -(C 1 -C 6 )alkylcyano, -(C 0 -C 6 )alkyl, -(C 2 - C 6 )alkynyl, -(C 2 -C 6 )alkenyl, -(C 3 -C 7 )cycloalkyl, -(C 4 -C 10 )alkylcycloalkyl, heteroaryl, -(C 1 -C 6 )alkylheteroaryl, aryl, -(C 1 -C 6 )alkylaryl, -(C 2 -C 6 )alkynyl-(C 3 -C 7 )cycloalkyl, -(C 2 -C 6 )alkynyl-heteroaryl, -(C 2 -C 6 )alkyn
- the invention provides a compound according to any one of Formulas (II-cl), (II-c2) and (II-c3),
- Z 5 ,Z 6 ,Z 7 , Z 8 and Z 9 are selected from C or N, provided that at least 2 carbons are present and that a free position may further be substituted by 1 to 5 radicals B m ;
- R 2 , R 3 , A 1 , A 2 , A 3 and A 4 are each independently selected from the group of hydrogen, halogen, -CN, -CF 3 , -OCF 3 , and an optionally substituted radical selected from the group of -(C 1 -C 6 )alkyl, -(C 2 -C 6 )alkynyl, -(C 2 -C 6 )alkenyl, -(C 3 -C 7 )cycloalkyl, -(C 3 -C 8 )- cycloalkenyl, -(C 1 -C 6 )alkylhalo, -(C 0 -C 3 )alkyl-O-(C 1 -C 6 )alkyl, -(C 0 -C 3 )alkyl-O-(C 2 - C 6 )alkynyl, -(C 0 -C 3 )alkyl-O-(C 2 -C
- the invention provides a compound according to Formula (III),
- Z 1 , Z 2 , Z 3 and Z 4 are each independently, selected from the group of a covalent bond, C, S, N and O, representing a 5 or 6 membered heteroaryl or aryl ring which may further be substituted by 1 to 4 radicals A n ;
- a n radicals are each independently selected from the group of hydrogen, halogen, -CN, -OH, -NO 2 , -CF 3 , -SH, -NH 2 , and an optionally substituted radical selected from the group of -(C 1 -C 6 )alkyl, -(C 1 -C 6 )alkylhalo, -(C 2 -C 6 )alkynyl, -(C 2 -C 6 )alkenyl, -(C 3 -C 7 )- cycloalkyl, -(C 1 -C 6 )alkylcyano, -O-(C 1 -C 6 )alkyl, -
- R 18 , R 19 , R 20 and R 21 are each independently hydrogen or an optionally substituted radical selected from the group of -(C 1 -C 6 )alkylhalo, -(C 1 -C 6 )alkyl, -(C 1 -C 6 )alkylcyano, -(C 2 -C 6 )alkynyl, -(C 2 -C 6 )alkenyl, -(C 3 -C 7 )cycloalkyl, -(C 4 -C 10 )alkylcycloalkyl, heteroaryl, -(C 1 -C 6 )alkylheteroaryl, aryl, -(C 1 -C 6 )alkylaryl, -(C 2 -C 6 )alkynyl-(C 3 -C 7 )- cycloalkyl, -(C 2 -C 6 )alkynyl-heteroaryl, -(C 2
- Figure B In a preferred aspect of Formula (III) the invention provides a compound of Formula (III-a),
- Z 5 , Z 6 , Z 7 , Z 8 and Z 9 are each independently selected from the group of a covalent bond, C, S, N and O, representing a 5 or 6 membered heteroaryl or aryl ring which may optionally be substituted by 1 to 5 radicals B m ;
- B m radicals are each independently selected from the group of hydrogen, halogen, -CN, -OH, -NO2, -CF 3 , -SH, -NH2, and an optionally substituted radical selected from the group of -(C 1 -C 6 )alkyl, -(C 1 -C 6 )alkylhalo, -(C 2 -C 6 )alkynyl, -(C 2 -C 6 )alkenyl, -(C 3 -C 7 )- cycloalkyl, -(C 1 -C 6 )alkylcyano, -O-(C 1 -C 6 )alkyl, -O-(C 1 -C 6 )alkylhalo, -O-(C 1 -C 6 )- alkylcyano, -O-(C 3 -C 6 )alkynyl, -O-(C 3 -C 7 )cycloalkyl, -
- R 5 R 5 R and R are each independently selected from hydrogen or an optionally substituted radical selected from the group of -(C 1 -C 6 )alkylhalo, -(C 1 -C 6 )alkyl, -(C 1 - C 6 )alkylcyano, -(C 2 -C 6 )alkynyl, -(C 2 -C 6 )alkenyl, -(C 3 -C 7 )cycloalkyl, -(C 4 -C 10 )- alkylcycloalkyl, heteroaryl, -(C 1 -C 6 )alkylheteroaryl, aryl, -(C 1 -C 6 )alkylaryl, -(C 2 -C 6 )- alkynyl-(C 3 -C 7 )cycloalkyl, -(C 2 -C 6 )alkynyl-heteroaryl, -(C 2 -C 6
- the invention provides a compound according to Formula (III-a),
- R 26 and R 27 are each independently hydrogen or an optionally substituted radical selected from the group of -(C 1 -C 6 )alkylhalo, -(C 1 -C 6 )alkylcyano, -(C 0 -C 6 )alkyl, -(C 2 - C 6 )alkynyl, -(C 2 -C 6 )alkenyl, -(C 3 -C 7 )cycloalkyl, -(C 4 -C 10 )alkylcycloalkyl, heteroaryl, -(C 1 -C 6 )alkylheteroaryl, aryl, -(C 1 -C 6 )alkylaryl, -(C 2 -C 6 )alkynyl-(C 3 -C 7 )cycloalkyl, -(C 2 -C 6 )alkynyl-heteroaryl, -(C 2 -C 6 )alkyn
- R 26 and R 27 may be taken together to form an optionally substituted 3 to 10 membered non-aromatic heterocyclic ring or an optionally substituted 5 to 10 membered aromatic heterocyclic ring.
- the invention provides a compound of Formula (III-c),
- the invention provides a compound according to any one of (III-cl), (III-c2) or (III-c3),
- Z 5 , Z 6 , Z 7 , Z 8 and Z 9 are selected from C or N, provided that at least 2 carbons are present and that a free position may further be substituted by 1 to 5 radicals B m ;
- R 4 , R 5 , A 1 , A 2 , A 3 and A 4 are each independently selected from the group of hydrogen, halogen, -CN, -CF 3 , -OCF 3 , and an optionally substituted radical selected from the group of -(C 1 -C 6 )alkyl, -(C 2 -C 6 )alkynyl, -(C 2 -C 6 )alkenyl, -(C 3 -C 7 )cycloalkyl, -(C 3 -C 8 )- cycloalkenyl, -(C 1 -C 6 )alkylhalo, -(C 0 -C 3 )alkyl-O-(C 1 -C 6 )alkyl, -(C 0 -C 3 )alkyl-O-(C 2 - C 6 )alkynyl, -(C 0 -C 3 )alkyl-O-(C 2 -C
- the invention provides a compound according to Formula (IV)
- R 2 , R 3 and R 5 are each independently selected from the group of hydrogen, halogen, -CN, -OH, -NO 2 , -CF 3 , -SH, -NH 2 , and an optionally substituted radical selected from the group of -(C 1 -C 6 )alkyl, -(C 1 -C 6 )alkylhalo, -(C 2 -C 6 )alkynyl, -(C 2 -C 6 )alkenyl, -(C 3 - C 7 )cycloalkyl, -(C 1 -C 6 )alkylcyano, -O-(C 1 -C 6 )alkyl, -O-(C 1 -C 6 )alkylhalo, -O-(C 1 -C 6 )- alkylcyano, -O-(C 3 -C 6 )alkynyl, -O-(C 3 -C 7 )cyclo
- R 18 , R 19 , R 20 and R 21 are each independently selected from hydrogen and an optionally substituted radical selected from the group of -(C 1 -C 6 )alkylhalo, -(C 1 -C 6 )alkyl, -(C 1 - C 6 )alkylcyano, -(C 2 -C 6 )alkynyl, -(C 2 -C 6 )alkenyl, -(C 3 -C 7 )cycloalkyl, -(C 4 -C 10 )- alkylcycloalkyl, heteroaryl, -(C 1 -C 6 )alkylheteroaryl, aryl, -(C 1 -C 6 )alkylaryl, -(C 2 -C 6 )- alkynyl-(C 3 -C 7 )cycloalkyl, -(C 2 -C 6 )alkynyl-heteroaryl, -(
- R 18 , R 19 , R 20 and R 21 may be taken together to form an optionally substituted 3 to 10 membered non-aromatic heterocyclic ring or an optionally substituted 5 to 10 membered aromatic heterocyclic ring.
- the invention provides a compound of Formula (V)
- R 2 , R 4 and R 5 are each independently selected from the group of hydrogen, halogen, -CN, -OH, -NO 2 , -CF 3 , -SH, -NH 2 , and an optionally substituted radical selected from the group of -(C 1 -C 6 )alkyl, -(C 1 -C 6 )alkylhalo, -(C 2 -C 6 )alkynyl, -(C 2 -C 6 )alkenyl, -(C 3 - C 7 )cycloalkyl, -(C 1 -C 6 )alkylcyano, -O-(C 1 -C 6 )alkyl, -O-(C 1 -C 6 )alkylhalo, -O-(C 1 -C 6 )- alkylcyano, -O-(C 3 -C 6 )alkynyl, -O-(C 3 -C 7 )cyclo
- R 18 , R 19 , R 20 and R 21 are each independently selected from hydrogen and an optionally substituted radical selected from the group of -(C 1 -C 6 )alkylhalo, -(C 1 -C 6 )alkyl, -(C 1 - C 6 )alkylcyano, -(C 2 -C 6 )alkynyl, -(C 2 -C 6 )alkenyl, -(C 3 -C 7 )cycloalkyl, -(C 4 -C 10 )- alkylcycloalkyl, heteroaryl, -(C 1 -C 6 )alkylheteroaryl, aryl, -(C 1 -C 6 )alkylaryl, -(C 2 -C 6 )- alkynyl-(C 3 -C 7 )cycloalkyl, -(C 2 -C 6 )alkynyl-heteroaryl, -(
- R 18 , R 19 , R 20 and R 21 may be taken together to form an optionally substituted 3 to 10 membered non-aromatic heterocyclic ring or an optionally substituted 5 to 10 membered aromatic heterocyclic ring.
- the invention provides a compound according to Formula (V-a),
- R 2 , R 4 and R 5 are each independently selected from the group of hydrogen, halogen, -CN, -OH, -NO 2 , -CF 3 , -SH, -NH 2 , and an optionally substituted radical selected from the group of -(C 1 -C 6 )alkyl, -(C 1 -C 6 )alkylhalo, -(C 2 -C 6 )alkynyl, -(C 2 -C 6 )alkenyl, -(C 3 - C 7 )cycloalkyl, -(C 1 -C 6 )alkylcyano, -O-(C 1 -C 6 )alkyl, -O-(C 1 -C 6 )alkylhalo, -O-(C 1 -C 6 )- alkylcyano, -O-(C 3 -C 6 )alkynyl, -O-(C 3 -C 7 )cyclo
- the invention provides a compound according to Formula (V-a), wherein :
- the invention provides a compound of Formula (V-b)
- R 7 is a radical selected from the group of hydrogen, -(C 1 -C 6 )alkyl, -(C 1 -C 6 )alkylhalo, -(C 2 -C 6 )alkynyl, -(C 2 -C 6 )alkenyl, -(C 3 -C 7 )cycloalkyl or -(C 1 -C 6 )alkylcyano; and
- Mi and M 2 are each independently hydrogen or an optionally substituted radical selected from the group of aryl, heteroaryl and (C 3 -C 7 )cycloalkyl.
- the invention provides a compound according to Formula (V-b) wherein :
- Vi is -(C 1 -C 6 )alkyl, optionally substituted by one or more -OCH 3 , -OCF 3 , -CF 3 , fluoro or cyano radicals ;
- Mi and M 2 are each independently an optionally substituted radical selected from hydrogen, aryl, thienyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, benzoimidazolyl, benzooxazolyl, benzothiazolyl, thionaphtyl, indolyl, pyrimidinyl, quinolyl, cyclohexyl and cyclopentyl.
- the invention relates to compounds according to Formulla (I), a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof and an JV-oxide form thereof, wherein :
- R 1 is an optionally substituted radical selected from the group of -(C 1 -C 6 )alkyl, -(Ci- C 6 )alkylhalo and a radical -Vi-Ti-Mi;
- R 2 and R 3 or (R 4 and R 5 ) taken together may form an aryl optionally substituted with n radicals A n equal to -V 2 -M 2 ;
- M 1 and M 2 are each independently selected from the group of hydrogen, an optionally substituted -(C 1 -C 6 )alkyl-radical and an optionally substituted 3 to 10 membered ring selected from the group of (C 1-6 )cycloalkyl ; aryl, preferably phenyl or naphthyl ; heteroaryl and heterocyclic, preferably pyridinyl, indolyl, , imidazolyl, oxadiazolyl, isoxazolyl, furyl, thienyl, thiazolyl, benzothiazolyl, pyridinyl, pyrimidinyl, indolyl, quinolinyl, quinoxalinyl, benzoxazolyl, benzodioxolyl, benzotetrahydrofuryl and benzothienyl ; wherein the optional substitution on any of the aforementioned rings is selected from the group of (C 1 -C 6 )alkyl
- R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 are each independently hydrogen or an optionally substituted -(C 1 -C 6 )alkyl-radical ;
- a n is hydrogen or halo ; and n is an integer equal to 0 or 1.
- Particular preferred compounds of the invention are compounds as mentioned in the following list (List of Particular Preferred Compounds), as well as a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof and an JV-oxide form thereof.
- (C 1 -C 6 ) means a carbon radical having 1, 2, 3, 4, 5 or 6 carbon atoms.
- (C 0 -C 6 ) means a carbon radical having 0, 1, 2, 3, 4, 5 or 6 carbon atoms.
- C means a carbon atom
- N means a nitrogen atom
- S means a sulphur atom.
- a subscript is the integer 0 (zero) the radical to which the subscript refers, indicates that the radical is absent, i.e. there is a direct bond between the radicals.
- alkyl includes both straight and branched chain alkyl radicals and may be methyl, ethyl, n-propyl, i-propyl, n-butyl, i- butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, t-pentyl, neo-pentyl, n-hexyl or i-hexyl, t- hexyl.
- (C 0 -C 3 )alkyl refers to an alkyl radical having 0, 1, 2 or 3 carbon atoms, and may be methyl, ethyl, n-propyl and i-propyl.
- cycloalkyl refers to an optionally substituted carbocycle containing no heteroatoms, including mono-, bi-, and tricyclic saturated carbocycles, as well as fused ring systems.
- fused ring systems can include one ring that is partially or fully unsaturated such as a benzene ring to form fused ring systems such as benzo- iused carbocycles.
- Cycloalkyl includes such fused ring systems as spirofused ring systems.
- cycloalkyl examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, decahydronaphthalene, adamantane, indanyl, fluorenyl, 1,2,3,4-tetrahydronaphthalene and the like.
- (C 3 -C 7 )cycloalkyl may be cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
- alkenyl includes both straight and branched chain alkenyl radicals.
- (C 2 -C 6 )alkenyl refers to an alkenyl radical having 2 to 6 carbon atoms and one or two double bonds, and may be, but is not limited to vinyl, allyl, propenyl, i-propenyl, butenyl, i-butenyl, crotyl, pentenyl, i- pentenyl and hexenyl.
- alkynyl includes both straight and branched chain alkynyl radicals.
- aryl refers to an optionally substituted monocyclic or bicyclic hydrocarbon ring system containing at least one unsaturated aromatic ring.
- aryl examples and suitable values of the term “aryl” are phenyl, naphtyl, 1,2,3,4-tetrahydronaphthyl, indyl , indenyl and the like.
- heteroaryl refers to an optionally substituted monocyclic or bicyclic unsaturated, aromatic ring system containing at least one heteroatom selected independently from N, O or S.
- heteroaryl may be, but are not limited to thiophene, thienyl, pyridyl, thiazolyl, isothiazolyl, furyl, pyrrolyl, triazolyl, imidazolyl, oxadiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolonyl, oxazolonyl, thiazolonyl, tetrazolyl and thiadiazolyl, benzoimidazolyl, benzooxazolyl, benzothiazolyl, tetrahydrotriazolopyridyl, tetrahydrotriazolopyrimidinyl, benzofuryl, thionaphtyl, indolyl, isoindolyl, pyridonyl, pyridazinyl, pyrazinyl, pyrimidinyl, quinolyl,
- alkylaryl refers respectively to a substituent that is attached via the alkyl radical to an aryl, heteroaryl or cycloalkyl radical, respectively.
- (C 1 - C 6 )alkylaryl includes aryl-Ci-Ce-alkyl radicals such as benzyl, 1-phenylethyl, 2- phenylethyl, 1-phenylpropyl, 2-phenylpropyl, 3-phenylpropyl, 1-naphtylmethy, 2- naphtylmethyl, or the like.
- (C 1 -C 6 )alkyheteroaryl includes heteroaryl-Ci- C 3 -alkyl radicals, wherein examples of heteroaryl are the same as those illustrated in the above definition, such as 2-furylmethyl, 3-furylmethyl, 2-thienylmethyl, 3- thienylmethyl, 1-imidazolylmethyl, 2-imidazolylmethyl, 2-thiazolyhnethyl, 2- pyridylmethyl, 3-pyridylmethyl, 1-quinolylmethyl, or the like.
- heterocycle refers to an optionally substituted, monocyclic or bicyclic saturated, partially saturated or unsaturated ring system containing at least one heteroatom selected independently from N, O and S.
- a 5- or 6-membered ring containing one or more atoms independently selected from C, N, O and S includes aromatic and heteroaromatic rings as well as carbocyclic and heterocyclic rings which may be saturated or unsaturated.
- Such rings may be, but are not limited to, furyl, isoxazolyl, isothiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, thiazolyl, thienyl, imidazolyl, imidazolidinyl, imidazolinyl, triazolyl, morpholinyl, piperazinyl, piperidyl, piperidonyl, pyrazolidinyl, pyrazolinyl, pyrrolidinyl, pyrrolinyl, tetrahydropyranyl, thiomorpholinyl, phenyl, cyclohexyl, cyclopentyl, cyclohexenyl, and the like.
- a 3- to 10-membered ring containing one or more atoms independently selected from C, N, O and S includes aromatic and heteroaromatic rings as well as carbocyclic and heterocyclic rings which may be saturated or unsaturated.
- rings may be, but are not limited to imidazolidinyl, imidazolinyl, morpholinyl, piperazinyl, piperidyl, piperidonyl, pyrazolidinyl, pyrazolinyl, pyrrolidinyl, pyrrolinyl, tetrahydropyranyl, thiomorpholinyl, tetrahydrothiopyranyl, furyl, pyrrolyl, isoxazolyl, isothiazolyl, oxazolyl, oxazolidinonyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, thiazolyl, thienyl, imidazolyl, triazolyl, phenyl, cyclopropyl, aziridinyl, cyclobutyl, azetidinyl, cyclopent
- alkylhalo means an alkyl radical as defined above, substituted with one or more halo radicals.
- (C 1 - C 6 )alkylhalo may include, but is not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl and difluoroethyl.
- the term "O-Ci-Ce-alkylhalo” may include, but is not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy and fluoroethoxy.
- alkylcyano means an alkyl radical as defined above, substituted with one or more cyano. (This paragraph will be cleaned up tomorrow)
- optionally substituted refers to radicals further bearing one or more substituents which are preferably selected from the group of (C 1 -C 6 )alkyl; (C 1 -C 6 )alkyloxy; hydroxy(C 1 -C 6 )alkyloxy; (C 1 -C 6 )alkyloxy(C 1 - C 6 )alkyl; (C 1 -C 6 )alkyloxy(C 1 -C 6 )alkyloxy; (C 1 -C 6 )alkyloxycarbonyl; (C 1 -C 6 )alkyloxy- carbonyl(C 1 -C 6 )alkyl; (C 1 -C 6 )alkyloxycarbonyloxy; (C 1 -C 6 )alkyloxycarbonyloxy; (C 1 -C 6 )alkyloxy
- solvate refers to a complex of variable stoichiometry formed by a solute (e.g. a compound of Formula (I)) and a solvent.
- the solvent is a pharmaceutically acceptable solvent as preferably water ; such solvent may not interfere with the biological activity of the solute.
- positive allosteric modulator of mGluR2 or “allosteric modulator of mGluR2” refers also to a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof and an N-oxide form thereof.
- Positive allosteric modulators of mGluR2 described herein, and the pharmaceutically acceptable salts, solvates and hydrates thereof can be used in pharmaceutical preparations in combination with a pharmaceutically acceptable carrier or diluent.
- Suitable pharmaceutically acceptable carriers include inert solid fillers or diluents and sterile aqueous or organic solutions.
- the positive allosteric modulators of mGluR2 will be present in such pharmaceutical compositions in amounts sufficient to provide the desired dosage amount in the range described herein. Techniques for Formulation and administration of the compounds of the instant invention can be found in Remington: the Science and Practice of Pharmacy, 19 th edition, Mack Publishing Co., Easton, PA (1995).
- the amount of positive allosteric modulators of mGluR2, administered to the subject will depend on the type and severity of the disease or condition and on the characteristics of the subject, such as general health, age, sex, body weight and tolerance to drugs. The skilled artisan will be able to determine appropriate dosages depending on these and other factors. Effective dosages for commonly used CNS drugs are well known to the skilled person.
- the total daily dose usually ranges from about 0.05 - 2000 mg.
- the present invention relates to pharmaceutical compositions which provide from about 0.01 to 1000 mg of the active ingredient per unit dose.
- the compositions may be administered by any suitable route.
- parenterally in the form of solutions for injection parenterally in the form of solutions for injection, topically in the form of onguents or lotions, ocularly in the form of eye-drops, rectally in the form of suppositories, intranasally or transcutaneously in the form of delivery system like patches.
- the positive allosteric modulators of mGluR2 thereof can be combined with a suitable solid or liquid carrier or diluent to form capsules, tablets, pills, powders, syrups, solutions, suspensions and the like.
- the tablets, pills, capsules, and the like contain from about 0.01 to about 99 weight percent of the active ingredient and a binder such as gum tragacanth, acacias, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid, a lubricant such as magnesium stearate; and a sweetening agent such as sucrose lactose or saccharin.
- a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.
- a liquid carrier such as a fatty oil.
- Various other materials may be present as coatings or to modify the physical form of the dosage unit.
- tablets may be coated with shellac, sugar or both.
- a syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor.
- the disclosed positive allosteric modulators of mGluR2 can be combined with sterile aqueous or organic media to form injectable solutions or suspensions.
- solutions in sesame or peanut oil, aqueous propylene glycol and the like can be used, as well as aqueous solutions of water-soluble pharmaceutically-acceptable salts of the compounds.
- Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
- the compounds may also be formulated as a depot preparation.
- Such long acting formulations may be administered by implantation, for example, subcutaneously or intramuscularly or by intramuscular injection.
- implantation for example, subcutaneously or intramuscularly or by intramuscular injection.
- sparingly soluble derivatives for example, as sparingly soluble salts.
- Preferably disclosed positive allosteric modulators of mGluR2 or pharmaceutical formulations containing these compounds are in unit dosage form for administration to a mammal.
- the unit dosage form can be any unit dosage form known in the art including, for example, a capsule, an IV bag, a tablet, or a vial.
- the quantity of active ingredient in a unit dose of composition is an effective amount and may be varied according to the particular treatment involved. It may be appreciated that it may be necessary to make routine variations to the dosage depending on the age and condition of the patient.
- the dosage will also depend on the route of administration which may be by a variety of routes including oral, aerosol, rectal, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal and intranasal.
- the compounds provided in this invention are positive allosteric modulators of metabotropic receptors, in particular they are positive allosteric modulators of mGluR2.
- the compounds of the present invention do not appear to bind to the glutamate recognition site, the orthosteric ligand site, but instead to an allosteric site within the seven transmembrane region of the receptor.
- the compounds of this invention increase the mGluR2 response.
- the compounds provided in this invention are expected to have their effect at mGluR2 by virtue of their ability to increase the response of such receptors to glutamate or mGluR2 agonists, enhancing the response of the receptor.
- the present invention relates to a compound for use as a medicine, as well as to the use of a compound according to the invention or a pharmaceutical composition according to the invention for the manufacture of a medicament for treating or preventing a condition in a mammal, including a human, the treatment or prevention of which is affected or facilitated by the neuromodulatory effect of mGluR2 allosteric modulators, in particular positive mGluR2 allosteric modulators.
- the present invention relates to the use of a compound according to the invention or a pharmaceutical composition according to the invention for the manufacture of a medicament for treating, or preventing, ameliorating, controlling or reducing the risk of various neurological and psychiatric disorders associated with glutamate dysfunction in a mammal, including a human, the treatment or prevention of which is affected or facilitated by the neuromodulatory effect of mGluR2 positive allosteric modulators.
- the invention is said to relate to the use of a compound or composition according to the invention for the manufacture of a medicament for e.g. the treatment of a mammal, it is understood that such use is to be interpreted in certain jurisdictions as a method of e.g. treatment of a mammal, comprising administering to a mammal in need of such e.g. a treatment, an effective amount of a compound or composition according to the invention.
- the neurological and psychiatric disorders associated with glutamate dysfunction include one or more of the following conditions or diseases: acute neurological and psychiatric disorders such as cerebral deficits subsequent to cardiac bypass surgery and grafting, stroke, cerebral ischemia, spinal cord trauma, head trauma, perinatal hypoxia, cardiac arrest, hypoglycemic neuronal damage, dementia (including AIDS-induced dementia), Alzheimer's disease, Huntington's Chorea, amyotrophic lateral sclerosis, ocular damage, retinopathy, cognitive disorders, idiopathic and drug- induced Parkinson's disease, muscular spasms and disorders associated with muscular spasticity including tremors, epilepsy, convulsions, migraine (including migraine headache), urinary incontinence, substance tolerance, substance withdrawal (including substances such as opiates, nicotine, tobacco products, alcohol, benzodiazepines, cocaine, sedatives, hypnotics, etc.), psychosis, schizophrenia, anxiety (including generalized anxiety disorder, panic disorder, and obsessive
- condition or disease is a central nervous system disorder selected from the group of anxiety disorders, psychotic disorders, personality disorders, substance- related disorders, eating disorders, mood disorders, migraine, epilepsy or convulsive disorders, childhood disorders, cognitive disorders, neurodegeneration, neurotoxicity and ischemia.
- the central nervous system disorder is an anxiety disorder, selected from the group of agoraphobia, generalized anxiety disorder (GAD), obsessive-compulsive disorder (OCD), panic disorder, posttraumatic stress disorder (PTSD), social phobia and other phobias.
- GAD generalized anxiety disorder
- OCD obsessive-compulsive disorder
- PTSD posttraumatic stress disorder
- social phobia other phobias.
- the central nervous system disorder is a psychotic disorder selected from the group of schizophrenia, delusional disorder, schizoaffective disorder, schizophreniform disorder and substance-induced psychotic disorder
- the central nervous system disorder is a personality disorder selected from the group of obsessive-compulsive personality disorder and schizoid, schizotypal disorder.
- the central nervous system disorder is a substance-related disorder selected from the group of alcohol abuse, alcohol dependence, alcohol withdrawal, alcohol withdrawal delirium, alcohol-induced psychotic disorder, amphetamine dependence, amphetamine withdrawal, cocaine dependence, cocaine withdrawal, nicotine dependence, nicotine withdrawal, opioid dependence and opioid withdrawal.
- the central nervous system disorder is an eating disorder selected from the group of anorexia nervosa and bulimia nervosa.
- the central nervous system disorder is a mood disorder selected from the group of bipolar disorders (I & II), cyclothymic disorder, depression, dysthymic disorder, major depressive disorder and substance-induced mood disorder.
- bipolar disorders I & II
- cyclothymic disorder depression
- dysthymic disorder major depressive disorder
- substance-induced mood disorder substance-induced mood disorder
- the central nervous system disorder is migraine.
- the central nervous system disorder is epilepsy or a convulsive disorder selected from the group of generalized nonconvulsive epilepsy, generalized convulsive epilepsy, petit mal status epilepticus, grand mal status epilepticus, partial epilepsy with or without impairment of consciousness, infantile spasms, epilepsy partialis continua, and other forms of epilepsy.
- the central nervous system disorder is attention-deficit/hyperactivity disorder.
- the central nervous system disorder is a cognitive disorder selected from the group of delirium, substance-induced persisting delirium, dementia, dementia due to HIV disease, dementia due to Huntington's disease, dementia due to Parkinson's disease, dementia of the Alzheimer's type, substance-induced persisting dementia and mild cognitive impairment.
- DSM-IV Diagnostic & Statistical Manual of Mental Disorders
- DSM-IV Diagnostic & Statistical Manual of Mental Disorders
- the person skilled in the art will recognize that alternative nomenclatures, nosologies, and classification systems for neurological and psychiatric disorders described herein exist, and that these evolve with medical and scientific progresses. Because such positive allosteric modulators of mGluR2, including compounds of Formula (I), enhance the response of mGluR2 to glutamate, it is an advantage that the present methods utilize endogenous glutamate.
- positive allosteric modulators of mGluR2, including compounds of Formula (I) enhance the response of mGluR2 to agonists
- the present invention extends to the treatment of neurological and psychiatric disorders associated with glutamate dysfunction by administering an effective amount of a positive allosteric modulator of mGluR2, including compounds of Formula (I), in combination with an mGluR2 agonist.
- the compounds of the present invention may be utilized in combination with one or more other drugs in the treatment, prevention, control, amelioration, or reduction of risk of diseases or conditions for which compounds of Formula (I) or the other drugs may have utility, where the combination of the drugs together are safer or more effective than either drug alone.
- the compounds according to the invention in particular the compounds according to the Formula (I), (II), (II-a), (II-b), (II-c), (II-cl), (II-c2), (II-c3), (III), (III-a), (III-b), (III-c), (III-cl), (III-c2), (III-c3), (IV), (V), (V-a) and (V-b), may be prepared by methods known in the art of organic synthesis or by the following synthesis schemes. In all of the schemes described below it is understood that protecting groups for sensitive or reactive groups are employed where necessary in accordance with the general principles of organic chemistry. Protecting groups are manipulated according to standard methods (T.W. Green and P.G.M.
- the compounds according to the invention may be represented as a mixture of enantiomers which may be resolved into their individual R- or 5-enantiomers. If for instance, a particular enantiomer is required it may be prepared by asymmetric synthesis or by derivation with a chiral auxiliary and the resulting diastereomeric mixture separated. The auxiliary group can then be cleaved to provide the desired pure enantiomers.
- resolution may be performed by fractional crystallization from various solvents as the salt of an optical active acid or by other methods known in the literature (e.g. chiral column chromatography) .
- Resolution of the final product, an intermediate or a starting material may be performed by any suitable method known in the art (E.L. Eliel, S.H. Wilen and L.N. Mander, 1984, Stereochemistry of Organic Compounds, Wiley-Interscience).
- heterocyclic compounds of Formula (I) to (V-b) where M 1 or M 2 is a heteroaromatic or heterocyclic group may be prepared using synthetic routes well known in the art (A.R. Katrizky and C. W. Rees, 1984, Comprehensive Heterocyclic Chemistry, Pergamon Press).
- the invention provides compounds of Formula V, where the V 1 T 1 M 1 group can be introduced by alkylation (N-C, bond formation) using the appropriate starting materials (i.e. pyridine derivatives or pyridinone derivatives).
- the V 1 T 1 M 1 group can be introduced by an alkylation (O-C or N-C, bond formation), a reductive amination (C-N, bond formation), or by displacement of a leaving group Cl, Br, I or OP, where OP is defined as a leaving group (e.g.
- the group V 1 T 1 M 1 can be introduced by reaction of a suitably substituted 2-methoxypyridine with an elaborated W-V 1 T 1 M 1 where W is Cl, Br or OP (Scheme 2).
- V 2 T 2 M 2 The introduction of the V 2 T 2 M 2 can be done through carbon-carbon bond formation (Scheme 3).
- the Suzuki-Miyaura (Method A, Scheme 3) carbon-carbon coupling reaction requires a catalyst such as PdCl 2 (PPh 3 ) 2 , Pd(PPh 3 ) 4 , Pd 2 (dba) 3 , Pd 2 (d ⁇ f) or Pd(OAc) 2 and an aqueous or non-aqueous base such as sodium carbonate, potassium carbonate, sodium hydroxide or cesium fluoride in a suitable solvent such as dioxane, toluene, dimethoxyethane or DMF.
- a catalyst such as PdCl 2 (PPh 3 ) 2 , Pd(PPh 3 ) 4 , Pd 2 (dba) 3 , Pd 2 (d ⁇ f) or Pd(OAc) 2
- an aqueous or non-aqueous base such as sodium carbonate, potassium carbonate, sodium hydroxide or cesium fluoride in a suitable solvent such as dioxane, tolu
- the Sonogashira (Method B, Scheme 3) carbon-carbon coupling reaction requires a catalyst such as PdCl 2 (PPh 3 ) 2 , Pd(PPh 3 ) 4 or Pd(OAc) 2 in a suitable solvent such as DMF, acetonitrile or benzene.
- a co-catalyst such as copper (I) iodide and a base such as triethylamine, diisopropylamine, or KOAc will also be present in the reaction mixture.
- the Suzuki-Miyaura and Sonogashira reactions typically react at temperatures ranging from 0°C to 150°C. Typically, the reaction is maintained for 1 to 24 hours, with 12 hours usually being sufficient.
- the product of the reaction can be isolated and purified using standard techniques such as solvent extraction, column chromatography, crystallization, distillation and sublimation.
- compound g7 can be hydrogenated under catalytic conditions using for example Pd/C and H 2 or ammonium formate (as hydrogen source) to afford the partially reduced analogs g8 which are also part of this invention. It is noteworthy that a full hydrogenated version cannot be achieved under these conditions and therefore another approach should be envisaged to achieve fully reduced compounds (Scheme 8).
- V 1 T 1 M 1 may not be compatible with the aforementioned carbon-carbon bond forming reaction (i.e. Sonogashira, Heck or Suzuki-Miyaura). Therefore, the V 1 T 1 M 1 group can be introduced later in the synthesis (Scheme 4, Method A) and for example the Sonogashira reaction could be performed in the first step on a suitably substituted 2-methoxypyridine 5- boronic acid g9.
- the synthesis of such boronic acid is well described in the literature (J. Org. Chem., 2002, 67, 7541-7543) from commercial precursors with aryl and heteroaryl triflates or bromides. Aryl and heteroaryl bromides are available from commercial sources.
- the synthesis can also be performed from a suitably substituted 2- methoxypyridine having in position 5 an halide or a triflate reacting in a Suzuki- Miyaura reaction with a boronic compound Q-M 2 where Q is B(OR) 2 .
- V2T2M2 (in this case V 2 and T 2 are bonds and M 2 is aryl, alkenearyl, aryl or heteroaryl) group can be introduced onto g2 in the first step (Scheme 5), to yield compound gl2 which is then subjected to W-V 1 T 1 M 1 under conditions similar to those described in Scheme 1, Step 2.
- the acid compound generated from the ester g5 is an excellent anchoring point for heterocycle formation such as benzothiazole, oxadiazole, benzoxazole or isoxazole.
- the composition of the invention is not limited only to the aforementioned heterocycles but extends to our preferred list of heterocycles which may be synthesized through a similar scheme. (A. R. Katrizky and C. W. Rees, 1984, Comprehensive Heterocyclic Chemistry, Pergamon Press).
- iunctionalities present in compound g5 (where Y is COOMe, CN or CHO) may be further transformed into compounds gl4, gl5, gl6 and gl7 (Scheme 7).
- V 1 T 1 M 1 group assembly may be constructed stepwise to afford compounds g20 and g22 (Scheme 9).
- the acid moiety present in g21 is an excellent anchoring point for heterocycle formation such as benzothiazole g23, benzoxazole g24, oxadiazole g25 and isoxazole (Scheme 10) which are also compounds of this invention.
- the composition of the invention is not limited only to the aforementioned heterocycles but extend to our preferred list of heterocycles which can be synthesized through a similar scheme (A. R. Katrizky and C. W. Rees, 1984, Comprehensive Heterocyclic Chemistry, Pergamon Press; Chem. Pharm. Bull., 1999, 47, 120-122).
- the invention provides compounds of Formula (II) (Scheme 11).
- Scheme 11 The synthesis of starting materials ⁇ i.e. isoquinolin-1-one derivatives) when not commercially available are well described in the literature (Chem. Ber., 1972, 3726- 3747; Chem. Pharm. Bull., 1982, 1680-1691, Chem. Pharm. Bull., 1986, 2754-2759).
- the preferred substituents as defined in the claims can be introduced using similar chemistry.
- V 1 T 1 M 1 may be introduced using an elaborated W-V 1 T 1 M 1 (where W is Cl, Br or OP) in the presence of base such as NaH, K 2 CO 3 or NaHMDS in a suitable solvent such as THF or DMF. It is noteworthy that these procedures may lead to undesired O-alkylated product which can be separated by crystallization or column chromatography.
- the invention provides compounds of Formula (III) (Scheme
- V 1 T 1 M 1 can be introduced using an elaborated W-V 1 T 1 M 1 (where W is Cl, Br or OP) in presence of base such as NaH or K 2 CO 3 or alternatively, with HO-V 1 T 1 M 1 using Mitsunobu condition (Tetrahedron Letters, 1994, 2819-2822) It is noteworthy that this procedure may lead to undesired O-alkylated product which can be separated by crystallization or column chromatography.
- compounds of Formula (V) may be prepared in accordance with Scheme 14.
- Compound g31 can be deprotected in the presence Of BBr 3 (J. Med. Chem., 1997, 40, 2085-2101).
- the resulting alcohol g32 can be alkylated by XCH 2 R where X may be a good leaving group such as Cl, Br, I or OP in the presence of a base such as K 2 CO 3 , Cs 2 CO 3 or NaH in a suitable solvent such as DMF, acetone or tetrahydroiuran at an appropriate temperature or acylated by XCOR where X is Cl in the presence of a base such as Et 3 N or DIEA in a suitable solvent.
- the compounds of Formula (V) may be prepared according to the synthetic sequences illustrated in Scheme 15.
- Compound g35 may be hydrolyzed by standard procedures followed by reaction with a primary or secondary amine in order to lead to compound g37 (Scheme 6).
- Compounds g36 and g38 represent an excellent anchoring point (acid, nitrile or amide) for heterocycle formation such as thiazole, oxadiazole, oxazole or isoxazole.
- the composition of the invention is not limited only to the aforementioned heterocycles but extends to our preferred list of heterocycles which can be synthesized through a similar scheme (A. R. Katrizky and C. W. Rees, 1984, Comprehensive Heterocyclic Chemistry, Pergamon Press).
- compounds of Formula (V) may be prepared in accordance with Scheme 16.
- aldehyde g4 can be reduced using LiAlH 4 to afford the alcohol g40 which can be alkylated using either R'X (where X is Cl, Br or OP) in the presence of a base such as K 2 CO 3 , Cs 2 CO 3 or NaH in a suitable solvent such as DMF, acetone or tetrahydroiuran or alternatively, using R'OH with Mitsunobu conditions as described in Scheme 1.
- R'X where X is Cl, Br or OP
- compounds of Formula (V-b) may be prepared according to the synthetic sequences illustrated in Scheme 17.
- Compound g3 can be transformed into boronic esters via metal-halogen exchange in the presence of Pd(PPh 3 ) 4 .
- the resulting boronic esters can be coupled to M 2 via Suzuki-Miyaura coupling as described in Scheme 3.
- compounds of Formula (V) may be prepared in accordance with Scheme 18.
- ester g44 can be reduced using LiAlH 4 to afford the alcohol g45.
- the compounds of Formula (V) may be also prepared according to the synthetic sequences illustrated in Scheme 19.
- Compound g3 can be submitted to Suzuki-Miyaura coupling with boronic compounds being substituted by a protected amino moiety.
- Method A the removal of the Boc group in compound g46 may be achieved under classical conditions well known in the art such as HCl or TFA.
- the resulting primary amine can then be either acylated by standard procedure or submitted to reductive amination (Scheme 7).
- compound g46 can be submitted first to alkylation using preferentially NaH as base and tetrahydroiurane as organic solvent followed by deprotection under acidic conditions (for example the reaction can be done in an organic solvent such as DCM with an acid such as TFA typically at room temperature to give compound g48b.
- organometallic reagents such as the Grignard reagent exemplified here (Scheme 20).
- Scheme 20 organometallic reagents
- many alternative organometallic reagents may be used and their preparation and use is well exemplified in the literature (M. Schlosser, 1994, Organometallics in Synthesis, John Wiley & Sons, Inc.).
- Scheme 20 Another embodiment of the invention provides compounds of Formula (IV) (exemplified in Scheme 21).
- Substituted 3-bromo-pyridine or 3-iodopyridine g51 can be subjected to directed ortho metalation at low temperatures (e.g. -78°C) in a solvent such as. THF or diethyl ether with lithium diisopropylamide and subsequently quenched with an electrophilic halogen source (e.g. Br 2 or I 2 ).
- 4-halopyridine g52 can then be functionalized by carbon-carbon bond forming reaction (Step 2, exemplified here by Suzuki-Miyaura or Stille reaction) under condition similar to those described in Scheme 3.
- Displacement of 2-halopyridine g53 by sodium methoxide in methanol yielded 2-methoxypyridine g54.
- Subsequent alkylation was then performed as described in Scheme 2 to yield pyridinone g55.
- Another embodiment of the invention provides compounds of Formula (V) (exemplified in Scheme 22).
- Method A substituted 5-bromo-2-methoxy-pyridine g4 was subjected to lithium-halogen exchange at -78°C in an a solvent such as THF or diethyl ether with butyl lithium and quenched with a substituted alkyl bromide (M 2 V 2 T 2 X) to give compound g56.
- Alkylation was then performed as described in example 1 to give compound g57.
- Another embodiment of the invention provides compounds of Formula (V-b) (Scheme 25). Alkylation of 2-hydroxypyridine g2 was performed as described in example 1.
- bromopyridine 3 was first functionalized by carbon-carbon bond forming reaction (exemplified here by Suzuki-Miyaura reaction) under conditions similar to those described in Scheme 3.
- the alcohol g65 was then alkylated to obtain compound g66.
- Or bromination of compound g65 was achieved using PPh 3 , NBS and Et 2 O at - 20°C (Step 3).
- the resulting bromide was alkylated using standard Williamson ether synthesis to yield ether g66 (Step 4, alkyl alcohol, NaH and DMF at 0°C).
- Another embodiment of the invention provides compounds of Formula (V-b) (Scheme 26).
- Step 1 lithium-halogen exchange on substituted 5-bromo-2-methoxy-pyridine g4 at -78°C in THF with butyl lithium was reacted with a substituted carbonyl compounds.
- the resulting alcohol g67 was then eliminated using MsCl, TEA and DCM at room temperature (Step 2).
- the olefin g68 was then hydrogenated using standard conditions (H 2 , Pd/C in EtOH). Finally, the compound was alkylated as described for Scheme 2 to give compound g70.
- Another embodiment of the invention provides compounds of Formula (I) (Scheme 27).
- W is Cl, Br, I and OTf
- pyrazine g71 was alkylated using standard conditions (Step 1). NaH, DMF or K 2 CO 3 , MeCN, at room temperature, elevated temperatures or with microwave irradiation.
- W is OH
- alkylation could be performed by Mitsunobu reaction using, DEAD, PPh 3 , THF at room temperature or 60°C.
- the bromopyrazine g72 was then subjected to a carbon-carbon bond forming reaction (Step 2, exemplified here by Suzuki-Miyaura reaction) under conditions similar to those described in Scheme 3 to give compound g73.
- the compounds of Formula (II) may be prepared according to the synthetic sequences illustrated in Scheme 28.
- Isoquinoline g74 can be converted into isoquinolone g76 (Heterocycles, 1996, 42, 415) via oxidation with mCPBA followed by rearrangement of the N-oxide in the presence of acetic anhydride and then by basic sodium hydroxide cleavage.
- the compounds of Formula (II) may be prepared according to the synthetic sequences illustrated in Scheme 29.
- Compound g77 can be submitted to a Sonogashira coupling and reduced (Scheme 8) to yield compound g79.
- the isoquinoline may be transformed into alkylated isoquinolone g82 as presented in Scheme 29.
- compounds of Formula (V-b) can be prepared in accordance with Scheme 30.
- Bromopyridine g83 can be functionalized by carbon-carbon bond forming reaction (exemplified here by Suzuki-Miyaura reaction) under condition similar to those described in Scheme 3.
- the resulting pyridine g84 can be lithiated by strong base such as butyl lithium or LDA in THF at low temperatures (e.g. -78°C) and subsequently quenched with paraformaldehyde to give alcohol g86 after workup.
- N-Alkylation by NaI in acetonitrile at elevated temperatures using W- V 1 T 1 M 1 yields compound g86.
- the resulting alcohol g86 can be alkylated by the methods described in Scheme 24, step 3.
- compounds of Formula (V-b) can be prepared in accordance with Scheme 31.
- Pyridine g84 was prepared as described in Scheme 30. Bromination with NBS under UV light in CCl 4 at reflux gave compound g88. Alkylation using ROH and sodium methoxide at reflux gave compound g89. The resulting alcohol g89 can then be alkylated by the methods described in Scheme 1.
- Compound g93 (Scheme 32) can be synthesized from either bromide g91 or alcohol g92 using any one of the procedures known in the art, for example, using a copper catalyzed coupling reaction conditions when R is aryl or via a Mitsunobu reaction conditions when R is alkyl respectively. Finally, the resulting ether g93 can be alkylated with for example alkyl halide, in an organic solvent such as acetonitrile or dimethylformamide and with a base such as K 2 CO 3 .
- Scheme 32 Compound g96 (Scheme 33) can be synthesized from pyridine g95 (prepared as described in Schemes 1 and 3) via halogen exchange. Then the iodopyridine may be coupled through Sonogashira or Heck conditions to alkynes or alkenes respectively. The resulting insaturated compound g97 can then be reduced as exemplified earlier by hydrogenation to give compound g98.
- the compounds of Formula (II) may be prepared according to the synthetic sequences illustrated in Scheme 34.
- Isoquinoline g99 can be converted into his iV-oxide glOO via oxidation in the presence of MCPBA followed by standard alkylation.
- Rearrangement of iV-oxide glOl in the presence of acetic anhydride and basic sodium hydroxide cleavage yielded isoquinolone glO2.
- the resulting isoquinolone glO2 can be alkylated as described in Scheme 1. It is obvious that introduction of V 1 T 1 M 1 or V2T2M2 groups can be done through the same process as described earlier.
- the microwave oven used is an apparatus from Biotage (OptimizerTM) equipped with an internal probe that monitors reaction temperature and pressure, and maintains the desired temperature by computer control.
- Step 1 A mixture of 2-hydroxypyridine (leq, lOQmmol, 10.0g) in AcOH (100mL) was treated with NBS (l.O ⁇ eq, l lOmmol, 19.8g) at room temperature for 4 hours. The mixture was concentrated, azeotroped twice with EtOH then the solid was taken up in hot EtOH (100mL). After cooling to room temperature, the precipitate was removed by filtration and recrystallized from EtOH to provide 5- bromopyridin-2(lH)-one (51.7mmol, 9.00g, 49%) as a pale brown solid.
- Step 2 l-(4-Chloro-2-fluorobenzyl)-5-bromopyridin-2(lH)-one
- Step 2 K 2 CO 3 (lOeq, O.l lmmol, 16.0g) and l-(bromomethyl)- 4-chloro-2-fluorobenzene (1.5eq, 17.0mmol, 3.90g) was added to a solution of 5- bromopyridin-2(lH)-one (leq, ll.Ommol, 2.00g), in T ⁇ F (100mL). The suspension was stirred for 2 hours at room temperature and 17 hours at 60°C. The reaction mixture was filtered and the mother liquor was concentrated under reduced pressure.
- Step 3 l-(4-Chloro-2-fluorobenzyl)-5-(6-methoxypyridin-3-yl)pyridin-2(lH)-one
- Method A To a mixture of l-(4-chloro-2-fluorobenzyl)-5- bromopyridin-2(lH)-one (leq, 1.00mmol, 0.40g) in dioxane/K 3 PO 4 (2M, 10mL), were added Pd(PPh 3 ) 4 (0.3eq, 0.4mmol, 0.4g) and 6-methoxypyridin-3-ylboronic acid (1.5eq, 2.00mmol, 0.30g) then the reaction mixture was heated at 80°C for 17 hours.
- Step 1 l-(4-Chlorobenzyl)-5-bromopyridin-2(lH)-one
- Step 2 l-(4-Chlorobenzyl)-5-(4-(3-hydroxypropyl)phenyl)pyridin-2(lH)-one
- Method A To a solution of l-(4-chlorobenzyl)-5- bromopyridin-2(lH)-one (leq, O.33mmol, 0.10g) in dioxane/saturated aqueous NaHCO 3 (1:1, 6mL) was added Pd(PPh 3 ) 4 (0.15eq, 0.05mmol, 58mg) and 4-(3- hydroxypropyl)phenylboronic acid (1.5eq, 0.50mmol, 90.0mg).
- Step 2 The title compound was prepared from 5- bromopyridin-2(lH)-one (leq, 0.01mol, 1.73g) and 1-isopentylbromide (leq, 0.01mmol, 1.5Ig) according to the procedure described for Example 1 Step 2. Reaction conditions: 3 hours under reflux in acetonitrile. The crude product was purified by flash chromatography over silica gel (AIT Flashsmart prepacked column SiO 2 ) using CH 2 Cl 2 /AcOEt (80/20) as the eluent to afford 5-bromo-l-isopentylpyridin-2(lH)-one (6.23mmol, 1.52g, 62%) as a brown oil.
- Step 2 N-(3-(l-Isopentyl-6-oxo-l,6-dihydropyridin-3-yl)phenyl)methanesulfonamide
- scheme 3 Method A: The title compound was prepared from 5-bromo-l- isopentylpyridin-2(lH)-one (leq, 0.41mmol, 0.10g) and 3-
- Step 1 4-Methoxy-3-(methylsulfonamido)phenylboronic acid
- Step 2 N-(5-(l-(4-Chlorobenzyl)-6-oxo-l,6-dihydropyridin-3-yl)-2-methoxyphenyl) methane sulphonamide
- Step 1 l-(3-Fluorobenzyl)-5-bromopyridin-2(lH)-one
- Step 2 l-(3-Fluorobenzyl)-5-bromopyridin-2(lH)-one was prepared from 5-bromopyridin-2(lH)-one (Example 1 Step 1) and 3-fluorobenzyl bromide according to the procedure described for Example 2 Step 1. The crude product was washed with pentane/Et 2 ⁇ 50/50 to afford l-(3-fluorobenzyl)-5-bromopyridin- 2(lH)-one (10.7mmol, 3.00g, 62%) as a white solid.
- Step 2 l-(3-Fluorobenzyl)-5-(2-(pyridin-3-yl)ethynyl)pyridin-2(lH)-one hydro ⁇ chloride
- Step 1 2-(6-Methoxypyridin-3-yl)benzo[d]thiazole According to Scheme 4 Method A: The title compound was prepared from 2- bromobenzo[d]thiazole (leq, 0.91mmol, 0.20g) and 6-methoxypyridin-3-ylboronic acid (1.5eq, 1.36mmol, 0.2Ig) according to the procedure described for Example 2 Step 2.
- Step 2 l-(4-Chloro-3-fluorobenzyl)-5-(betizo[d]thiazol-2-yl)pyridin-2(lH)-one
- Step 1 A mixture of 2-(6-methoxypyridin-3- yl)benzo[ ⁇ /]thiazole (leq, 0.25mmol, 60mg), NaI (5eq, 1.20mmol, 0.19g) and 4-chloro- 3-fluorobenzylbromide (5eq, 1.20mmol, 0.28g) in acetonitrile (10mL) was stirred for 14 hours at 90°C. The crude residue was partitioned between CH 2 Cl 2 and water.
- the aqueous layer was extracted with CH 2 Cl 2 .
- the combined organic layers were dried over MgSO 4 , filtered and evaporated.
- the crude product was purified by silica gel chromatography (AIT Flashsmart prepacked column 25g SiO 2 ) using CH 2 Cl 2 /AcOEt 95/5 as eluent to afford l-(4-chloro-3-fluorobenzyl)-5-(benzo[d]thiazol-2-yl)pyridin- 2(lH)-one (0.14mmol, 0.05g, 58%) as a beige solid.
- Step 1 5-(4-Methoxyphenyl)-(lH)-pyridin-2-one
- Step 1 The title compound was prepared from 5- bromopyridin-2(lH)-one (leq, 17.2mmol, 3.00g, Example 1 Step 1) and 4- methoxyphenylboronic acid (1.5eq, 25.9mmol, 3.93g) according to the procedure described for Example 2 Step 2. Reaction conditions: 4.5 hours at 120°C.
- Step 2 5-(4-Methoxyphenyl)-l-(2-phenoxyethyl)pyridin-2(lH)-one
- Step 2 To a solution of 5-(4-methoxyphenyl)-(lH)-pyridin-2- one (leq, 0.30mmol, 60mg) in T ⁇ F (3mL) was added K 2 CO 3 (10eq, 3.00mmol, 0.4Ig). The reaction was stirred at room temperature for 30 minutes then l-(2- bromoethoxy)benzene (3eq, 0.90mmol, 0.18g) was added. The reaction was stirred at 60°C for 12 hours.
- Step 2 The title compound was prepared from 5-(4- methoxyphenyl)-(lH)-pyridin-2-one (leq, 0.50mmol, 0.10g, Example 7 Step 1) and 5- (chloromethyl)-2-(trifluoromethyl)pyridine (1.5eq, 0.74mmol, 0.15g) according to the procedure described for Example 1 Step 2. Reaction conditions: 6 hours at 70°C and 48 hours at room temperature. The crude product was purified by silica gel chromatography (AIT Flashsmart prepacked column 10g SiO 2 , CH 2 Cl 2 AAcOEt 90/10). The purified oil was dissolved in Et 2 O and HCl (4M in dioxane) was added.
- Step 1 l-(4-Chlorobenzyl)-6-oxo-l,6-dihydropyridine-3-carbaldehyde
- Step 2 l-(4-Chlorobenzyl)-5-((methyl(phenyl)amino)methyl)pyridin-2(lH)-one
- Method A A solution of N-methylbenzenamine (leq, 0.40mmol, 0.04mL) and l-(4-chlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carbaldehyde (leq, 0.40mmol, 0.10g) in CH2CI2 (8mL) was stirred for 10 min. at room temperature then AcOH (leq, 0.40mmol, 0.02mL) and NaBH(OAc) 3 (1.5eq, 0.60mmol, 0.10g) were added.
- the reaction mixture was stirred 3 hours at room temperature, was quenched with water and the aqueous phase was extracted with CH 2 CI 2 . The organic layer was dried over Na2SO 4 , filtered and evaporated.
- the crude product was purified by silica gel chromatography (AIT Flashsmart prepacked column 25g Si ⁇ 2) using CH 2 Cl 2 /MeOH 95/5 followed by crystallization in pentane/diisopropyl ether to afford l-(4-chlorobenzyl)-5-((methyl(phenyl)amino)methyl)pyridin-2(lH)-one (0.12mmol, 0.04g, 29%) as a white solid.
- Step 1 5-(3-Methoxyphenethynyl)-2-methoxypyridine
- Et 3 N (15eq, 12.0mmol, 1.68mL)
- PdCl 2 (PPh 3 ) 2 0.05eq, 0.04mmol, 17.5mg
- PPh 3 0.2eq, O.l ⁇ mmol, 41.8mg
- 5-bromo-2- methoxypyridine leq, 0.80mmol, 0.15g
- l-ethynyl-3-methoxybenzene (l.leq, 0.88mmol, 0.12g) was added and the mixture was heated under microwaves (120°C/25min) and was stirred overnight at room temperature. The resulting solution was poured onto water and extracted with AcOEt. The combined organic layers were dried over MgSO 4 , filtered and evaporated under reduced pressure.
- Step 2 2-Methoxy-5-(2-(3-methoxyphenyl)ethyl)pyridine
- Step 2 A suspension of 5-(3-methoxyphenethynyl)-2- methoxypyridine (leq, 0.64mmol, 154mg) and Pd/C (15mg) in MeOH (10mL) was stirred overnight at room temperature under H 2 at atmospheric pressure. The resulting mixture was then filtered on a pad of celite and washed with MeOH. The filtrate was concentrated under reduced pressure to afford 2-methoxy-5-(2-(3- methoxyphenyl)ethyl)pyridine (0.49mmol, 0.12g, 77%) as a colorless oil.
- Step 3 5-(3-Methoxyphenethyl)-l-(4-chloro-3-fluorobenzyl)pyridin-2(lH)-one
- Step 3 The title compound was prepared from 2-methoxy-5- (2-(3-methoxyphenyl)ethyl)pyridine (leq, 0.25mmol, 0.06g) and 4-chloro-3- fluorobenzylbromide (2eq, 0.49mmol, 0.1 Ig) according to the procedure described for Example 6 Step 2. Reaction conditions: 12 hours at 100°C.
- Step 1 Ethyl 2-(5-(4-methoxyphenyl)-2-oxopyridin-l(2H)-yl)acetate
- Step 1 The title compound was prepared from 5-(4- methoxyphenyl)pyridin-2(lH)-one (leq, 3.73mmol, 0.75g, Example7 Step 1) and ethylbromoacetate (1.2eq, 4.47mmol, 0.50mL) according to the procedure described for Example 1 Step 2.
- the reaction was stirred at 60°C for 12 hours.
- the reaction was filtered and concentrated under reduced pressure to yield a yellow oil.
- the product was triturated from diisopropyl ether to afford ethyl 2-(5-(4-methoxyphenyl)-2-oxopyridin- 1 (2H)-yl)acetate (3.38mmol, 0.97g, 91 %) as a white solid.
- Step 2 2-(5-(4-Methoxyphenyl)-2-oxopyridin-l(2H)-yl)acetic acid
- Step 2 To a solution of ethyl 2-(5-(4-methoxyphenyl)-2- oxopyridin-l(2H)-yl)acetate (leq, 3.38mmol, 0.97g) in water/EtO ⁇ (1:1, 20mL) at 0°C was added lithium hydroxide (10eq, 33.8mmol, 1.44g).
- Step 3 N-(3-Chlorobenzyl)-2-(5-(4-methoxyphenyl)-2-oxopyridin-l(2H)-yl)-N-methyl- acetamide
- Step 3 To a solution of (3-chlorophenyl)-N- methylmethanamine (leq, 0.19mmol, 0.03g), 2-(5-(4-methoxyphenyl)-2-oxopyridin- l(2H)-yl)acetic acid (leq, 0.19mmol, 0.05g) and hydroxybenzotriazole (l.leq, 0.21mmol, 0.03g) in CH 2 Cl 2 (2mL) at room temperature was added EDCI.HC1 (1.5eq, 0.29mmol, 55mg). The reaction was stirred at room temperature for 12 hours then diluted with AcOEt. The reaction was washed with brine and the organic phase extracted (x3).
- reaction mixture was stirred at room temperature for 2 days.
- the solvent was removed under reduced pressure and the residue was dissolved in C ⁇ 2 CI 2 and NH 4 OH.
- the aqueous phase was extracted 3 times with CH2CI2.
- the combined organic fractions were washed with brine, dried over Na2SO 4 , filtered and concentrated under reduced pressure.
- Method B A mixture of 2-(5-(4-methoxyphenyl)-2- oxopyridin-l(2H)-yl)acetic acid (leq, 0.23mmol, 60mg, Example 14 Step 2), 4- fluorophenylamidoxime (1.2eq, 0.28mmol, 43mg), 1-hydroxybenzotriazole (leq, 0.23mmol, 35mg), EDCI. ⁇ C1 (1.5eq, 0.35mmol, 67mg) in dioxane (2mL) was stirred at room temperature for 12 hours, then heated at 100°C for 3 days. The solution was poured onto brine and AcOEt and the aqueous phase was extracted twice with AcOEt.
- Step 1 l-(3-Fluorobenzyl)-4-(3-fluorobenzyloxy)pyridin-2(lH)-one
- Step 1 The title compound was prepared from pyridine-2,4-diol (leq, 2.52mmol, 0.28g) and l-(bromomethyl)-3-fluorobenzene (3eq, 7.56mmol, 0.93mL) according to the procedure described for Example 1 Step 2. Reaction conditions: 17h under reflux in DMF. The crude product was purified by flash chromatography on silica gel (CH 2 Cl 2 /AcOEt 90/10) to afford l-(3-fluorobenzyl)-4-(3-fluorobenzyloxy)pyridin- 2(lH)-one as a white solid (0.95mmol, 0.29g, 36%).
- Step 2 l-(3-Fluorobenzyl)-4-hydroxypyridin-2(lH)-one
- Step 2 A suspension of l-(3-fluorobenzyl)-4-(3- fluorobenzyloxy)pyridin-2(lH)-one (leq, 0.95mmol, 0.29g) and Pd/C (0.3eq, 0.29mmol, 30.3mg) in MeOH (3mL) was hydrogenated until complete (30 min). The suspension was filtered through celite and the filtrate concentrated under vacuum to afford l-(3-fluorobenzyl)-4-hydroxypyridin-2(lH)-one (0.75mmol, 0.16g, 79%) as a white powder.
- Step 3 l-(3-Fluorobenzyl)-l,2-dihydro-2-oxopyridin-4-yl trifluoromethanesulfonate
- Method B To a solution of l-(3-fluorobenzyl)-4- hydroxypyridin-2(lH)-one (leq, l.OOmmol, 0.30g) and pyridine (3eq, 4.00mmol, 0.30mL) in CH 2 Cl 2 (10mL) at -78 °C was added dropwise a solution of trifluoromethanesulfonic anhydride (2eq, 3.00mmol, 0.50mL). The solution was allowed to warm to room temperature and further stirred for 1 hour.
- Step 4 l-(3-Fluorobenzyl)-4-(4-methoxyphenyl)pyridin-2(lH)-one
- Step 1 l-(2-Fluoro-4-chlorobenzyl)-5-(4-methoxyphenyl)pyridin-2(lH)-one
- Method A The title compound was prepared from l-(4-chloro- 2-fluorobenzyl)-5-bromopyridin-2(lH)-one (leq, 16.4mmol, 5.20g, Example 1 Step 2) and 4-methoxyphenylboronic acid (1.5eq, 25.0mmol, 3.80g) according to the procedure described for Example 1 Step 3.
- Step 2 l-(4-Chloro-2-fluorobenzyl)-5-(4-hydroxyphenyl)pyridin-2(lH)-one
- Step 1 BBr 3 (4eq, 65.6mmol, 6.56mL) was added to a solution of 1 -(2-fluoro-4-chlorobenzyl)-5-(4-methoxyphenyl)pyridin-2(lH)-one (16.4mmol, 5.64g) in CH 2 Cl 2 at -50°C. The reaction mixture was stirred 1.5 hour at - 40°C, overnight at room temperature then BBr 3 (20mL) was added at -30°C and the reaction mixture was stirred 4 hours at room temperature.
- Step 3 2-(4-(l-(4-Chloro-2-fluorobenzyl)-6-oxo-l,6-dihydropyridin-3-yl)phenoxy)- acetonitrile
- Step 1 2-(4-(l-(4-Chlorobenzyl)-l,6-dihydro-6-oxopyridin-3-yl)phenyl)acetic acid
- Scheme 3 Method A: The title compound was prepared according to Example 2 Step 2, from l-(4-chlorobenzyl)-5-bromopyridin-2(lH)-one (leq, 0.67mmol, 0.20g, Example 2 Step 1) and 2-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan- 2-yl)phenyl)acetic acid (1.5eq, 1.00mmol, 0.26g). Reaction conditions: 4.5 hours at 90°C.
- Step 2 2-(4-(l-(4-Chlorobenzyl)-l,6-dihydro-6-oxopyridin-3-yl)phenyl)-N-methyl acetamide
- Step 1 2-(4-(1-(4-Chlorobenzyl)-1,6-dihydro-6-oxopyridin-3-yl)phenyl)acetonitrile
- Scheme 3 Method A The title compound was synthesized as described in Example 2 Step 2 using 4-(cyanomethyl)phenyl boronic acid (1.5eq, 0.50mmol, 80.9mg) and l-(4-chlorobenzyl)-5-bromopyridin-2(lH)-one (leq, O.33mmol, 0.10g, Example 2 Step 1) as substrates.
- Step 2 5-(4-((2H-Tetrazol-5-yl)methyl)phenyl)-l-(4-chlorobenzyl)pyridin-2(lH)-one
- Method D 2-(4-(l-(4-Chlorobenzyl)-l,6-dihydro-6- oxopyridin-3-yl)phenyl)acetonitrile (leq, 0.24mmol, 0.08g) was heated at 110°C under nitrogen overnight with dibutyltin oxide (0.22eq, 0.05mmol, 0.01 g) and azidotrimethylsilane (6.0eq, 1.43mmol, 0.19mL) in toluene (4mL).
- Step 3 l-(3,4-Difluorobenzyl)-5-(phenoxymethyl)pyridin-2(lH)-one
- Method A The title compound was prepared from 2- methoxy-5-(phenoxymethyl)pyridine (leq, 0.46mmol, 0.10g) and 4-(bromomethyl)- 1,2-difluorobenzene (3eq, 1.39mmol, 0.18mL) according to the procedure described for Example 1 Step 2. Reaction conditions: under reflux for 3 days in DMF (5mL).
- Step 1 l-(4-Chloro-2-fluorobenzyl)-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)pyridin-2(lH)-one
- Step 1 To a solution of l-(4-chloro-2-fluorobenzyl)-5- bromopyridin-2(lH)-one (leq, 1.26mmol, 0.40g, Example 1 Step 2) in degazed dioxane (20mL) was added under nitrogen 4,4,5, 5-tetramethyl-2-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)-l,3,2-dioxaborolane (1.3eq, 1.64mmol, 0.42g), PdCl 2 (dppf) 2 (0.03eq, 38 ⁇ mol, 28mg), dppf (0.06eq, 76 ⁇ mol, 42mg) and KOAc (3
- the reaction mixture was stirred at 80°C for 4 hours, was quenched with water and the aqueous phase was extracted with AcOEt. The organic phase was dried over Na 2 SO 4 , filtered and concentrated.
- the crude product was purified by silica gel chromatography (AIT Flashsmart prepacked column 25g SiO 2 ) using C ⁇ 2 Cl 2 /AcOEt 90/10 as eluent to afford l-(4-chloro-2-fluorobenzyl)-5-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)pyridin-2(lH)-one (0.74mmol, 0.27g, 59%) as a pale oil.
- Step 2 l-(4-Chloro-2-fluorobenzyl)-5-(benzo[b]thiophen-5-yl)pyridin-2(lH)-one
- Step 2 The title compound was prepared from l-(4-chloro-2- fluorobenzyl)-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2(lH)-one (leq, 1.26mmol, 0.40g) and 5-bromobenzo[b]thiophene (1.5eq, 0.29mmol, 0.06g) according to the procedure described for Example 1 Step 2.
- Step 1 Methyl 1-(4-chlorobenzyl)-5-bromo-2-oxo-l,2-dihydropyridine-3-carboxylate
- Step 2 The title compound was prepared from methyl 5- bromo-2-oxo-l,2-dihydropyridine-3-carboxylate (leq, 10.0mmol, 3.00g) and 1- (bromomethyl)-4-chlorobenzene (1.5eq, 20.0mmol, 4.00g) according to the procedure described for Example 1 Step 2. Reaction conditions: 3 hours at 50°C in THF/DMF (2:1, 300mL).
- Step 3 l-(4-Chlorobenzyl)-3-(hydroxymethyl)-5-(4-methoxyphenyl)pyridin-2(lH)-one
- Scheme 18 To a solution of methyl l-(4-chlorobenzyl)-5-(4- methoxyphenyl)-2-oxo-l,2-dihydropyridine-3-carboxylate (leq, 0.52mmol, 0.20g) in Et 2 O (7mL) at -78°C was added DIBAL (3eq, 1.60mmol, 1.1 Ig). The reaction was stirred at -78°C for 30 minutes and 0°C for 1 hour.
- Step 1 tert-Butyl 4-(l-(4-chloro-2-fluorobenzyl)-6-oxo-l,6-dihydropyridin-3-yl) phenylcarbamate
- Step 1 The title compound was prepared from l-(4-chloro-2- fluorobenzyl)-5-bromopyridin-2(lH)-one (leq, 2.81mmol, 0.89g, Example 1 Step 2) and 4-(tert-butoxycarbonyl)aminophenylboronic acid (1.5eq, 4.20mmol, 1.00g) according to the procedure described for Example 1 Step 3. Reaction conditions: 2 hours at 80°C. The crude product was purified by silica gel chromatography (AIT Flashsmart prepacked column 50g SiO 2 , CH 2 Cl 2 /AcOEt 90/10).
- Step 2 l-(4-Chloro-2-fluorobenzyl)-5-(4-aminophenyl)pyridin-2(lH)-one hydrochloride
- Step 2 HCl/dioxane (10eq, 4M, 5.00mL) was added to a solution of tert-butyl 4-(l-(4-chloro-2-fluorobenzyl)-6-oxo-l,6-dihydropyridin-3- yl)phenylcarbamate (leq, 2.00mmol, 1.00g) in MeOH (20mL) at 0°C. The reaction was stirred for 2 days at 80°C, then the solvent was concentrated and Et 2 O was added.
- Step 1 tert-Butyl 2-(4-(l-(4-chloro-2-fluorobenzyl)-6-oxo-l,6-dihydropyridin-3- yl)phenoxy)ethylcarbamate
- the title compound was prepared from l-(4-chloro-2-fluorobenzyl)-5-(4- hydroxyphenyl)pyridin-2(lH)-one (leq, 0.60mmol, 0.20g, Example 20 Step 2) and tert-butyl 2-hydroxyethylcarbamate (1.5eq, 0.90mmol, 0.10g) according to the procedure described for Example 25 Step 2.
- Step 2 l-(4-Chloro-2-fluorobenzyl)-5-(4-(2-aminoethoxy)phenyl)pyridin-2(lH)-one
- Step 2 The title compound was prepared from tert-butyl 2-(4- ( 1 -(4-chloro-2-fluorobenzyl)-6-oxo- 1 ,6-dihydropyridin-3 -yl)phenoxy)ethylcarbamate (leq, 0.40mmol, 0.19g) according to the procedure described for Example 28 Step 2. Reaction conditions: room temperature overnight.
- Step 3 N-(2-(4-(l-(4-Chloro-2-fluorobenzyl)-6-oxo-l,6-dihydropyridin-3-yl)phenoxy) ethyl) acetamide
- Step 3 To a solution of l-(4-chloro-2-fluorobenzyl)-5-(4-(2- aminoethoxy)phenyl)pyridin-2(lH)-one (leq, 0.18mmol, 0.07g) in C ⁇ 2CI2 (5mL) at 0°C were added Et 3 N (6eq, l.lOmmol, 0.15mL) and 30 min. later acetyl chloride (1.5eq, 0.27mmol, 19 ⁇ L) and. The reaction mixture was stirred 1 hour at room temperature. The reaction mixture was quenched with water and extracted with CH2CI2. The organic phase was dried over Na2SO 4 , filtered and evaporated.
- EXAPLE 30 1-(4-Chlorobenzyl)-5-(4-(2-hydroxypropan-2-yl)phenyl)pyridin- 2(1H)-one (Final Compound 2-15)
- Step 1 l-(4-Chlorobenzyl)-5-(4-acetylphenyl)pyridin-2(lH)-one
- Step 2 l-(4-Chlorobenzyl)-5-(4-(2-hydroxypropan-2-yl)phenyl)pyridin-2(lH)-one
- Scheme 20 To a solution of l-(4-chlorobenzyl)-5-(4- acetylphenyl)pyridin-2(lH)-one (leq, 0.20mmol, 80mg) in T ⁇ F (5mL) at -50°C was added a solution of methyl magnesium bromide (3M, 1.3eq, 0.30mmol, 0.04g) and the reaction stirred at -50°C for 1 hour. The reaction was quenched at -78°C with saturated aqueous NH 4 Cl.
- the reaction was allowed to warm to room temperature and diluted with AcOEt and the organic phase extracted (x3). The combined organic fractions were dried (Na 2 SO 4 ), filtered and concentrated under reduced pressure.
- the crude product was purified by flash chromatography over silica gel (AIT Flashsmart prepacked column 25g SiO 2 ) using CH 2 Cl 2 /AcOEt 80/20 and was recrystallized from pentane/Et 2 O to afford l-(4-chlorobenzyl)-5-(4-(2-hydroxypropan-2-yl)phenyl)pyridin- 2(lH)-one (0.08mmol, 30mg, 36%) as a white solid.
- Step 1 2-Methoxy-5-(3-phenylpropyl)pyridine
- Step 2 1-(4-Chloro-2-fluorobenzyl)-5-(3-phenylpropyl)pyridin-2(lH)-one
- the title compound was prepared according to Example 6 Step 2, from 2-methoxy-5-(3-phenylpropyl)pyridine (leq, 0.44mmol, 0.10g) and l-(bromomethyl)-4-chloro-2-fluorobenzene (2eq, 0.88mmol, 0.20g). Reaction conditions: overnight at 90°C.
- Step 1 2,4-Dimethoxypyridine According to Scheme 23 Step 1 : To a solution of sodium methoxide (30% in MeOH, 2eq, 35mmol) was added 2-chloro-4-methoxypyridine (leq, 17.0mmol, 2.50g). The reaction was refluxed overnight. The reaction was allowed to cool, poured onto water (10mL) and extracted with CH 2 Cl 2 (3xl0mL). The combined organic fractions were dried (Na 2 SO 4 ), filtered and concentrated under reduced pressure to afford 2,4- dimethoxypyridine (lO.lmmol, 1.40g, 58%) as a colorless oil. The crude product was reacted on.
- Step 2 To a solution of KOH (0.5eq, O. ⁇ mmol, 40mg) in water (75mL) was added 2,4-dimethoxypyridine (leq, 2.00mmol, 0.2Ig) followed by the dropwise addition of Br 2 (leq, 2.00mmol, 0.20g) in IM aqueous KBr solution
- Step 3 2,4-Dimethoxy-5-(4-methoxyphenyl)pyridine
- the title compound was prepared from 5-bromo-2,4- dimethoxypyridine (leq, 1.40mmol, 0.30g) and 4-methoxyphenylboronic acid (1.5eq, 2.10mmol, 0.32g) according to the procedure described for Example 1 Step 3.
- the crude product was purified by flash chromatography over silica gel (AIT Flashsmart prepacked column 25g SiO 2 ) using CH 2 Cl 2 MeOH 98/2 to afford 2,4-dimethoxy-5-(4- methoxyphenyl)pyridine (1.39mmol, 0.34g, 99%) as a brown oil.
- Step 4 l-(4-Chloro-2-fluorobenzyl)-4-methoxy-5-(4-methoxyphenyl)pyridin-2(lH)-one According to Scheme 23 Step 4: The title compound was prepared from 2,4- dimethoxy-5-(4-methoxyphenyl)pyridine (leq, 0.20mmol, 0.05g) and 4-chlorobenzyl-
- Step 1 2-Methoxy-5-(4-methoxyphenyl)pyridine
- Method B The title compound was prepared according to Example 1 Step 3 from 5-bromo-2-methoxypyridine (12.1mmol, 2.30g) and 4- methoxyphenylboronic acid (18.2mmol, 2.76g), then purified by flash chromatography over silica gel (AIT Flashsmart prepacked column 25g SiO 2 , CH 2 Cl 2 /M eOH 100/0 to 95/5), yielding the title compound (1.60g, 61%).
- LC XTerra RP18, 3.5 ⁇ m, 3.0x50mm Column
- Step 2 l-(4-(Hydroxymethyl)benzyl)-5-(4-methoxyphenyl)pyridin-2(lH)-one
- Step 1 The title compound was prepared according to Example 6 Step 2, from 2-methoxy-5-(4-methoxyphenyl)pyridine (leq, 4.60mmol, 1.00g) and (4-(bromomethyl)phenyl)methanol (l.leq, 5.10mmol 1.00g). Reaction conditions: 5 hours at 70°C and room temperature overnight. The residue was triturated with pentane, yielding the title compound (3.70mmol, 1.20g, 80%).
- Step 3 l-(4-(Methoxymethyl)benzyl)-5-(4-methoxyphenyl)pyridin-2(lH)-one
- Step 3 A mixture of l-(4-(hydroxymethyl)benzyl)-5-(4- methoxyphenyl)pyridin-2(lH)-one (leq, 0.25mmol, 0.08g), NaH (55%, 1.5eq, 0.37mmol, 18mg) and iodomethane (3eq, 0.75mmol, 0.1 Ig) in DMF (2mL) was stirred at room temperature overnight. The crude was diluted with AcOEt.
- Step 1 l-(4-Chlorobenzyl)-5-(4-(hydroxymethyl)phenyl)pyridin-2(lH)-one
- Step 2 The title compound was prepared from l-(4- chlorobenzyl)-5-bromopyridin-2(lH)-one (leq, 3.30mmol, 1.00g, Example 2 Step 1) and 4-(hydroxymethyl)phenylboronic acid (1.5eq, 5.00mmol, 0.76g) according to the procedure described for Example 1 Step 3. Reaction conditions: overnight at 80°C.
- Step 2 l-(4-Chlorobenzyl)-5-(4-(ethoxymethyl)phenyl)pyridin-2(lH)-one
- Method A The title compound was prepared from 1-(4- chlorobenzyl)-5-(4-(hydroxymethyl)phenyl)pyridin-2(lH)-one (leq, 2.50mmol, 0.80g) and iodoethane (3eq, 7.40mmol, 1.10g) ) according to the procedure described for Example 34 Step 3.
- Step 1 l-(6-Methoxypyridin-3-yl)cyclohexanol According to Scheme 26 Step 1: To a stirred solution of 4-bromo-2-methoxypyridine (leq, 5.30mmol, 1.00g) in anhydrous THF (30mL) at -78°C under nitrogen was added dropwise a solution of butyl lithium (1.3eq, 2.5M solution in hexane, 6.90mmol, 2.8mL). The reaction was then stirred at -78°C for 2 hours. Cyclohexanone (5eq, 27.0mmol, 2.8mL) was then added dropwise over 5 minutes. The reaction was stirred at -78°C for two hours then allowed to warm to room temperature.
- Step 2 The title compound was prepared from l-(6- methoxypyridin-3-yl)cyclohexanol (leq, 1.21mmol, 0.25g) and methanesulfonyl chloride (4eq, 4.82mmol, 0.37mL) according to the procedure described for Example 4 Step 1.
- the crude residue was purified by chromatography over silicagel (AIT Flashsmart prepacked column 10g SiO 2 , AcOEt/pentane 30/10 to pure AcOEt), yielding the title compound (0.76mmol, 0.14g, 63%) as a colorless oil.
- Step 3 The title compound was prepared according to Example 19 Step 2, from 5-cyclohexenyl-2-methoxypyridine (leq, 0.74mmol, 0.14g). Reaction conditions: 32 hours at room temperature. The residue was purified by chromatography over silicagel (AIT Flashsmart prepacked column 10g SiO 2 , CH 2 Cl 2 /AcOEt 95/5), yielding the title compound (0.33mmol, 63mg, 45%) as a colorless oil.
- Step 1 1-(4-Chlorobenzyl)-5-bromopyrazin-2(lH)-one
- Step 1 The title compound was prepared from 5- bromopyrazin-2(lH)-one (leq, 2.86mmol, 0.50g) and 1-(bromomethyl)-4- chlorobenzene (1.5eq, 4.29mmol, 0.88g) according to the procedure described for Example 1 Step 2. Reaction conditions: 3 hours at 70°C in acetonitrile. The crude product was purified by flash chromatography over silica gel (AIT Flashsmart prepacked column 25g SiO 2 ) using pure AcOEt as eluent to afford l-(4-chlorobenzyl)- 5-bromopyrazin-2(lH)-one (2.48mmol, 0.74g, 87%) as a white solid.
- Step 2 l-(4-Chlorobenzyl)-5-(4-methoxyphenyl)pyrazin-2(lH)-one
- Step 2 The title compound was prepared from l-(4- chlorobenzyl)-5-bromopyrazin-2(lH)-one (leq, 0.67mmol, 0.20g) and 4- methoxyphenylboronic acid (1.5eq, 1.00mmol, 0.15g) according to the procedure described for Example 1 Step 3. Reaction conditions: 1 hour at 80°C.
- Step 1 A solution of MCPBA (1.9, 15.0mmol, 3.6g) and 5- chloroisoquinoline (leq, 7.80mmol, 1.27g) in CH2CI2 (30mL) was stirred for 2 hours at room temperature. The reaction mixture was diluted with CH2CI2 (20mL) and MeOH (10mL) and the organic phase was washed with 2M NaOH solution. The aqueous layer was extracted with CH2CI2. The organic fractions were combined, dried over MgSO 4 , filtered and evaporated to yield the title compound (6.20mmol, 1.12g, 79%) as an orange solid.
- Step 2 5-Chloroisoquinolin-l (2H)-one
- a solution of 5-chloroisoquinoline N-oxide (leq, 6.88mmol, 1.25g) in anhydride acetic (20mL) was stirred for 3 hours under reflux and overnight at room temperature.
- a solution of NaOH (2M, 10mL) was added and the reaction mixture was stirred for 1 hour at 50- 60°C.
- the precipitate was filtered, washed with water, dried under vacuum.
- the crude residue was taken up in CH2CI2 (20mL).
- the organic phase was washed with brine, dried over MgSO 4 , filtered and evaporated to yield the title compound (3.73mmol, 0.67g, 100%) as a brown solid.
- Step 4 5-(4-Methoxyphenethylamino)-2-propylisoquinolin-l(2H)-one
- Step 4 To a mixture of 5-chloro-2-propylisoquinolin-l(2H)- one (leq, 1.08mmol, 0.24g), NaOtBu (1.5eq, 1.62mmol, 0.16g), Pd 2 (dba) 3 (0.05eq, 54 ⁇ mol, 50mg), BINAP (0.05eq, 54 ⁇ mol, 34mg) in degassed and dried toluene (4mL) was added (1.5eq, 1.62mmol, 0.25g). The reaction mixture was microwaved at 180°C for 2 hours and 1 hour at 200°C. The reaction mixture was quenched with water and the aqueous phase was extracted with CH 2 Cl 2 .
- Step 5 5-(4-Hydroxyphenethylamino)-2-propylisoquinolin-l(2H)-one
- the title compound was prepared from 5-(4-methoxyphenethylamino)-2- propylisoquinolin-l(2H)-one (leq, 0.20mmol, 66mg) according to the procedure described for Example 20 Step 2.
- Step 1 4-(2-(4-Methoxyphenyl)ethynyl)isoquinoline
- Step 1 The title compound was prepared from 4- bromoisoquinoline (leq, 5.30mmol, l.l0g) and l-ethynyl-4-methoxybenzene (leq, 5.30mmol, 0.70g) according to the procedure described for Example 13 Step 1. Reaction conditions: 70°C for 4 hours. The crude product was purified by silica gel chromatography (AIT Flashsmart prepacked column SiO 2 , cyclohexane/AcOEt 90/10 to 80/20) to afford 4-(2-(4-methoxyphenyl)ethynyl)isoquinoline (3.11mmol, 0.8 Ig, 59%) as a white solid.
- Step 3 4-(4-Methoxyphenethyl)isoquinoline-N-oxide
- Step 4 4-(4-Methoxyphenethyl)isoquinolin-l(2H)-one
- the title compound was prepared from 4-(4- methoxyphenethyl)isoquinoline-N-oxide (leq, 1.33mmol, 0.37g) according to the procedure described for Example 38 Step 2.
- the crude product was used without being purified and yielded 4-(4-methoxyphenethyl)isoquinolin-l(2H)-one (0.36mmol, 0.10g, 27%) as a brown solid.
- Step 5 4-(4-Methoxyphenethyl)-2-propylisoquinolin-l(2H)-one
- the title compound was prepared from 4-(4- methoxyphenethyl)isoquinolin-l(2H)-one (leq, 0.36mmol, 0.10g) 1-bromopropane (1.5eq, 0.54mmol, 49 ⁇ L) according to the procedure described for Example 1 Step 2.
- the title compound was prepared from 2,3-dimethoxypyridine (leq, 7.19mmol, 1.00g) according to the procedure described for Example 1 Step 1. Reaction conditions: 48 hours at room temperature. The crude product was purified by flash chromatography over silica gel (AIT Flashsmart prepacked column 25g SiO 2 ) using cyclohexane/AcOEt 96/4 to afford 5-bromo-2,3-dimethoxypyridine (3.81mmol, 0.83g, 53%).
- Step 2 2,3-Dimethoxy-5-(4-methoxyphenyl)pyridine
- Step 3 l-(4-Chloro-2-fluorobenzyl)-3-methoxy-5-(4-methoxyphenyl)pyridin-2(lH)-one
- Step 1 The title compound was prepared from 2,3-dimethoxy- 5-(4-methoxyphenyl)pyridine (leq, 0.41mol, 0.10g) and l-(bromomethyl)-4-chloro-2- fluorobenzene (2eq, 0.82mmol, 0.18g) according to the procedure described for Example 6 Step 2. Reaction conditions: 14 hours at 80°C in acetonitrile.
- the crude product was purified by silica gel chromatography (AIT Flashsmart prepacked column 10g SiO 2 ) using cyclohexane/AcOEt 70/30 to 50/50 as eluent to afford l-(4-Chloro-2- fluorobenzyl)-3-methoxy-5-(4-methoxyphenyl)pyridin-2(lH)-one (0.24mmol, 0.09g, 59%).
- the crude product was purified by flash chromatography over silica gel (AIT Flashsmart prepacked column 25g SiO 2 ) using C ⁇ 2 Cl 2 /AcOEt 80/20 and by recristallization in pentane to afford l-(3-fluorobenzyl)-4-phenethoxypyridin-2(lH)- one (0.13mmol, 43mg, 58%) as a white solid.
- Step 1 l-(4-Chlorobenzyl)-5-(hydroxymethyl)pyridin-2(lH)-one
- Method B A solution of l-(4-chlorobenzyl)-6-oxo-l,6- dihydropyridine-3-carbaldehyde (leq, 1.41mmol, 0.35g, Example 10 Step 1) and DIBAL (3eq, 4.20mmol, 4.20mL) in THF (5mL) was stirred for 30 min. at -78°C and 1 hour at room temperature. After addition of AcOEt, the reaction mixture was diluted with water. The organic layer was washed with saturated NH 4 Cl solution, dried over Na 2 SO 4 , filtered through celite and evaporated.
- Step 2 l-(4-Chlorobenzyl)-5-((4-methoxyphenoxy)methyl)pyridin-2(lH)-one
- Method B 4-Methoxyphenol (1.5eq, 0.68mmol, 84.3mg), PPh 3 (2.0eq, 0.91mmol, 0.30g) and DEAD (2eq, 0.91mmol, 0.16g) were added to a solution of l-(4-chlorobenzyl)-5-(hydroxymethyl)pyridin-2(lH)-one (leq, 0.45mmol, 0.1 Ig) in T ⁇ F (5mL).
- reaction mixture was stirred overnight at room temperature. After evaporation of the solvent, the reaction mixture was diluted with water. The organic layer was washed with saturated NaHCO 3 solution, dried over Na 2 SO 4 , filtered and evaporated.
- the crude product was purified by silica gel chromatography (AIT Flashsmart prepacked column 25g SiO 2 ) using cyclohexane/AcOEt 80/20 to afford 1- (4-chlorobenzyl)-5-((4-methoxyphenoxy)methyl)pyridin-2(lH)-one (0.19mmol, 0.07g, 42%) as a white solid.
- Step 1 tert-Butyl 4-(l-(4-chlorobenzyl)-6-oxo-l,6-dihydropyridin-3-yl)phenyl carbamate
- Step 1 A suspension of l-(4-chlorobenzyl)-5-bromopyridin- 2(lH)-one (3.35mmol, 1.00g, Example 2 Step 1), N-tert-butoxycarbonyl-4- aminophenylboronic acid (6.03mmol, 1.42g), Pd(PPh 3 ) 4 (0.17mmol, 195mg), Na 2 CO 3 (13.4mmol, 1.42g) in DME (20mL) and H 2 O (5mL) was degassed to remove the oxygen. The mixture was heated at 85°C for 20 hours. The resulting suspension was filtered off and the filtrate was washed with CH 2 Cl 2 .
- Step 2 tert-Butyl 4-(l-(4-chlorobenzyl)-6-oxo-l,6-dihydropyridin-3-yl)phenyl(2- (dimethylamino) ethyl) carbamate
- Step 4 tert-Butyl 4-(l-(4-chlorobenzyl)-6-oxo-l,6- dihydropyridin-3-yl)phenylcarbamate (0.34mmol 0.14g) was dissolved in dry THF (4mL) and the resulting solution was cooled at 0°C. Then, NaH (60% mineral oil; 1.02mmol, 40.8mg) was added, the mixture was stirred at 0°C for 10 minutes, warmed at room temperature and stirred for 30 minutes. After, N,N-dimethylaminoethyl chloride (0.69mmol) and KI (0.34mmol, 57.0mg) were added and the reaction mixture was heated at 90°C for 16 hours.
- Step 3 l-(4-Chlorobenzyl)-5-(4-(2-(dimethylamino)ethylamino)phenyl)pyridin-2(lH)- one
- Step 5 tert-Butyl 4-(l-(4-chlorobenzyl)-6-oxo-l,6- dihydropyridin-3-yl)phenyl(2-(dimethylamino)ethyl)carbamate (0.16mmol, 79.0mg) was dissolved in dry CH 2 Cl 2 (30mL). Then TFA (7mL) was added dropwise and the resulting solution was stirred at room temperature for 3 hours. Then the solvent was evaporated under reduced pressure and the resulting residue thus obtained was resulting suspension was taken up in CH 2 Cl 2 , washed with a saturated aqueous NaHCO 3 solution.
- the organic solvent was separated, dried (Na 2 SO 4 ) and the solvent was evaporated under reduced pressure.
- the residue was purified in a manifold (vac.) using a Sep-Pak silica cartridge CH 2 Cl 2 /MeOH(NH 3 )sat. 95/5.
- Step 1 N-(4-Fluorophenyl)-6-methoxy-N-methylpyridin-3-amine
- Method B To a mixture of 5-bromo-2-methoxypyridine (leq, 1.06mmol, 0.14mL), KOtBu (1.5eq, 1.60mmol, 0.18g), Pd(OAc) 2 (0.02eq, 21 ⁇ mol, 48mg), BINAP (0.04eq, 42 ⁇ mol, 26mg) in degassed DMF (1.5mL) was added 4- fluoro-N-methylbenzenamine (1.2eq, 1.28mmol, 0.14mL). The reaction mixture was micro waved at 130°C for 5min.
- the reaction mixture was quenched with water and the aqueous phase was extracted with AcOEt. The organic fraction was washed brine, dried over Na 2 SO 4 , filtered and concentrated under reduced pressure.
- the crude product was purified by silica gel chromatography (AIT Flashsmart prepacked column 15g SiO 2 , CH 2 Cl 2 /AcOEt 90/10) to afford N-(4-fluorophenyl)-6-methoxy-N-methylpyridin-3- amine (0.08mmol, 20mg, 8%) as a yellow oil.
- Step 2 l-(4-Chlorobenzyl)-5-((4-fluorophenyl)(methyl)amino)pyridin-2(lH)-one
- Step 2 The title compound was prepared from N-(4- fluorophenyl)-6-methoxy-N-methylpyridin-3 -amine (leq, 86 ⁇ mol, 20mg) and 4- chloro-benzylbromide (1.7eq, 0.15mmol, 30mg) according to the procedure described for Example 6 Step 2. Reaction conditions: 12 hours at 80°C in acetonitrile.
- the crude product was purified by silica gel chromatography (AIT Flashsmart prepacked column 10g SiO 2 ) using CH 2 Cl 2 /AcOEt 50/50 as eluent to afford l-(4-chlorobenzyl)-5-((4- fluorophenyl)(methyl)amino)pyridin-2(lH)-one (29 ⁇ mol, lOmg, 34%) as a yellow oil.
- Step 1 1-(4-Chlorobenzyl)-5-(4-(bromomethyl)phenyl)pyridin-2(1H)-one
- Step 3 To a solution of l-(4-chlorobenzyl)-5-(4- (hydroxymethyl)phenyl)pyridin-2(lH)-one (leq, 3.07mmol, 1.00g, Example 35 Step 1) in T ⁇ F (8mL) were added NBS (1.22eq, 3.74mmol, 0.67g) and PPh 3 (1.20eq, 3.68mmol, 0.97g) at -20°C for 4 hours.
- Step 4 The title compound was prepared from l-(4- chlorobenzyl)-5-(4-(bromomethyl)phenyl)pyridin-2(lH)-one (leq, 0.26mmol, 0.10g) and (1.5eq, 0.39mmol, 0.04g) according to the procedure described for Example 34 Step 3.
- Step 1 2-Methoxy-5-(4-methoxyphenyl)-4-methylpyridine
- Step 1 The title compound was prepared from 5-bromo-2- methoxy-4-methylpyridine (leq, 15.8mmol, 3.20g) and 4-methoxyphenylboronic acid
- Step 2 2-(2-Methoxy-5-(4-methoxyphenyl)pyridin-4-yl)ethanol
- Step 2 To a stirred solution of 2-methoxy-5-(4- methoxyphenyl)-4-methylpyridine (leq, lO.Ommol, 2.30g) in anhydrous THF (66mL) at -78°C under argon was added dropwise butyl lithium (2.5M, 1.5eq, 15.1mmol, 6.0mL). The reaction mixture was stirred for one hour and then allowed to warm slowly to 0°C and stirred at 0°C for a further 30 minutes.
- reaction mixture was then cooled to -78°C and paraformaldehyde (6.07g) was added. The reaction mixture was then allowed to warm to room temperature and was stirred for 2 hours. The reaction was quenched with saturated aqueous NH 4 Cl (30mL), diluted with AcOEt and the aqueous phase was extracted (x3). The combined organic fractions were dried (Na 2 SO 4 ), filtered and concentrated under reduced pressure. HCl 3M (15mL) was added to the solution of the crude residue diluted in acetonitrile (l0mL). The reaction mixture was stirred for 2 hours at 60°C. The aqueous phase was extracted with Et 2 O, then neutralized with NaHCO 3 (40mL).
- the aqueous phase was extracted with CH 2 Cl 2 .
- the combined organic fractions were dried (Na 2 SO 4 ), filtered and concentrated under reduced pressure.
- the crude product was purified by flash chromatography over silica gel (AIT Flashsmart prepacked column 20g SiO 2 ) using CH 2 Cl 2 /AcOEt (99/1) as the eluent to afford 2-(2-methoxy-5-(4-methoxyphenyl)pyridin-4-yl)ethanol (0.62mmol, 0.16g, 6%) as a colorless oil.
- Step 3 l-(4-Chlorobenzyl)-4-(2-hydroxyethyl)-5-(4-methoxyphenyl)pyridin-2(lH)-one
- the title compound was prepared from 2-(2-methoxy- 5-(4-methoxyphenyl)pyridin-4-yl)ethanol (leq, 0.62mmol, 0.16g) and 1- (bromomethyl)-4-chlorobenzene (1.5eq, 0.93mmol, 0.19g) according to the procedure described for Example 6 Step 2. Reaction conditions: 19 hours under 90°C.
- Step 4 l-(4-Chlorobenzyl)-4-(2-methoxyethyl)-5-(4-methoxyphenyl)pyridin-2(lH)-one
- Step 4 The title compound was prepared from l-(4- chlorobenzyl)-4-(2-hydroxyethyl)-5-(4-methoxyphenyl)pyridin-2(lH)-one (leq,
- Step 1 4-(Bromomethyl)-2-methoxy-5-(4-methoxyphenyl)pyridine
- Step 2 To a solution of 2-methoxy-5-(4-methoxyphenyl)-4- methylpyridine (2.20mmol, 0.50g, Example 48 Step 1) in CCl 4 (10mL) was added NBS (2eq, 4.40mmol, 0.78g). The reaction was then heated to reflux and subjected to UV light for 48 hours. The reaction was allowed to cool, filtered and concentrated under reduced pressure to afford crude 4-(bromomethyl)-2-methoxy-5-(4- methoxyphenyl)pyridine (0.70g) as a yellow oil which was used without any purification in the next step.
- Step 2 2-Methoxy-4-(methoxymethyl)-5-(4-methoxyphenyl)pyridine
- Step 3 The title compound was prepared from 4- (bromomethyl)-2-methoxy-5-(4-methoxyphenyl)pyridine (leq, 2.30mmol, 0.70g) according to the procedure described for Example 33 Step 1. After work up, 2- methoxy-4-(methoxymethyl)-5-(4-methoxyphenyl)pyridine (0.66mmol, 0.17g) as a light yellow oil.
- LC XTerra RP 18 , 3.5 ⁇ m, 3.0x50mm Column
- RT 4.56min
- MS m/z (CI) [MH] + 260.
- Step 3 l-(4-Chloro-2-fluorobenzyl)-4-(methoxymethyl)-5-(4-methoxyphenyl)pyridin- 2(lH)-one
- Step 4 The title compound was prepared from 2-methoxy-4- (methoxymethyl)-5-(4-methoxyphenyl)pyridine (leq, 0.66mmol, 0.17g) and 1- (bromomethyl)-4-chloro-2-fluorobenzene (1.5eq, 0.98mmol, 0.22g) according to the procedure described for Example 6 Step 2. Reaction conditions: 12 hours at 80°C.
- the crude product was purified by silica gel chromatography (AIT Flashsmart prepacked column 25g SiO 2 ) using CH 2 Cl 2 MeOH 98/2 as the eluent to afford l-(4-chloro-2- fluorobenzyl)-4-(methoxymethyl)-5-(4-methoxyphenyl)pyridin-2(lH)-one (5 ⁇ mol, 2mg, 1%) as yellow oil.
- Step 1 5-(4-Fluorophenoxy)-2-methoxypyridine
- the organic layer was separated, dried (Na 2 SO 4 ) and the solvent was evaporated under reduced pressure.
- the residue was purified in a manifold (vac.) using a Sep-Pak silica cartridge (heptane/AcOEt, 80/20).
- the product fractions were collected and the solvent was evaporated to give a mixture of the desired product contaminated with 4- fluorobenzylalcohol.
- This residue was taken up in AcOEt and washed with aqueous solution of NaOH IN.
- the organic layer was separated, dried (Na 2 SO 4 ) and the solvent was evaporated under reduced pressure giving 5-(4-fluorophenoxy)-2-methoxypyridine (520mg, 45%).
- Step 2 l-(4-Chlorobenzyl)-5-(4-fluorophenoxy)pyridin-2(lH)-one
- Step 1 5-(4-Fluorophenoxy)-2-methoxypyridine (2.37mmol, 520mg), 4-chlorobenzylchloride (3.55mmol, 603mg), NaI (2.37mmol, 356mg) in acetonitrile (15mL) was heated at 150°C for 20 minutes under microwave conditions. The cooled crude reaction was washed with water, extracted with AcOEt. The organic layer was collected, dried (Na 2 SO 4 ) and the solvent was evaporated under reduced pressure.
- Step 1 2-Methoxy-5-(4-methoxybenzyloxy)pyridine
- Method B To a mixture of 2-methoxy-5-hydroxypyridine (2.87mmol, 0.36g), 4-methoxybenzyl alcohol (5.75mmol, 0.72mL) and PPh 3 (5.29mmol, 1.4g) in THF (3.75mL) cooled with an ice-water bath, was added dropwise DEAD (5.47mmol, 0.86ml). The resulting mixture was irradiated under microwave conditions at 90°C for 30 minutes. The resulting reaction mixture was cooled, washed with a 1 N NaOH solution and extracted with AcOEt.
- Step 2 l-(4-Chlorobenzyl)-5-(4-methoxybenzyloxy)pyridine-2(lH)-one
- Step 1 2-Methoxy-5-(4-methoxybenzyloxy)pyridine (1.38mmol, 339mg), 4-chlorobenzylchloride (2.76mmol, 468mg), NaI (1.38mmol, 207mg) in acetonitrile (15mL) was heated at 150°C for 50 minutes under microwave conditions. The cooled crude reaction was washed with water, extracted with AcOEt. The organic layer was collected, dried (Na 2 SO 4 ) and the solvent was evaporated under reduced pressure.
- Step I l-((6-Chloropyridin-3-yl)methyl)-5-(4-methoxyphenyl)pyridin-2(lH)-one 5-(4-Methoxyphenyl)pyridine-2(lH)-one (4.20mmol, 0.85g), 2-chloro-5- (chloromethyl)pyridine (1.5eq, 6.30mmol, 1.02g), K 2 CO 3 (2eq, 8.40mmol, 1.17g) in T ⁇ F (10mL) were heated at 70°C for 2 hours. Then, the reaction was cooled to room temperature. The suspension was filtered off and the filtrate was evaporated under reduced pressure.
- Step 2 l-((6-Iodopyridin-3-yl)methyl)-5-(4-methoxyphenyl)pyridin-2(lH)-one
- Step 1 l-((6-Chloropyridin-3-yl)methyl)-5-(4- methoxyphenyl)pyridin-2(lH)-one (2.54mmol, 0.83g), trimethylsilyl chloride (3.3mmol, 0.42mL) and NaI (7.60mmol, 1.14g) in propionitrile (20mL) were heated at 140°C for 20 minutes under microwave irradiation conditions. Then the suspension was filtered off and the solid obtained was partitioned between C ⁇ 2 Cl 2 /water.
- Step 2 A mixture of l-((6-iodopyridin-3-yl)methyl)-5-(4- methoxyphenyl)pyridin-2(lH)-one (0.48mmol, 200mg), PdCl 2 (PPh 3 ) 2 (33 ⁇ mol, 23mg),
- Step 4 l-((6-Ethynylpyridin-3-yl)methyl)-5-(4-methoxyphenyl)pyridin-2(lH)-one
- Step 5 l-((6-Ethylpyridin-3-yl)methyl)-5-(4-methoxyphenyl)pyridin-2(lH)-one
- Step 3 To a suspension of PdVC 10% (0.05 eq) in MeOH (10mL) under N 2 atmosphere, a solution of l-((6-ethynylpyridin-3-yl)methyl)-5-(4- methoxyphenyl)pyridin-2(1H)-one (0.15mmol, 48mg) was added at room temperature. The flask was evacuated and filled with hydrogen until the pressure reached 20 psi. The resulting suspension was shaken at room temperature for 1 hour.
- Step 1 The title compound was prepared from isoquinolin-5- ol (leq, 6.89mmol, 1.00g) according to the procedure described for Example 38 Step 1. The crude residue was recrystallized in CH 2 Cl 2 .to yield 5-chloroisoquinoline-N-oxide (6.58mmol, 1.06g, 96%) as a beige solid. Step 2 : 5-(4-Methoxyphenethoxy)isoquinoline-N-oxide
- Step 2 The title compound was prepared from 5- chloroisoquinoline-N-oxide (leq, 6.21mmol, 1.00g) and l-(2-chloroethyl)-4- methoxybenzene (2eq, 12.4mmol, 2.12g) according to the procedure described for Example 1 Step 2. Reaction conditions: microwaved at 180°C for 15 min in acetonitrile. The crude product was purified by silica gel chromatography (AIT Flashsmart prepacked column 70g SiO 2 ) using cyclohexane/AcOEt 85/15 to 50/50 and MeOH to afford 5-(4-methoxyphenethoxy)isoquinoline-N-oxide (2.73mmol, 0.8 Ig,
- Step 3 5-(4-Methoxyphenethoxy)isoquinolin-l(2H)-one
- Step 4 5-(4-Methoxyphenethoxy)-2-propylisoquinolin-l(2H)-one
- ACE-C 18 column (3.0 ⁇ m, 4.6 x 30 mm) from Advanced Chromatography Technologies, with a flow rate of 1.5 mL/min.
- the standard gradient conditions used are: 80 % A (0.5 g/1 ammonium acetate solution), 10 % B (acetonitrile), 10 % C (methanol) to 50 % B and 50 % C in 6.5 min., to 100 % B at 7 min. and equilibrated to initial conditions at 7.5 min. until 9.0 min. A 5 ⁇ L volume of the sample was injected. In some cases sodium bicarbonate (lg/1) was used as buffer. All mass spectra were taken under electrospray ionisation (ESI) methods.
- ESI electrospray ionisation
- the compounds provided in the present invention are positive allosteric modulators of mGluR2. As such, these compounds do not appear to bind to the orthosteric glutamate recognition site, and do not activate the mGluR2 by themselves. Instead, the response of mGluR2 to a concentration of glutamate or mGluR2 agonist is increased when compounds of Formula (I) are present. Compounds of Formula (I) are expected to have their effect at mGluR2 by virtue of their ability to enhance the function of the receptor.
- Example A Formula (I), at mGluR2 is shown in Example A, which is suitable for the identification of such compounds.
- the [ 35 S]GTPyS binding is a functional membrane-based assay used to study G-protein coupled receptor (GPCR) function. This method is using a binding assay to assess the initial step in receptor-mediated G protein activation in membranes prepared from cells expressing recombinant GPCR or using membranes from discrete area of the rat brain.
- GPCR G-protein coupled receptor
- the assay is measuring the activation of G proteins by catalyzing the exchange of guanosine 5 '-diphosphate (GDP) by guanosine 5 '-triphosphate (GTP) at the ⁇ subunit.
- GDP guanosine 5 '-diphosphate
- GTP guanosine 5 '-triphosphate
- the GTP-bounded G proteins dissociate into two subunits, G ⁇ -GTP and G ⁇ , which in turn regulate intracellular enzymes and ion channels.
- GTP is rapidly hydro lysed by the G ⁇ -subunit (GTPases) and the G protein is deactivated and ready for new GTP exchange cycle (Harper (1998) Curr Protoc Pharmacol 2.6.1-10, John Wiley
- mGluR2 receptors are expressed in the rat brain cortex (Mutel et al (1998) J. Neurochem. 71:2558-64; Schaffhauser et al (1998) MoI. Pharmacol. 53:228-33) and are coupled to Go ⁇ -protein, a preferential coupling for this method.
- the study of the pharmacological characterisation of metabotropic glutamate receptor- mediated high-affinity GTPase activity (Nishi et al (2000) Br. J. Pharmacol.
- rat cortical membrane 1.5 ⁇ g were incubated in 96-well microplates for 15 min at 30°C in assay buffer (50 mM HEPES pH 7.4, 100 mM NaCl, 5 mM MgCl 2 , 10 ⁇ M GDP, 10 ⁇ g/ml saponin, EGTA 0.2 mM) with increasing concentrations of positive allosteric modulator (from 1 nM to 10 ⁇ M) and a minimal concentration of DCG-IV or LY379268, a selective mGluR2 agonist, that has been determined in previous experiments and that corresponds to the EC 20 , a concentration that gives 20 % of the maximal response of the agonist, and is in accordance to published data (Pin et al.
- the incubation was stopped by rapid vacuum filtration over glass-fiber filter plates (Unifilter 96-well GF/C filter plates, Perkin-Elmer, Schwerzenbach, Switzerland) microplate using a 96-well plate cell harvester (Filtermate, Perkin-Elmer, Downers Grove, USA).
- the Unifilter plate was washed three times with 300 ⁇ l of ice-cold wash buffer (20 mM HEPES pH 7.4, 100 mM NaCl). When filters are dried, 40 ⁇ l of liquid scintillation cocktail (Microscint 20) was added to each well. The amount of membrane-bound [ 35 S]GTPyS is measured using a 96-well plate reader (Top-Count, Perkin-Elmer, Downers Grove, USA).
- Non specific [ 35 S]GTPyS binding is determined in the presence of 10 ⁇ M of GTP.
- Said compound has no statistically significant agonistic activity when tested in the absence of 50 nM DCG-IV, as compared to buffer value (0% of maximal response). Instead, when compounds are added together with an mGluR2 agonist like glutamate or DCG-IV, the effect measured is significantly potentiated compared to the effect of the agonist alone at the same concentration.
- Each bar graph is the mean and S.E.M. of triplicate data points and is representative of three independent experiments.
- Table 19 shows representative compounds of the present invention that were clustered into three classes according to their ability to leftward-shift the concentration-response curve of a selective mGluR2 agonist such as LY379268 and/or to increase its maximal efficacy.
- Table 19 Activity data for selected compounds
- (+) left-ward shift of agonist mGluR2 concentration-response curve [ ⁇ 2]
- (+++) left-ward shift of agonist mGluR2 concentration-response curve [> 3.5]
- the positive allosteric modulators provided in the present invention are expected to increase the effectiveness of glutamate or mGluR2 agonists at mGluR2, and therefore, these positive allosteric modulators are expected to be useful for treatment of various neurological and psychiatric disorders associated with glutamate dysfunction described to be treated herein and others that can be treated by such positive allosteric modulators.
- Phencyclidine (PCP) model of schizophrenia PCP-induced increases in locomotor ambulation are a widely accepted animal model of schizophrenia. This model is based on the evidence that phencyclidine induces a schizophrenia-like syndrome in humans including increased motor behaviors, disruption of cognition and impairment of working memory (Steinfeld RE (1996) Behav Br Res. 74:45-55; Abi-Saab et al. (1998) Pharmacopsychiatry, 31:104-109). Further, it has also been shown that antipsychotic drugs that are effective in the treatment of schizophrenia reduce the locomotor activating effect of PCP (Gleason & Shannon (1997) Psychopharmacology, 129:79-84). These results demonstrate that locomotor activation induced by PCP is a useful model for screening of compounds which may be useful in the treatment of schizophrenia.
- Amphetamine model of schizophrenia Amphetamine-induced increases in locomotor ambulation are well known and are widely used as a model of the positive symptoms of schizophrenia. This model is based on evidence that amphetamine increases motor behaviors and can induce a psychotic state in humans (Yui et al. (2000) Ann NY Acad
- mice Male C57BL6/J mice (20-30 g) 7 weeks of age at the time of delivery were group housed in a temperature and humidity controlled facility on a 12 hour light /dark cycle for at least 5 days before use. Mice had access to food and water ad libitum except during locomotor activity experiments.
- locomotor (ambulatory) activity The effects of compounds on PCP- or amphetamine-induced locomotor activation in mice were tested. Locomotor activity of mice was tested in white plastic boxes 35 cm X 35 cm square with walls 40 cm in height.
- Locomotor activity was monitored by a videotracking system (VideoTrack, Viewpoint, Champagne au Mont d'Or, France) that recorded the ambulatory movements of mice. Mice were na ⁇ ve to the apparatus prior to testing. On test days, test compounds (200 mg/kg i.p. (intraperitoneal)) or vehicle were administered immediately before the PCP (5 mg/kg s.c.(sub-cutaneous), amphetamine (3.0 mg/kg s.c.) or saline injection. Mice were placed into the locomotor boxes immediately after the PCP, amphetamine or saline vehicle injection and their locomotor activity, defined as the distance traveled in centimeters (cm), was measured for 60 minutes.
- a videotracking system VideoTrack, Viewpoint, Champagne au Mont d'Or, France
- Compound administration Compounds were dissolved in dimethyl sulfoxide (DMSO) (4% of final volume) and then mixed with Labrafil Ml 944 CS (apricot kernel oil - Gattefosse, Saint Priest, France) (40% of final volume), sterile water (56% of final volume) and Tween 80 (lO ⁇ L per 10 ml solution) and administered in a volume of 10 ml/kg.
- DMSO dimethyl sulfoxide
- Labrafil Ml 944 CS apricot kernel oil - Gattefosse, Saint Priest, France
- sterile water 56% of final volume
- Tween 80 lO ⁇ L per 10 ml solution
- Compound- vehicle-treated mice received the equivalent volume of vehicle solution i.p. in the absence of added compound.
- PCP hydrochloride (Sigma, Switzerland) was dissolved in saline and was administered at a dose of 5 mg/kg s.c. in a volume of 10 ml/kg.
- PCP-vehicle-treated mice received an equal volume of saline vehicle injected s.c.
- D-amphetamine sulfate (Amino AG, Neuenhof, Switzerland) was dissolved in saline and administered at a dose of 3.0 mg/kg s.c. in a volume of 10 ml/kg.
- D-amphetamine-vehicle-treated mice received an equivalent volume of saline vehicle injected s.c.
- Statistical analyses were performed using GraphPad PRISM statistical software (GraphPad, San Diego, CA, USA). Data were analyzed using unpaired t-tests. The significance level was set at p ⁇ 0.05.
- Compound 4-16 can be replaced with the same amount of any of the compounds according to the present invention, in particular by the same amount of any of the exemplified compounds.
- An aqueous suspension is prepared for oral administration so that each 1 milliliter contains 1 to 5 mg of one of the active compounds , 50 mg of sodium carboxymethyl cellulose, 1 mg of sodium benzoate, 500 mg of sorbitol and water ad 1 ml.
- a parenteral composition is prepared by stirring 1.5 % by weight of active ingredient of the invention in 10% by volume propylene glycol and water.
- Compound 4-16 can be replaced with the same amount of any of the compounds according to the present invention, in particular by the same amount of any of the exemplified compounds.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/575,433 US8399493B2 (en) | 2004-09-17 | 2005-09-16 | Pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors |
CA2581144A CA2581144C (en) | 2004-09-17 | 2005-09-16 | Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors |
ES05787278.0T ES2527418T3 (en) | 2004-09-17 | 2005-09-16 | Novel pyridinone derivatives and their use as positive allosteric modulators of mGluR2 receptors |
CN2005800367503A CN101061098B (en) | 2004-09-17 | 2005-09-16 | Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors |
BRPI0515412-0A BRPI0515412A (en) | 2004-09-17 | 2005-09-16 | compound, pharmaceutical composition, and use of a compound or pharmaceutical composition |
JP2007531759A JP5179873B2 (en) | 2004-09-17 | 2005-09-16 | Novel pyridinone derivatives and their use as mGluR2 positive allosteric modulators |
EA200700617A EA013740B1 (en) | 2004-09-17 | 2005-09-16 | Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors |
UAA200703393A UA98098C2 (en) | 2004-09-17 | 2005-09-16 | Pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors |
EP05787278.0A EP1799646B1 (en) | 2004-09-17 | 2005-09-16 | Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors |
MX2007003006A MX2007003006A (en) | 2004-09-17 | 2005-09-16 | Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors. |
NZ554041A NZ554041A (en) | 2004-09-17 | 2005-09-16 | Novel pyridinone derivatives and their use as positive allosteric modulators of MGLUR2-receptors |
AU2005284098A AU2005284098B2 (en) | 2004-09-17 | 2005-09-16 | Novel pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors |
IL181742A IL181742A0 (en) | 2004-09-17 | 2007-03-06 | Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors |
NO20071660A NO20071660L (en) | 2004-09-17 | 2007-03-29 | Novel pyridinone derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
US13/721,230 US20130109652A1 (en) | 2004-09-17 | 2012-12-20 | Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0420722A GB0420722D0 (en) | 2004-09-17 | 2004-09-17 | Novel allosteric modulators |
GB0420722.1 | 2004-09-17 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/721,230 Division US20130109652A1 (en) | 2004-09-17 | 2012-12-20 | Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006030032A1 true WO2006030032A1 (en) | 2006-03-23 |
Family
ID=33306768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/054636 WO2006030032A1 (en) | 2004-09-17 | 2005-09-16 | Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors |
Country Status (20)
Country | Link |
---|---|
US (2) | US8399493B2 (en) |
EP (1) | EP1799646B1 (en) |
JP (2) | JP5179873B2 (en) |
KR (1) | KR20070085262A (en) |
CN (1) | CN101061098B (en) |
AU (1) | AU2005284098B2 (en) |
BR (1) | BRPI0515412A (en) |
CA (1) | CA2581144C (en) |
EA (1) | EA013740B1 (en) |
ES (1) | ES2527418T3 (en) |
GB (1) | GB0420722D0 (en) |
IL (1) | IL181742A0 (en) |
MX (1) | MX2007003006A (en) |
NO (1) | NO20071660L (en) |
NZ (1) | NZ554041A (en) |
SG (1) | SG155938A1 (en) |
TW (1) | TW200633982A (en) |
UA (1) | UA98098C2 (en) |
WO (1) | WO2006030032A1 (en) |
ZA (1) | ZA200703088B (en) |
Cited By (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007104783A3 (en) * | 2006-03-15 | 2007-11-08 | Janssen Pharmaceutica Nv | 1,4 -di substituted 3-cyano-pyridone derivatives and their use as positive mglur2-recept0r modulators |
US7402596B2 (en) | 2005-03-24 | 2008-07-22 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
WO2008107481A1 (en) * | 2007-03-07 | 2008-09-12 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
WO2008107480A1 (en) * | 2007-03-07 | 2008-09-12 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mglur2 -receptor modulators |
WO2008107479A1 (en) * | 2007-03-07 | 2008-09-12 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | 3-cyano-4-(4-phenyl-piperidin-1-yl)-pyridin-2-one derivatives |
WO2009004430A1 (en) * | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors |
WO2009033702A1 (en) * | 2007-09-14 | 2009-03-19 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones |
JP2009529344A (en) * | 2006-03-13 | 2009-08-20 | ピュラック バイオケム ビー.ブイ. | Food containing calcium salt mixture or calcium double salt |
WO2009110901A1 (en) * | 2008-03-06 | 2009-09-11 | Sanofi-Aventis | Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones, preparation and use thereof as allosteric modulators of mglur |
US7670591B2 (en) | 2006-06-19 | 2010-03-02 | Astrazeneca Ab | Heteroaryl substituted benzoxazoles |
WO2010025890A1 (en) * | 2008-09-02 | 2010-03-11 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
US7772256B2 (en) | 2007-03-06 | 2010-08-10 | Astrazeneca Ab | 2-heteroaryl substituted benzothiophenes and benzofuranes 709 |
WO2010130422A1 (en) * | 2009-05-12 | 2010-11-18 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
WO2011024872A1 (en) | 2009-08-26 | 2011-03-03 | 武田薬品工業株式会社 | Fused heterocyclic ring derivative and use thereof |
WO2011024869A1 (en) | 2009-08-26 | 2011-03-03 | 武田薬品工業株式会社 | Fused heterocyclic ring derivative and use thereof |
WO2011024873A1 (en) | 2009-08-26 | 2011-03-03 | 武田薬品工業株式会社 | Fused heterocyclic ring derivative and use thereof |
WO2011024871A1 (en) | 2009-08-26 | 2011-03-03 | 武田薬品工業株式会社 | Fused heterocyclic ring derivative and use thereof |
US7998984B2 (en) | 2006-05-08 | 2011-08-16 | Astrazeneca Ab | 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial |
WO2011114103A1 (en) * | 2010-03-18 | 2011-09-22 | Biolipox Ab | Pyrimidinones for use as medicaments |
US8063073B2 (en) | 2003-09-18 | 2011-11-22 | Astrazeneca Ab | 2-pyridone derivatives as neutrophil elastase inhibitors and their use |
US8114881B2 (en) | 2006-05-08 | 2012-02-14 | Astrazeneca Ab | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial |
US8163928B2 (en) | 2006-01-27 | 2012-04-24 | Astrazeneca Ab | Heteroaryl substituted benzothiazoles |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
US8207181B2 (en) | 2008-03-06 | 2012-06-26 | Sanofi | Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones, preparation and use thereof |
US8217176B2 (en) | 2008-02-26 | 2012-07-10 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivative and use thereof |
US8232296B2 (en) | 2009-02-20 | 2012-07-31 | Astrazeneca Ab | Salt 628 |
US8314120B2 (en) | 2010-03-30 | 2012-11-20 | Abbott Gmbh & Co. Kg | Small molecule potentiators of metabotropic glutamate receptors |
US8399493B2 (en) | 2004-09-17 | 2013-03-19 | Janssen Pharmaceuticals, Inc. | Pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors |
US8466284B2 (en) | 2007-11-06 | 2013-06-18 | Astra Zeneca Ab | Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase |
EP2603079A1 (en) * | 2010-08-12 | 2013-06-19 | Merck Sharp & Dohme Corp. | Positive allosteric modulators of mglur2 |
US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
US20130252934A1 (en) * | 2012-03-01 | 2013-09-26 | Genentech, Inc. | Serine/threonine kinase inhibitors |
US8604032B2 (en) | 2010-05-21 | 2013-12-10 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
US8642604B2 (en) | 2006-04-04 | 2014-02-04 | The Regents Of The University Of California | Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents |
US8664214B2 (en) | 2010-03-30 | 2014-03-04 | AbbVie Deutschland GmbH & Co. KG | Small molecule potentiators of metabotropic glutamate receptors I |
US8691813B2 (en) | 2008-11-28 | 2014-04-08 | Janssen Pharmaceuticals, Inc. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
US8697689B2 (en) | 2008-10-16 | 2014-04-15 | Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
US8697709B2 (en) | 2008-10-16 | 2014-04-15 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
US8703777B2 (en) | 2008-01-04 | 2014-04-22 | Intellikine Llc | Certain chemical entities, compositions and methods |
US8716480B2 (en) | 2009-05-12 | 2014-05-06 | Janssen Pharmaceuticals, Inc. | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
WO2014088085A1 (en) | 2012-12-06 | 2014-06-12 | 協和発酵キリン株式会社 | Pyridone compound |
US8785454B2 (en) | 2009-05-07 | 2014-07-22 | Intellikine Llc | Heterocyclic compounds and uses thereof |
US8785470B2 (en) | 2011-08-29 | 2014-07-22 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8809349B2 (en) | 2011-01-10 | 2014-08-19 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
US8835449B2 (en) | 2011-11-11 | 2014-09-16 | Pfizer Inc. | 2-thiopyrimidinones |
WO2014154794A1 (en) | 2013-03-28 | 2014-10-02 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders |
US8901133B2 (en) | 2010-11-10 | 2014-12-02 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8937060B2 (en) | 2009-05-12 | 2015-01-20 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2014096965A3 (en) * | 2012-12-21 | 2015-02-26 | Rvx Therapeutics Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
US8969347B2 (en) | 2008-06-03 | 2015-03-03 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
US8969363B2 (en) | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
TWI475995B (en) * | 2007-09-14 | 2015-03-11 | Janssen Pharmaceuticals Inc | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1,4'] bipyridinyl-2'-ones |
US8980899B2 (en) | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
US8993591B2 (en) | 2010-11-08 | 2015-03-31 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
US9012448B2 (en) | 2010-11-08 | 2015-04-21 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
WO2015063093A1 (en) | 2013-10-30 | 2015-05-07 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
US9034900B2 (en) | 2013-10-18 | 2015-05-19 | Quanticel Pharmaceuticals, Inc. | Bromodomain inhibitors |
US9056877B2 (en) | 2011-07-19 | 2015-06-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9096611B2 (en) | 2008-07-08 | 2015-08-04 | Intellikine Llc | Kinase inhibitors and methods of use |
US9133187B2 (en) | 2011-02-28 | 2015-09-15 | Array Biopharma Inc. | Serine/threonine kinase inhibitors |
US9187462B2 (en) | 2011-08-04 | 2015-11-17 | Array Biopharma Inc. | Substituted quinazolines as serine/threonine kinase inhibitors |
US9242933B2 (en) | 2007-05-25 | 2016-01-26 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) |
US9271967B2 (en) | 2010-11-08 | 2016-03-01 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
WO2016046164A1 (en) * | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
WO2016046157A1 (en) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives |
US9321772B2 (en) | 2011-09-02 | 2016-04-26 | The Regents Of The University Of California | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof |
US9359379B2 (en) | 2012-10-02 | 2016-06-07 | Intermune, Inc. | Anti-fibrotic pyridinones |
US9359365B2 (en) | 2013-10-04 | 2016-06-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9359349B2 (en) | 2007-10-04 | 2016-06-07 | Intellikine Llc | Substituted quinazolines as kinase inhibitors |
US9388171B2 (en) | 2012-08-27 | 2016-07-12 | Genetech, Inc. | Serine/threonine kinase inhibitors |
US9475809B2 (en) | 2013-07-23 | 2016-10-25 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives and use thereof as factor xia/plasma |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
US9512125B2 (en) | 2004-11-19 | 2016-12-06 | The Regents Of The University Of California | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents |
US9527816B2 (en) | 2005-05-10 | 2016-12-27 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
WO2017005725A1 (en) | 2015-07-09 | 2017-01-12 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
WO2017037051A1 (en) | 2015-09-04 | 2017-03-09 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
US9629843B2 (en) | 2008-07-08 | 2017-04-25 | The Regents Of The University Of California | MTOR modulators and uses thereof |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
US9708315B2 (en) | 2013-09-06 | 2017-07-18 | Janssen Pharmaceutica Nv | 1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of MGLUR2 receptors |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9771332B2 (en) | 2015-05-05 | 2017-09-26 | Pfizer Inc. | 2-thiopyrimidinones |
US9775844B2 (en) | 2014-03-19 | 2017-10-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2017184491A1 (en) | 2016-04-19 | 2017-10-26 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
WO2017184462A1 (en) | 2016-04-18 | 2017-10-26 | Celgene Quanticel Research, Inc. | Therapeutic compounds |
US20170305917A1 (en) * | 2011-12-21 | 2017-10-26 | Ono Pharmaceutical Co., Ltd. | Compounds |
US9855271B2 (en) | 2013-07-31 | 2018-01-02 | Zenith Epigenetics Ltd. | Quinazolinones as bromodomain inhibitors |
US10010556B2 (en) | 2013-06-21 | 2018-07-03 | Zenith Epigenetics Ltd. | Bicyclic bromodomain inhibitors |
US10071995B2 (en) | 2014-09-24 | 2018-09-11 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
US10077265B2 (en) | 2014-09-24 | 2018-09-18 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
US10106542B2 (en) | 2013-06-04 | 2018-10-23 | Janssen Pharmaceutica Nv | Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors |
US10131668B2 (en) | 2012-09-26 | 2018-11-20 | The Regents Of The University Of California | Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1 |
US10160761B2 (en) | 2015-09-14 | 2018-12-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
US10166215B2 (en) | 2013-06-21 | 2019-01-01 | Zenith Epigenetics Ltd. | Substituted bicyclic compounds as bromodomain inhibitors |
US10167280B2 (en) | 2014-09-24 | 2019-01-01 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
US10179125B2 (en) | 2014-12-01 | 2019-01-15 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
US10233195B2 (en) | 2014-04-02 | 2019-03-19 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10231953B2 (en) | 2014-12-17 | 2019-03-19 | Zenith Epigenetics Ltd. | Inhibitors of bromodomains |
US10292968B2 (en) | 2014-12-11 | 2019-05-21 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
US10407426B2 (en) | 2014-12-10 | 2019-09-10 | Ono Pharmaceutical Co., Ltd. | Dihydroindolizinone derivative |
US10414731B2 (en) | 2014-09-24 | 2019-09-17 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
WO2019197244A1 (en) | 2018-04-10 | 2019-10-17 | Bayer Pharma Aktiengesellschaft | A substituted oxopyridine derivative |
US10537573B2 (en) | 2014-01-21 | 2020-01-21 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
WO2020127504A1 (en) | 2018-12-21 | 2020-06-25 | Bayer Aktiengesellschaft | Substituted oxopyridine derivatives |
WO2020127508A1 (en) | 2018-12-21 | 2020-06-25 | Bayer Aktiengesellschaft | Substituted oxopyridine derivatives |
US10710992B2 (en) | 2014-12-01 | 2020-07-14 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP3831383A1 (en) | 2015-04-15 | 2021-06-09 | Celgene Quanticel Research, Inc. | Bromodomain inhibitors |
US11110096B2 (en) | 2014-04-16 | 2021-09-07 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US11147818B2 (en) | 2016-06-24 | 2021-10-19 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US11369606B2 (en) | 2014-01-21 | 2022-06-28 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
US11655237B2 (en) | 2020-03-30 | 2023-05-23 | Gilead Sciences, Inc. | Solid forms of a Cot inhibitor compound |
US11827662B2 (en) | 2019-06-14 | 2023-11-28 | Gilead Sciences, Inc. | Cot modulators and methods of use thereof |
US11845737B2 (en) | 2020-04-02 | 2023-12-19 | Gilead Sciences, Inc. | Process for preparing a Cot inhibitor compound |
EP4299124A1 (en) | 2022-06-30 | 2024-01-03 | Universite De Montpellier | Anti-mglur2 nanobodies for use as biomolecule transporter |
US11905299B2 (en) | 2015-07-06 | 2024-02-20 | Gilead Sciences, Inc. | Cot modulators and methods of use thereof |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200821305A (en) * | 2006-10-05 | 2008-05-16 | Astrazeneca Ab | MGluR5 modulators |
JP5351056B2 (en) * | 2007-03-09 | 2013-11-27 | サノフイ | Substituted dihydro and tetrahydrooxazolopyrimidinones, their preparation and use |
MX2010002537A (en) | 2007-09-14 | 2010-08-10 | Ortho Mcneil Janssen Pharm | 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones. |
US8785486B2 (en) | 2007-11-14 | 2014-07-22 | Janssen Pharmaceuticals, Inc. | Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
BR112012007322A2 (en) * | 2009-10-02 | 2017-06-06 | Astrazeneca Ab | 2-pyridone compound used as neutrophil elastase inhibitors |
EP2563143A4 (en) * | 2010-04-29 | 2013-09-25 | Merck Sharp & Dohme | Substituted 1,3-benzothiazol-2(3h)-ones and [1,3]thiazolo[5,4-b]pyridin-2(1h)-ones as positive allosteric modulators of mglur2 |
EP2579717A4 (en) * | 2010-06-09 | 2013-12-11 | Merck Sharp & Dohme | Positive allosteric modulators of mglur2 |
EP4289813A3 (en) | 2011-12-28 | 2024-05-15 | Global Blood Therapeutics, Inc. | Intermediates to obtain substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
US9012450B2 (en) | 2011-12-28 | 2015-04-21 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
KR20150023722A (en) * | 2012-06-12 | 2015-03-05 | 애브비 인코포레이티드 | Pyridinone and pyridazinone derivatives |
US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
CN105189460B (en) | 2013-02-08 | 2021-03-09 | 通用磨坊公司 | Low sodium food |
US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
EP3919056A1 (en) | 2013-03-15 | 2021-12-08 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
EP2968299B1 (en) | 2013-03-15 | 2021-01-20 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
PE20161035A1 (en) | 2013-03-15 | 2016-11-13 | Global Blood Therapeutics Inc | COMPOUNDS AND USES OF THESE FOR THE MODULATION OF HEMOGLOBIN |
US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
CA2902709A1 (en) * | 2013-03-15 | 2014-09-25 | Global Blood Therapeutics, Inc. | Compositions and methods for the modulation of hemoglobin (s) |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
EA202092627A1 (en) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION |
EA038715B1 (en) * | 2014-01-24 | 2021-10-08 | Селджен Квонтисел Рисёрч, Инк. | Bromodomain inhibitors |
DK3102208T3 (en) | 2014-02-07 | 2021-03-08 | Global Blood Therapeutics Inc | CRYSTALLINIC POLYMORPH OF THE FREE BASE OF 2-HYDROXY-6 - ((2- (1-ISOPROPYL-1H-PYRAZOL-5-YL) PYRIDIN-3-YL) METHOXY) BENZALDEHYDE |
US10702517B2 (en) | 2015-04-22 | 2020-07-07 | Celgene Quanticel Research, Inc. | Bromodomain inhibitor |
TW201642860A (en) * | 2015-04-22 | 2016-12-16 | 塞爾基因定量細胞研究公司 | Bromodomain inhibitor |
SG11201804647TA (en) | 2015-12-04 | 2018-06-28 | Global Blood Therapeutics Inc | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
TWI825524B (en) | 2016-05-12 | 2023-12-11 | 美商全球血液治療公司 | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1hpyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde |
TWI778983B (en) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
JP2020516672A (en) | 2017-04-18 | 2020-06-11 | セルジーン クオンティセル リサーチ,インク. | Therapeutic compound |
EP3459939A1 (en) * | 2017-09-26 | 2019-03-27 | Pragma Therapeutics | Novel heterocyclic compounds as modulators of mglur7 |
US11014884B2 (en) | 2018-10-01 | 2021-05-25 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0373423A1 (en) * | 1988-12-14 | 1990-06-20 | Bayer Ag | Substituted 2-pyridones and pyride-2-thiones, process for their preparation and their use in medicine |
EP0542059A1 (en) * | 1991-11-12 | 1993-05-19 | Bayer Ag | Substituted biphenylpyridinones as angiotensin II antagonists |
WO2003059884A1 (en) * | 2001-12-21 | 2003-07-24 | X-Ceptor Therapeutics, Inc. | Modulators of lxr |
WO2005002585A1 (en) * | 2003-07-02 | 2005-01-13 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor |
Family Cites Families (141)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE790440A (en) | 1971-10-23 | 1973-04-24 | Bayer Ag | |
SU509588A1 (en) * | 1974-06-10 | 1976-04-05 | Донецкое Отделение Физико-Органическойхимии Института Физическойхимии Ан Украинской Сср | Method for preparing imidazo (4,5-c) quinolines |
IE43079B1 (en) * | 1975-03-20 | 1980-12-17 | Ici Ltd | Quinolone derivatives |
GB1502312A (en) | 1975-03-20 | 1978-03-01 | Ici Ltd | Quinolone derivatives |
CA1082514A (en) * | 1976-03-01 | 1980-07-29 | Wilbert J. Humphlett | Dry heat-activated bleaching of silver images |
JPS5721371A (en) * | 1980-07-11 | 1982-02-04 | Daito Koeki Kk | Quinolinoneiminecarboxylic ester derivative, its preparation and anti-inflammatory and analgesic agent composition containing the same |
US4358453A (en) * | 1982-01-08 | 1982-11-09 | Schering Corporation | 1,2,4-Triazolo[4,3-a]pyridines |
US4550166A (en) * | 1984-05-21 | 1985-10-29 | American Cyanamid Company | (Pyridinyl)-1,2,4-triazolo[4,3-a]pyridines |
GB8804448D0 (en) | 1988-02-25 | 1988-03-23 | Smithkline Beckman Intercredit | Compounds |
US5236917A (en) * | 1989-05-04 | 1993-08-17 | Sterling Winthrop Inc. | Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof |
AU622330B2 (en) * | 1989-06-23 | 1992-04-02 | Takeda Chemical Industries Ltd. | Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides |
IL96432A0 (en) | 1989-11-30 | 1991-08-16 | Schering Ag | Pesticidal compositions containing pyridine derivatives and novel pyridine derivatives |
SU1731773A1 (en) * | 1990-03-16 | 1992-05-07 | Институт биофизики | Method of producing 2-iminothiazolidine derivatives |
GB9104238D0 (en) | 1990-03-16 | 1991-04-17 | Ici Pharma | 3-tetrazolylthiomethyl cephalosporin antibiotics |
AU651337B2 (en) | 1990-03-30 | 1994-07-21 | Dowelanco | Thienopyrimidine derivatives |
RU1796625C (en) | 1990-06-27 | 1993-02-23 | Киевский Государственный Университет Им.Т.Г.Шевченко | 3-amino-7-nitro-4-(2,3,4-trimethoxyphenyl)-2-phenyl-1(2h) isoquinolone having analeptic effect |
KR920008026A (en) * | 1990-10-24 | 1992-05-27 | 오노 화아마슈티칼 캄파니 리미팃드 | Isoquinolinone derivatives or nontoxic acid addition salts thereof or hydrates thereof, methods for preparing the same, and pharmaceutical compositions comprising the same |
JP2878531B2 (en) * | 1991-12-16 | 1999-04-05 | 富士写真フイルム株式会社 | Silver halide photographic material |
DE4326758A1 (en) | 1993-08-10 | 1995-02-16 | Basf Ag | [1,3,4] triazolo [1,5-a] pyridines |
SG73535A1 (en) * | 1993-10-18 | 2002-07-23 | Arch Chem Inc | Substituted pyridine-2-ones and substituted pyridine-2-thiones as biocides |
US5424435A (en) | 1993-10-18 | 1995-06-13 | Olin Corporation | 1-hydroxy-6-substituted-2-pyridones |
FR2728900B1 (en) * | 1994-12-29 | 1997-01-31 | Synthelabo | 3-PHENYLISOQUINOLEIN-1 (2H) -ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
DE19510965A1 (en) * | 1995-03-24 | 1996-09-26 | Asta Medica Ag | New pyrido / 3,2-e / pyrazinone with anti-asthmatic activity and process for their preparation |
BR9610579A (en) | 1995-09-15 | 1999-07-06 | Sanofi Synthelabo | Quinoline-2 (1H) -one derivatives as serotonin antagonists |
EP1162201B1 (en) | 1995-12-08 | 2006-03-29 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives |
DE19632423A1 (en) * | 1996-08-12 | 1998-02-19 | Merck Patent Gmbh | Thienopyrimidines |
WO1998011075A1 (en) * | 1996-09-16 | 1998-03-19 | Du Pont Pharmaceuticals Company | Pyrazinones and triazinones and their derivatives thereof |
DE19644228A1 (en) | 1996-10-24 | 1998-04-30 | Merck Patent Gmbh | Thienopyrimidines |
HUP0001140A3 (en) | 1996-12-05 | 2002-05-28 | Amgen Inc Thousand Oaks | Substituted pyrimidinone and pyridone compounds and methods of use |
GB2321454A (en) * | 1997-01-24 | 1998-07-29 | Norsk Hydro As | Gemcitabine esters and amides |
WO1998032762A1 (en) | 1997-01-24 | 1998-07-30 | Norsk Hydro Asa | Gemcitabine derivatives |
BR9909976A (en) * | 1998-04-27 | 2000-12-26 | Centre Nat Rech Scient | Compound, process for obtaining compounds, lithium derivative, pharmaceutical compositions, and processes for treating HIV-related diseases and treating HIV infection |
JP2002517396A (en) | 1998-06-04 | 2002-06-18 | アボット・ラボラトリーズ | Anti-inflammatory compounds that inhibit cell adhesion |
FR2781218B1 (en) * | 1998-07-15 | 2001-09-07 | Lafon Labor | PHARMACEUTICAL COMPOSITIONS COMPRISING 2-QUINOLONES |
JP2000072751A (en) | 1998-08-26 | 2000-03-07 | Tanabe Seiyaku Co Ltd | Isoquinolinone derivative |
US6133271A (en) * | 1998-11-19 | 2000-10-17 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives |
US5948911A (en) * | 1998-11-20 | 1999-09-07 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to thienopyrimidine derivatives |
EP1006112A1 (en) | 1998-12-01 | 2000-06-07 | Cerebrus Pharmaceuticals Limited | 3-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengers |
ATE354569T1 (en) | 1998-12-04 | 2007-03-15 | Bristol Myers Squibb Co | 3-SUBSTITUTED-4-ARYLCINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS |
EP1048293A1 (en) | 1999-04-23 | 2000-11-02 | The School Of Pharmacy, University Of London | Headlice treatment compositions |
BR9916746A (en) | 1999-06-03 | 2005-01-11 | Abbott Lab | Antiinflammatory compounds that inhibit cell adhesion |
PT1226136E (en) * | 1999-10-19 | 2005-04-29 | Merck & Co Inc | TIROSIN KINASE INHIBITORS |
AU1071301A (en) | 1999-11-01 | 2001-05-14 | Eli Lilly And Company | Pharmaceutical compounds |
US6800651B2 (en) | 2000-02-03 | 2004-10-05 | Eli Lilly And Company | Potentiators of glutamate receptors |
DE10012373A1 (en) | 2000-03-14 | 2001-09-20 | Dresden Arzneimittel | Treating erectile dysfunction using new or known imidazo(1,5-a)pyrido(3,2-e)pyrazinone derivatives, as cGMP-selective phosphodiesterase V inhibitors free of cardiovascular side-effects |
GB0007108D0 (en) | 2000-03-23 | 2000-05-17 | Novartis Ag | Organic compounds |
EP1277754B8 (en) | 2000-04-27 | 2005-09-28 | Astellas Pharma Inc. | Imidazopyridine derivatives |
EP1300396B1 (en) * | 2000-06-12 | 2009-01-14 | Eisai R&D Management Co., Ltd. | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
JP2002012533A (en) * | 2000-06-27 | 2002-01-15 | Kao Corp | Hair dye composition |
JP2002040252A (en) | 2000-07-27 | 2002-02-06 | Shiseido Co Ltd | Optical sheet containing cholesteric liquid crystal layer, information recording body using the same, method for recording information and method for discriminating information |
DE10038019A1 (en) | 2000-08-04 | 2002-02-14 | Bayer Ag | Substituted triazolopyride (az) ine |
PT1650203E (en) | 2000-09-11 | 2008-05-13 | Novartis Vaccines & Diagnostic | Process of preparation of benzimidazol-2-yl quinolinone derivatives |
IL155163A0 (en) * | 2000-10-02 | 2003-10-31 | Janssen Pharmaceutica Nv | Metabotropic glutamate receptor antagonists |
JP2002308882A (en) | 2001-02-08 | 2002-10-23 | Yamanouchi Pharmaceut Co Ltd | Thienopyrimidine derivative |
WO2002074025A2 (en) | 2001-03-08 | 2002-09-19 | Ilfa Industrieelektronik Und Leiterplattenfertigung Aller Art Gmbh | Multilayer printed circuit board |
SE0101579D0 (en) | 2001-05-04 | 2001-05-04 | Astrazeneca Ab | New compounds |
IL158669A0 (en) * | 2001-05-14 | 2004-05-12 | Bristol Myers Squibb Pharma Co | Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands |
WO2002096363A2 (en) | 2001-05-30 | 2002-12-05 | Alteon, Inc. | Method for treating fibrotic diseases or other indications |
EP1414464A4 (en) | 2001-05-30 | 2005-06-22 | Alteon Inc | Method for treating glaucoma v |
CA2451057A1 (en) * | 2001-06-14 | 2002-12-27 | Banyu Pharmaceutical Co., Ltd. | Novel isoxazolopyridone derivatives and use thereof |
WO2003029209A2 (en) | 2001-10-02 | 2003-04-10 | Smithkline Beecham Corporation | Chemical compounds |
US6921762B2 (en) | 2001-11-16 | 2005-07-26 | Amgen Inc. | Substituted indolizine-like compounds and methods of use |
WO2003062392A2 (en) | 2002-01-18 | 2003-07-31 | Ceretek Llc | Methods of treating conditions associated with an edg receptor |
US20050113283A1 (en) * | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
JP2005516988A (en) | 2002-02-07 | 2005-06-09 | ユニバーシティー オブ マイアミ | Treatment based on Schwann cells and phosphodiesterase inhibitors |
EP1484320A1 (en) * | 2002-02-13 | 2004-12-08 | Takeda Chemical Industries, Ltd. | Jnk inhibitor |
GEP20063937B (en) | 2002-02-14 | 2006-10-10 | Pharmacia Corp | Substituted pyridinones as modulators of p38 map kinase |
ME00077B (en) * | 2002-03-01 | 2010-06-10 | Chiesi Farm Spa | Formoterol superfine formulation |
WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
CA2495756A1 (en) | 2002-08-26 | 2004-03-04 | Merck & Co., Inc. | Acetophenone potentiators of metabotropic glutamate receptors |
MY139563A (en) | 2002-09-04 | 2009-10-30 | Bristol Myers Squibb Co | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
US7067658B2 (en) | 2002-09-30 | 2006-06-27 | Bristol-Myers Squibb Company | Pyridino and pyrimidino pyrazinones |
DE10306250A1 (en) | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituted N-aryl heterocycles, processes for their preparation and their use as pharmaceuticals |
KR100751604B1 (en) * | 2003-03-03 | 2007-08-22 | 에프. 호프만-라 로슈 아게 | 2,5- and 2,6-substituted tetrahydroisoquinolines for use as 5-ht6 modulators |
ITFI20030058A1 (en) | 2003-03-06 | 2004-09-07 | Univ Firenze | PHARMACEUTICAL FORMULATIONS CONTAINING THIAZOLIDINEDIONI |
WO2004092123A2 (en) | 2003-04-10 | 2004-10-28 | Microbia, Inc. | Inhibitors of fungal invasion |
ES2300798T3 (en) | 2003-04-15 | 2008-06-16 | Astrazeneca Ab | BENZOSULFONAMIDS REPLACED AS POTENTIALS OF GLUTAMATE RECEIVERS. |
US20070053831A1 (en) | 2003-05-20 | 2007-03-08 | Barrio Jorge R | Methods for binding agents to b-amyloid plaques |
BRPI0413861A (en) | 2003-08-29 | 2006-10-24 | Vernalis Cambridge Ltd | pyrimidothiophene compounds |
GB0320300D0 (en) | 2003-08-29 | 2003-10-01 | Cancer Rec Tech Ltd | Pyrimidothiophene compounds |
GB0322016D0 (en) | 2003-09-19 | 2003-10-22 | Merck Sharp & Dohme | New compounds |
TW200533664A (en) | 2004-02-18 | 2005-10-16 | Astrazeneca Ab | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists |
US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
GB0413605D0 (en) * | 2004-06-17 | 2004-07-21 | Addex Pharmaceuticals Sa | Novel compounds |
US8063004B2 (en) | 2004-07-22 | 2011-11-22 | Malcera, L.L.C. | Chemical composition of matter for the liquefaction and dissolution of asphaltene and paraffin sludges into petroleum crude oils and refined products at ambient temperatures and method of use |
CA2574971A1 (en) | 2004-07-30 | 2006-02-09 | Merck & Co., Inc. | Indanone potentiators of metabotropic glutamate receptors |
CN1993326A (en) | 2004-07-30 | 2007-07-04 | 默克公司 | Heterocyclic acetophenone potentiators of metabotropic glutamate receptors |
BRPI0514015A (en) | 2004-08-02 | 2008-05-27 | Sanol Arznei Schwarz Gmbh | indolizine carboxamides and their derivatives aza and diaza |
WO2006024970A1 (en) | 2004-08-11 | 2006-03-09 | Koninklijke Philips Electronics, N.V. | Ultrasonic diagnosis of ischemic cardiodisease |
TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
MX2007001612A (en) | 2004-08-18 | 2007-04-10 | Upjohn Co | Triazolopyridine compounds useful for the treatment of inflammation. |
GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
GB0420719D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
US7434262B2 (en) * | 2004-12-08 | 2008-10-07 | At&T Intellectual Property I, L.P. | Methods and systems that selectively resurrect blocked communications between devices |
US7456289B2 (en) | 2004-12-31 | 2008-11-25 | National Health Research Institutes | Anti-tumor compounds |
US7572807B2 (en) * | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
US7579360B2 (en) * | 2005-06-09 | 2009-08-25 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
BRPI0617166A2 (en) | 2005-09-17 | 2011-07-12 | Speedel Experimenta Ag | 5-amino-4-hydroxy-7- (imidazo [1,2-a] pyridin-6-ylmethyl) -8-methyl-nonamidia derivatives and related compounds as renin inhibitors for the treatment of hypertension |
EP1764099A3 (en) | 2005-09-17 | 2007-05-09 | Speedel Experimenta AG | Diaminoalcohol derivatives for the treatment of Alzheimer, malaria, HIV |
WO2008051197A2 (en) | 2005-09-20 | 2008-05-02 | Mayo Foundation For Medical Education And Research | Small-molecule botulinum toxin inhibitors |
EP1934214B1 (en) | 2005-09-27 | 2010-04-07 | F.Hoffmann-La Roche Ag | Oxadiazolyl pyrazolo-pyrimidines as mglur2 antagonists |
DE602006021645D1 (en) | 2005-11-15 | 2011-06-09 | Array Biopharma Inc | Process and intermediates for the preparation of N4-phenyl quinazoline-4-amine derivatives |
JP2009528388A (en) | 2006-03-02 | 2009-08-06 | スミスクライン・ビーチャム・コーポレイション | Thiazolone used as a PI3 kinase inhibitor |
TWI417095B (en) * | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors |
GB0606774D0 (en) | 2006-04-03 | 2006-05-10 | Novartis Ag | Organic compounds |
GB0608263D0 (en) | 2006-04-26 | 2006-06-07 | Glaxo Group Ltd | Compounds |
WO2007135529A2 (en) | 2006-05-23 | 2007-11-29 | Pfizer Products Inc. | Azabenzimidazolyl compounds as mglur2 potentiators |
WO2007135527A2 (en) | 2006-05-23 | 2007-11-29 | Pfizer Products Inc. | Benzimidazolyl compounds |
EP2046788A1 (en) | 2006-07-12 | 2009-04-15 | Syngeta Participations AG | Triazolopyridine derivatives as herbicides |
US8198448B2 (en) * | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
PE20121506A1 (en) | 2006-07-14 | 2012-11-26 | Amgen Inc | TRIAZOLOPYRIDINE COMPOUNDS AS C-MET INHIBITORS |
US8217177B2 (en) * | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
WO2008012622A2 (en) | 2006-07-25 | 2008-01-31 | Pfizer Products Inc. | Azabenzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor |
CA2665195C (en) | 2006-10-11 | 2011-08-09 | Amgen Inc. | Imidazo- and triazolo-pyridine compounds and methods of use thereof |
US7994190B2 (en) | 2006-11-01 | 2011-08-09 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
TW200831085A (en) | 2006-12-13 | 2008-08-01 | Merck & Co Inc | Non-nucleoside reverse transcriptase inhibitors |
MX2009006706A (en) | 2006-12-22 | 2009-07-02 | Astex Therapeutics Ltd | Bicyclic heterocyclic compounds as fgfr inhibitors. |
AU2007337895C1 (en) | 2006-12-22 | 2014-07-31 | Astex Therapeutics Limited | Tricyclic amine derivatives as protein tyrosine kinase inhibitors |
ES2320955B1 (en) | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | NEW DERIVATIVES OF 3 - ((1,2,4) TRIAZOLO (4,3-A) PIRIDIN-7-IL) BENZAMIDA. |
TW200900391A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-phenyl-piperidin-1-yl)-pyridin-2-one derivatives |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
WO2008124085A2 (en) | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
MX2010002537A (en) | 2007-09-14 | 2010-08-10 | Ortho Mcneil Janssen Pharm | 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones. |
DK2200985T3 (en) * | 2007-09-14 | 2011-10-24 | Ortho Mcneil Janssen Pharm | 1,3-Disubstituted 4- (aryl-X-phenyl) -1H-pyridin-2-ones |
SI2203439T1 (en) | 2007-09-14 | 2011-05-31 | Ortho Mcneil Janssen Pharm | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-y1, 4' bipyridinyl-2'-ones |
US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US8785486B2 (en) | 2007-11-14 | 2014-07-22 | Janssen Pharmaceuticals, Inc. | Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
DE102008001056A1 (en) | 2008-04-08 | 2009-10-15 | Robert Bosch Gmbh | Deflection device for a beam of an electromagnetic wave |
TWI496779B (en) | 2008-08-19 | 2015-08-21 | Array Biopharma Inc | Triazolopyridine compounds as pim kinase inhibitors |
US8557809B2 (en) | 2008-08-19 | 2013-10-15 | Array Biopharma Inc. | Triazolopyridine compounds as PIM kinase inhibitors |
WO2010025890A1 (en) | 2008-09-02 | 2010-03-11 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
RU2517181C2 (en) | 2008-10-16 | 2014-05-27 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | Indole and benzomorpholine derivatives as modulator of metabotropic glutamate receptors |
US8691813B2 (en) | 2008-11-28 | 2014-04-08 | Janssen Pharmaceuticals, Inc. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
AT507619B1 (en) | 2008-12-05 | 2011-11-15 | Oesterreichisches Forschungs Und Pruefzentrum Arsenal Ges M B H | PROCESS FOR APPROXIMATING THE TIMELY OF TRAFFIC DATA |
EP2393807B1 (en) | 2009-02-04 | 2013-08-14 | Boehringer Ingelheim International GmbH | Cyclic inhibitors of 11 -hydroxysteroid dehydrogenase 1 |
WO2010117926A1 (en) | 2009-04-07 | 2010-10-14 | Schering Corporation | Substituted triazolopyridines and analogs thereof |
DK2421754T3 (en) | 2009-04-23 | 2017-01-16 | Saab Ab | Dispensing unit with closable countermeasures |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
JP5707390B2 (en) | 2009-05-12 | 2015-04-30 | ジャンセン ファーマシューティカルズ, インコーポレイテッド | 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of the mGluR2 receptor |
CN102002040A (en) | 2009-09-01 | 2011-04-06 | 上海药明康德新药开发有限公司 | Synthesis method of triazol pyridine ring compound |
-
2004
- 2004-09-17 GB GB0420722A patent/GB0420722D0/en not_active Ceased
-
2005
- 2005-09-16 US US11/575,433 patent/US8399493B2/en active Active
- 2005-09-16 ES ES05787278.0T patent/ES2527418T3/en active Active
- 2005-09-16 KR KR1020077008762A patent/KR20070085262A/en not_active Application Discontinuation
- 2005-09-16 EA EA200700617A patent/EA013740B1/en not_active IP Right Cessation
- 2005-09-16 CN CN2005800367503A patent/CN101061098B/en not_active Expired - Fee Related
- 2005-09-16 UA UAA200703393A patent/UA98098C2/en unknown
- 2005-09-16 MX MX2007003006A patent/MX2007003006A/en not_active Application Discontinuation
- 2005-09-16 NZ NZ554041A patent/NZ554041A/en not_active IP Right Cessation
- 2005-09-16 SG SG200906238-1A patent/SG155938A1/en unknown
- 2005-09-16 EP EP05787278.0A patent/EP1799646B1/en active Active
- 2005-09-16 WO PCT/EP2005/054636 patent/WO2006030032A1/en active Application Filing
- 2005-09-16 AU AU2005284098A patent/AU2005284098B2/en not_active Ceased
- 2005-09-16 CA CA2581144A patent/CA2581144C/en not_active Expired - Fee Related
- 2005-09-16 BR BRPI0515412-0A patent/BRPI0515412A/en not_active IP Right Cessation
- 2005-09-16 JP JP2007531759A patent/JP5179873B2/en not_active Expired - Fee Related
- 2005-09-16 ZA ZA200703088A patent/ZA200703088B/en unknown
- 2005-09-19 TW TW094132375A patent/TW200633982A/en unknown
-
2007
- 2007-03-06 IL IL181742A patent/IL181742A0/en not_active IP Right Cessation
- 2007-03-29 NO NO20071660A patent/NO20071660L/en not_active Application Discontinuation
-
2012
- 2012-10-26 JP JP2012236973A patent/JP5723850B2/en not_active Expired - Fee Related
- 2012-12-20 US US13/721,230 patent/US20130109652A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0373423A1 (en) * | 1988-12-14 | 1990-06-20 | Bayer Ag | Substituted 2-pyridones and pyride-2-thiones, process for their preparation and their use in medicine |
EP0542059A1 (en) * | 1991-11-12 | 1993-05-19 | Bayer Ag | Substituted biphenylpyridinones as angiotensin II antagonists |
WO2003059884A1 (en) * | 2001-12-21 | 2003-07-24 | X-Ceptor Therapeutics, Inc. | Modulators of lxr |
WO2005002585A1 (en) * | 2003-07-02 | 2005-01-13 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor |
Cited By (252)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8063073B2 (en) | 2003-09-18 | 2011-11-22 | Astrazeneca Ab | 2-pyridone derivatives as neutrophil elastase inhibitors and their use |
US8501784B2 (en) | 2003-09-18 | 2013-08-06 | Astrazeneca Ab | 2-pyridone derivatives as neutrophil elastase inhibitors and their use |
US8399493B2 (en) | 2004-09-17 | 2013-03-19 | Janssen Pharmaceuticals, Inc. | Pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors |
US9512125B2 (en) | 2004-11-19 | 2016-12-06 | The Regents Of The University Of California | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents |
US7402596B2 (en) | 2005-03-24 | 2008-07-22 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
US9527816B2 (en) | 2005-05-10 | 2016-12-27 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
US10010536B2 (en) | 2005-05-10 | 2018-07-03 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
US8957215B2 (en) | 2006-01-27 | 2015-02-17 | Navidea Biopharmaceuticals, Inc. | Heteroaryl substituted benzothiazoles |
US8163928B2 (en) | 2006-01-27 | 2012-04-24 | Astrazeneca Ab | Heteroaryl substituted benzothiazoles |
JP2009529344A (en) * | 2006-03-13 | 2009-08-20 | ピュラック バイオケム ビー.ブイ. | Food containing calcium salt mixture or calcium double salt |
US9266834B2 (en) | 2006-03-15 | 2016-02-23 | Janssen Pharmaceuticals, Inc. | 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors |
WO2007104783A3 (en) * | 2006-03-15 | 2007-11-08 | Janssen Pharmaceutica Nv | 1,4 -di substituted 3-cyano-pyridone derivatives and their use as positive mglur2-recept0r modulators |
US8841323B2 (en) | 2006-03-15 | 2014-09-23 | Janssen Pharmaceuticals, Inc. | 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors |
EA017914B1 (en) * | 2006-03-15 | 2013-04-30 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MODULATORS OF mGluR2-RECEPTORS |
EA017914B8 (en) * | 2006-03-15 | 2013-08-30 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MODULATORS OF mGluR2-RECEPTORS |
EP2426125A1 (en) * | 2006-03-15 | 2012-03-07 | Ortho-McNeil-Janssen Pharmaceuticals, Inc. | 1,4 disubstituted 3 cyano pyridone derivatives and their use as positive allosteric modulators of mGluR2 receptors |
US9493467B2 (en) | 2006-04-04 | 2016-11-15 | The Regents Of The University Of California | PI3 kinase antagonists |
US8642604B2 (en) | 2006-04-04 | 2014-02-04 | The Regents Of The University Of California | Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents |
US7998984B2 (en) | 2006-05-08 | 2011-08-16 | Astrazeneca Ab | 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial |
US8114881B2 (en) | 2006-05-08 | 2012-02-14 | Astrazeneca Ab | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial |
US7670591B2 (en) | 2006-06-19 | 2010-03-02 | Astrazeneca Ab | Heteroaryl substituted benzoxazoles |
US7772256B2 (en) | 2007-03-06 | 2010-08-10 | Astrazeneca Ab | 2-heteroaryl substituted benzothiophenes and benzofuranes 709 |
EA017280B1 (en) * | 2007-03-07 | 2012-11-30 | Аддекс Фарма С.А. | 3-cyano-4-(4-phenylpiperidin-1-yl)pyridin-2-one derivatives |
WO2008107479A1 (en) * | 2007-03-07 | 2008-09-12 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | 3-cyano-4-(4-phenyl-piperidin-1-yl)-pyridin-2-one derivatives |
US9067891B2 (en) | 2007-03-07 | 2015-06-30 | Janssen Pharmaceuticals, Inc. | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mGluR2-receptors |
WO2008107481A1 (en) * | 2007-03-07 | 2008-09-12 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
WO2008107480A1 (en) * | 2007-03-07 | 2008-09-12 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mglur2 -receptor modulators |
EA017294B1 (en) * | 2007-03-07 | 2012-11-30 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | 3-cyano-4-(4-tetrahydropyranphenyl)pyridin-2-one derivatives |
US8906939B2 (en) | 2007-03-07 | 2014-12-09 | Janssen Pharmaceuticals, Inc. | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
EA017267B1 (en) * | 2007-03-07 | 2012-11-30 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | 1,4-DISUBSTITUTED 3-CYANOPYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE mGluR2-RECEPTOR MODULATORS |
US8299101B2 (en) | 2007-03-07 | 2012-10-30 | Janssen Pharmaceuticals, Inc. | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mGluR2-receptor modulators |
AU2008223795B2 (en) * | 2007-03-07 | 2012-11-22 | Addex Pharma S.A. | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mGluR2 -receptor modulators |
US9242933B2 (en) | 2007-05-25 | 2016-01-26 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) |
WO2009004430A1 (en) * | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors |
WO2009033702A1 (en) * | 2007-09-14 | 2009-03-19 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones |
US9132122B2 (en) | 2007-09-14 | 2015-09-15 | Janssen Pharmaceuticals, Inc. | 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones |
US11071729B2 (en) | 2007-09-14 | 2021-07-27 | Addex Pharmaceuticals S.A. | 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones |
US9114138B2 (en) | 2007-09-14 | 2015-08-25 | Janssen Pharmaceuticals, Inc. | 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones |
US8748621B2 (en) | 2007-09-14 | 2014-06-10 | Janssen Pharmaceuticals, Inc. | 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones |
CN101848893B (en) * | 2007-09-14 | 2012-06-06 | 奥梅-杨森制药有限公司 | 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones |
EA019085B1 (en) * | 2007-09-14 | 2014-01-30 | Янссен Фармасьютикалз, Инк. | 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones |
TWI475995B (en) * | 2007-09-14 | 2015-03-11 | Janssen Pharmaceuticals Inc | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1,4'] bipyridinyl-2'-ones |
US9359349B2 (en) | 2007-10-04 | 2016-06-07 | Intellikine Llc | Substituted quinazolines as kinase inhibitors |
US8466284B2 (en) | 2007-11-06 | 2013-06-18 | Astra Zeneca Ab | Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase |
US9822131B2 (en) | 2008-01-04 | 2017-11-21 | Intellikine Llc | Certain chemical entities, compositions and methods |
US9655892B2 (en) | 2008-01-04 | 2017-05-23 | Intellikine Llc | Certain chemical entities, compositions and methods |
US11433065B2 (en) | 2008-01-04 | 2022-09-06 | Intellikine Llc | Certain chemical entities, compositions and methods |
US8785456B2 (en) | 2008-01-04 | 2014-07-22 | Intellikine Llc | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
US9216982B2 (en) | 2008-01-04 | 2015-12-22 | Intellikine Llc | Certain chemical entities, compositions and methods |
US8703777B2 (en) | 2008-01-04 | 2014-04-22 | Intellikine Llc | Certain chemical entities, compositions and methods |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
US8399449B2 (en) | 2008-02-26 | 2013-03-19 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivative and use thereof |
US8217176B2 (en) | 2008-02-26 | 2012-07-10 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivative and use thereof |
US8207181B2 (en) | 2008-03-06 | 2012-06-26 | Sanofi | Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones, preparation and use thereof |
WO2009110901A1 (en) * | 2008-03-06 | 2009-09-11 | Sanofi-Aventis | Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones, preparation and use thereof as allosteric modulators of mglur |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
US9637492B2 (en) | 2008-03-14 | 2017-05-02 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
US8969347B2 (en) | 2008-06-03 | 2015-03-03 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
US9290450B2 (en) | 2008-06-03 | 2016-03-22 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
USRE47142E1 (en) | 2008-06-03 | 2018-11-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
US9096611B2 (en) | 2008-07-08 | 2015-08-04 | Intellikine Llc | Kinase inhibitors and methods of use |
US9828378B2 (en) | 2008-07-08 | 2017-11-28 | Intellikine Llc | Kinase inhibitors and methods of use |
US9629843B2 (en) | 2008-07-08 | 2017-04-25 | The Regents Of The University Of California | MTOR modulators and uses thereof |
US8691849B2 (en) | 2008-09-02 | 2014-04-08 | Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
RU2510396C2 (en) * | 2008-09-02 | 2014-03-27 | Янссен Фармасьютикалз, Инк. | 3-azabicyclo[3,1,0]hexyl derivatives as modulators of metabotropic glutamate receptors |
AU2009289784B2 (en) * | 2008-09-02 | 2012-03-22 | Addex Pharma S.A. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
WO2010025890A1 (en) * | 2008-09-02 | 2010-03-11 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
US9790228B2 (en) | 2008-09-26 | 2017-10-17 | Intellikine Llc | Heterocyclic kinase inhibitors |
US9296742B2 (en) | 2008-09-26 | 2016-03-29 | Intellikine Llc | Heterocyclic kinase inhibitors |
US8697709B2 (en) | 2008-10-16 | 2014-04-15 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
US8697689B2 (en) | 2008-10-16 | 2014-04-15 | Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
US8691813B2 (en) | 2008-11-28 | 2014-04-08 | Janssen Pharmaceuticals, Inc. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
US8232296B2 (en) | 2009-02-20 | 2012-07-31 | Astrazeneca Ab | Salt 628 |
US8785454B2 (en) | 2009-05-07 | 2014-07-22 | Intellikine Llc | Heterocyclic compounds and uses thereof |
US9315505B2 (en) | 2009-05-07 | 2016-04-19 | Intellikine Llc | Heterocyclic compounds and uses thereof |
US9737533B2 (en) | 2009-05-12 | 2017-08-22 | Janssen Pharmaceuticals. Inc. | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders |
WO2010130422A1 (en) * | 2009-05-12 | 2010-11-18 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
US8946205B2 (en) | 2009-05-12 | 2015-02-03 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
US8937060B2 (en) | 2009-05-12 | 2015-01-20 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders |
US8716480B2 (en) | 2009-05-12 | 2014-05-06 | Janssen Pharmaceuticals, Inc. | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
US9085577B2 (en) | 2009-05-12 | 2015-07-21 | Janssen Pharmaceuticals, Inc. | 7-aryl-1,2,4-triazolo[4,3-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
CN102439015A (en) * | 2009-05-12 | 2012-05-02 | 杨森制药有限公司 | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
US10071095B2 (en) | 2009-05-12 | 2018-09-11 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders |
US9226930B2 (en) | 2009-05-12 | 2016-01-05 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders |
CN102439015B (en) * | 2009-05-12 | 2015-05-13 | 杨森制药有限公司 | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
US8569323B2 (en) | 2009-07-15 | 2013-10-29 | Intellikine, Llc | Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof |
US9206182B2 (en) | 2009-07-15 | 2015-12-08 | Intellikine Llc | Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof |
US9522146B2 (en) | 2009-07-15 | 2016-12-20 | Intellikine Llc | Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof |
US8907089B2 (en) | 2009-08-26 | 2014-12-09 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring derivative and use thereof |
WO2011024871A1 (en) | 2009-08-26 | 2011-03-03 | 武田薬品工業株式会社 | Fused heterocyclic ring derivative and use thereof |
WO2011024872A1 (en) | 2009-08-26 | 2011-03-03 | 武田薬品工業株式会社 | Fused heterocyclic ring derivative and use thereof |
US8486965B2 (en) | 2009-08-26 | 2013-07-16 | Takeda Pharmaceutical Company Limited | Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer |
WO2011024873A1 (en) | 2009-08-26 | 2011-03-03 | 武田薬品工業株式会社 | Fused heterocyclic ring derivative and use thereof |
US8614208B2 (en) | 2009-08-26 | 2013-12-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring derivative and use thereof |
US8927718B2 (en) | 2009-08-26 | 2015-01-06 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring derivative and use thereof |
WO2011024869A1 (en) | 2009-08-26 | 2011-03-03 | 武田薬品工業株式会社 | Fused heterocyclic ring derivative and use thereof |
US8980899B2 (en) | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
WO2011114103A1 (en) * | 2010-03-18 | 2011-09-22 | Biolipox Ab | Pyrimidinones for use as medicaments |
US8664214B2 (en) | 2010-03-30 | 2014-03-04 | AbbVie Deutschland GmbH & Co. KG | Small molecule potentiators of metabotropic glutamate receptors I |
US8314120B2 (en) | 2010-03-30 | 2012-11-20 | Abbott Gmbh & Co. Kg | Small molecule potentiators of metabotropic glutamate receptors |
US9181221B2 (en) | 2010-05-21 | 2015-11-10 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
US9738644B2 (en) | 2010-05-21 | 2017-08-22 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
US8604032B2 (en) | 2010-05-21 | 2013-12-10 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
EP2603079A4 (en) * | 2010-08-12 | 2014-01-22 | Merck Sharp & Dohme | Positive allosteric modulators of mglur2 |
US8993779B2 (en) | 2010-08-12 | 2015-03-31 | Merck Sharp & Dohme Corp. | Positive allosteric modulators of MGLUR2 |
EP2603079A1 (en) * | 2010-08-12 | 2013-06-19 | Merck Sharp & Dohme Corp. | Positive allosteric modulators of mglur2 |
US9012448B2 (en) | 2010-11-08 | 2015-04-21 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
US8993591B2 (en) | 2010-11-08 | 2015-03-31 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
US9271967B2 (en) | 2010-11-08 | 2016-03-01 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
US9388183B2 (en) | 2010-11-10 | 2016-07-12 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8901133B2 (en) | 2010-11-10 | 2014-12-02 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8809349B2 (en) | 2011-01-10 | 2014-08-19 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
US9290497B2 (en) | 2011-01-10 | 2016-03-22 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
US9840505B2 (en) | 2011-01-10 | 2017-12-12 | Infinity Pharmaceuticals, Inc. | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof |
USRE46621E1 (en) | 2011-01-10 | 2017-12-05 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
US11312718B2 (en) | 2011-01-10 | 2022-04-26 | Infinity Pharmaceuticals, Inc. | Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one |
US10550122B2 (en) | 2011-01-10 | 2020-02-04 | Infinity Pharmaceuticals, Inc. | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one and methods of use thereof |
US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
US9133187B2 (en) | 2011-02-28 | 2015-09-15 | Array Biopharma Inc. | Serine/threonine kinase inhibitors |
US9056877B2 (en) | 2011-07-19 | 2015-06-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9605003B2 (en) | 2011-07-19 | 2017-03-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9718815B2 (en) | 2011-07-19 | 2017-08-01 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8969363B2 (en) | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9187462B2 (en) | 2011-08-04 | 2015-11-17 | Array Biopharma Inc. | Substituted quinazolines as serine/threonine kinase inhibitors |
US9115141B2 (en) | 2011-08-29 | 2015-08-25 | Infinity Pharmaceuticals, Inc. | Substituted isoquinolinones and methods of treatment thereof |
US9546180B2 (en) | 2011-08-29 | 2017-01-17 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8785470B2 (en) | 2011-08-29 | 2014-07-22 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9895373B2 (en) | 2011-09-02 | 2018-02-20 | The Regents Of The University Of California | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof |
US9321772B2 (en) | 2011-09-02 | 2016-04-26 | The Regents Of The University Of California | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof |
US9399626B2 (en) | 2011-11-11 | 2016-07-26 | Pfizer Inc. | 2-thiopyrimidinones |
US8841314B2 (en) | 2011-11-11 | 2014-09-23 | Pfizer Inc. | 2-Thiopyrimidinones |
US8835449B2 (en) | 2011-11-11 | 2014-09-16 | Pfizer Inc. | 2-thiopyrimidinones |
US9873673B2 (en) | 2011-11-11 | 2018-01-23 | Pfizer Inc. | 2-thiopyrimidinones |
US10717738B2 (en) * | 2011-12-21 | 2020-07-21 | Ono Pharmaceutical Co., Ltd. | Pyrimidinone and its derivatives inhibiting factor XIa |
US20170305917A1 (en) * | 2011-12-21 | 2017-10-26 | Ono Pharmaceutical Co., Ltd. | Compounds |
US10519126B2 (en) | 2012-03-01 | 2019-12-31 | Array Biopharma Inc. | Serine/threonine kinase inhibitors |
US8697715B2 (en) * | 2012-03-01 | 2014-04-15 | Array Biopharma, Inc. | Serine/threonine kinase inhibitors |
US20130252934A1 (en) * | 2012-03-01 | 2013-09-26 | Genentech, Inc. | Serine/threonine kinase inhibitors |
US9708290B2 (en) | 2012-03-01 | 2017-07-18 | Array Biopharma Inc. | Serine/threonine kinase inhibitors |
US9259470B2 (en) | 2012-03-01 | 2016-02-16 | Array Biopharma Inc. | Serine/threonine kinase inhibitors |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9255108B2 (en) | 2012-04-10 | 2016-02-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9527847B2 (en) | 2012-06-25 | 2016-12-27 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
US9388171B2 (en) | 2012-08-27 | 2016-07-12 | Genetech, Inc. | Serine/threonine kinase inhibitors |
US10131668B2 (en) | 2012-09-26 | 2018-11-20 | The Regents Of The University Of California | Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1 |
US10822340B2 (en) | 2012-09-26 | 2020-11-03 | The Regents Of The University Of California | Substituted imidazolopyrazine compounds and methods of using same |
US11613544B2 (en) | 2012-09-26 | 2023-03-28 | The Regents Of The University Of California | Substituted imidazo[1,5-a]pyrazines for modulation of IRE1 |
US9675593B2 (en) | 2012-10-02 | 2017-06-13 | Intermune, Inc. | Anti-fibrotic pyridinones |
US9359379B2 (en) | 2012-10-02 | 2016-06-07 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10898474B2 (en) | 2012-10-02 | 2021-01-26 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10376497B2 (en) | 2012-10-02 | 2019-08-13 | Intermune, Inc. | Anti-fibrotic pyridinones |
WO2014088085A1 (en) | 2012-12-06 | 2014-06-12 | 協和発酵キリン株式会社 | Pyridone compound |
US9643952B2 (en) | 2012-12-06 | 2017-05-09 | Kyowa Hakko Kirin Co., Ltd. | Pyridone compound |
WO2014096965A3 (en) * | 2012-12-21 | 2015-02-26 | Rvx Therapeutics Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
AU2013365926B2 (en) * | 2012-12-21 | 2018-08-16 | Zenith Epigenetics Ltd. | Novel heterocyclic compounds as bromodomain inhibitors |
AU2013365926B9 (en) * | 2012-12-21 | 2019-01-17 | Zenith Epigenetics Ltd. | Novel heterocyclic compounds as bromodomain inhibitors |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
WO2014154794A1 (en) | 2013-03-28 | 2014-10-02 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders |
US10183932B2 (en) | 2013-03-28 | 2019-01-22 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives and use thereof cardiovascular disorders |
TWI633089B (en) * | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | Substituted oxopyridine derivatives |
EA028034B1 (en) * | 2013-03-28 | 2017-09-29 | Байер Фарма Акциенгезельшафт | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders |
US9434690B2 (en) | 2013-03-28 | 2016-09-06 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders |
US9822102B2 (en) | 2013-03-28 | 2017-11-21 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders |
US10584129B2 (en) | 2013-06-04 | 2020-03-10 | Janssen Pharmaceuticals Nv | Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors |
US10106542B2 (en) | 2013-06-04 | 2018-10-23 | Janssen Pharmaceutica Nv | Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors |
US10166215B2 (en) | 2013-06-21 | 2019-01-01 | Zenith Epigenetics Ltd. | Substituted bicyclic compounds as bromodomain inhibitors |
US10363257B2 (en) | 2013-06-21 | 2019-07-30 | Zenith Epigenetics Ltd. | Bicyclic bromodomain inhibitors |
US11026926B2 (en) | 2013-06-21 | 2021-06-08 | Zenith Epigenetics Ltd. | Substituted bicyclic compounds as bromodomain inhibitors |
US10010556B2 (en) | 2013-06-21 | 2018-07-03 | Zenith Epigenetics Ltd. | Bicyclic bromodomain inhibitors |
US10226451B2 (en) | 2013-06-21 | 2019-03-12 | Zenith Epigenetics Ltd. | Substituted bicyclic compounds as bromodomain inhibitors |
US9918969B2 (en) | 2013-07-23 | 2018-03-20 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives and use thereof as factor XIa/plasma |
US9475809B2 (en) | 2013-07-23 | 2016-10-25 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives and use thereof as factor xia/plasma |
US9855271B2 (en) | 2013-07-31 | 2018-01-02 | Zenith Epigenetics Ltd. | Quinazolinones as bromodomain inhibitors |
US10500209B2 (en) | 2013-07-31 | 2019-12-10 | Zenith Epigenetics Ltd. | Quinazolinones as bromodomain inhibitors |
US9708315B2 (en) | 2013-09-06 | 2017-07-18 | Janssen Pharmaceutica Nv | 1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of MGLUR2 receptors |
US10329299B2 (en) | 2013-10-04 | 2019-06-25 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9359365B2 (en) | 2013-10-04 | 2016-06-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9828377B2 (en) | 2013-10-04 | 2017-11-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9115114B2 (en) | 2013-10-18 | 2015-08-25 | Quanticel Pharmaceuticals, Inc. | Bromodomain inhibitors |
TWI771630B (en) * | 2013-10-18 | 2022-07-21 | 美商賽基昆堤塞爾研發公司 | Bromodomain inhibitors |
US10941160B2 (en) | 2013-10-18 | 2021-03-09 | Celgene Quanticel Research, Inc. | Bromodomain inhibitors |
US9598372B2 (en) | 2013-10-18 | 2017-03-21 | Celgene Quanticel Research, Inc. | Bromodomain inhibitors |
EP3640241A1 (en) | 2013-10-18 | 2020-04-22 | Celgene Quanticel Research, Inc. | Bromodomain inhibitors |
CN108558889A (en) * | 2013-10-18 | 2018-09-21 | 赛尔基因昆蒂赛尔研究公司 | Bu Luomo structural domain inhibitor |
US10562915B2 (en) | 2013-10-18 | 2020-02-18 | Celgene Quanticel Research, Inc. | Bromodomain inhibitors |
EP4134364A2 (en) | 2013-10-18 | 2023-02-15 | Celgene Quanticel Research, Inc. | Bromodomain inhibitors |
US11884680B2 (en) | 2013-10-18 | 2024-01-30 | Celgene Quanticel Research, Inc. | Bromodomain inhibitors |
US9034900B2 (en) | 2013-10-18 | 2015-05-19 | Quanticel Pharmaceuticals, Inc. | Bromodomain inhibitors |
TWI676619B (en) * | 2013-10-18 | 2019-11-11 | 賽基昆堤塞爾研發公司 | Bromodomain inhibitors |
EP3290407A1 (en) | 2013-10-18 | 2018-03-07 | Celgene Quanticel Research, Inc | Bromodomain inhibitors |
US10023592B2 (en) | 2013-10-18 | 2018-07-17 | Celgene Quanticel Research, Inc. | Bromodomain inhibitors |
WO2015063093A1 (en) | 2013-10-30 | 2015-05-07 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
US9765070B2 (en) | 2013-10-30 | 2017-09-19 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
US10537573B2 (en) | 2014-01-21 | 2020-01-21 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
US11103506B2 (en) | 2014-01-21 | 2021-08-31 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
US11369606B2 (en) | 2014-01-21 | 2022-06-28 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
US11541059B2 (en) | 2014-03-19 | 2023-01-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US10675286B2 (en) | 2014-03-19 | 2020-06-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9775844B2 (en) | 2014-03-19 | 2017-10-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US10233195B2 (en) | 2014-04-02 | 2019-03-19 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10544161B2 (en) | 2014-04-02 | 2020-01-28 | Intermune, Inc. | Anti-fibrotic pyridinones |
US11110096B2 (en) | 2014-04-16 | 2021-09-07 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US11944631B2 (en) | 2014-04-16 | 2024-04-02 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US10167280B2 (en) | 2014-09-24 | 2019-01-01 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
US10071995B2 (en) | 2014-09-24 | 2018-09-11 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
US10077265B2 (en) | 2014-09-24 | 2018-09-18 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
WO2016046157A1 (en) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives |
US10138236B2 (en) | 2014-09-24 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives |
US10414731B2 (en) | 2014-09-24 | 2019-09-17 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
WO2016046164A1 (en) * | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
US10941162B2 (en) | 2014-10-03 | 2021-03-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
US10253047B2 (en) | 2014-10-03 | 2019-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US10710992B2 (en) | 2014-12-01 | 2020-07-14 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
US10179125B2 (en) | 2014-12-01 | 2019-01-15 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
US10815233B2 (en) | 2014-12-10 | 2020-10-27 | Ono Pharmaceutical Co., Ltd. | Dihydroindolizinone derivative |
US10550119B2 (en) | 2014-12-10 | 2020-02-04 | Ono Pharmaceutical Co., Ltd. | Dihydroindolizinone derivative |
US11566027B2 (en) | 2014-12-10 | 2023-01-31 | Ono Pharmaceutical Co., Ltd. | Dihydroindolizinone derivative |
US10407426B2 (en) | 2014-12-10 | 2019-09-10 | Ono Pharmaceutical Co., Ltd. | Dihydroindolizinone derivative |
US10292968B2 (en) | 2014-12-11 | 2019-05-21 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
US10231953B2 (en) | 2014-12-17 | 2019-03-19 | Zenith Epigenetics Ltd. | Inhibitors of bromodomains |
EP3831383A1 (en) | 2015-04-15 | 2021-06-09 | Celgene Quanticel Research, Inc. | Bromodomain inhibitors |
US9771332B2 (en) | 2015-05-05 | 2017-09-26 | Pfizer Inc. | 2-thiopyrimidinones |
US11905299B2 (en) | 2015-07-06 | 2024-02-20 | Gilead Sciences, Inc. | Cot modulators and methods of use thereof |
US10421742B2 (en) | 2015-07-09 | 2019-09-24 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
WO2017005725A1 (en) | 2015-07-09 | 2017-01-12 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
US11180471B2 (en) | 2015-07-09 | 2021-11-23 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
WO2017037051A1 (en) | 2015-09-04 | 2017-03-09 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
US11247995B2 (en) | 2015-09-14 | 2022-02-15 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
US10160761B2 (en) | 2015-09-14 | 2018-12-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
US11939333B2 (en) | 2015-09-14 | 2024-03-26 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
WO2017184462A1 (en) | 2016-04-18 | 2017-10-26 | Celgene Quanticel Research, Inc. | Therapeutic compounds |
WO2017184491A1 (en) | 2016-04-19 | 2017-10-26 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
EP4011876A1 (en) | 2016-04-19 | 2022-06-15 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US11147818B2 (en) | 2016-06-24 | 2021-10-19 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US11884660B2 (en) | 2018-04-10 | 2024-01-30 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivative |
WO2019197244A1 (en) | 2018-04-10 | 2019-10-17 | Bayer Pharma Aktiengesellschaft | A substituted oxopyridine derivative |
WO2020127508A1 (en) | 2018-12-21 | 2020-06-25 | Bayer Aktiengesellschaft | Substituted oxopyridine derivatives |
WO2020127504A1 (en) | 2018-12-21 | 2020-06-25 | Bayer Aktiengesellschaft | Substituted oxopyridine derivatives |
US11827662B2 (en) | 2019-06-14 | 2023-11-28 | Gilead Sciences, Inc. | Cot modulators and methods of use thereof |
US11655237B2 (en) | 2020-03-30 | 2023-05-23 | Gilead Sciences, Inc. | Solid forms of a Cot inhibitor compound |
US11845737B2 (en) | 2020-04-02 | 2023-12-19 | Gilead Sciences, Inc. | Process for preparing a Cot inhibitor compound |
EP4299124A1 (en) | 2022-06-30 | 2024-01-03 | Universite De Montpellier | Anti-mglur2 nanobodies for use as biomolecule transporter |
WO2024003390A1 (en) | 2022-06-30 | 2024-01-04 | Universite De Montpellier | Anti-mglur2 nanobodies for use as biomolecule transporter |
Also Published As
Publication number | Publication date |
---|---|
MX2007003006A (en) | 2007-07-24 |
CA2581144C (en) | 2014-04-01 |
US20070213323A1 (en) | 2007-09-13 |
SG155938A1 (en) | 2009-10-29 |
UA98098C2 (en) | 2012-04-25 |
EA200700617A1 (en) | 2007-10-26 |
ES2527418T3 (en) | 2015-01-23 |
NZ554041A (en) | 2010-01-29 |
TW200633982A (en) | 2006-10-01 |
US8399493B2 (en) | 2013-03-19 |
KR20070085262A (en) | 2007-08-27 |
BRPI0515412A (en) | 2008-07-22 |
CN101061098B (en) | 2012-05-23 |
US20130109652A1 (en) | 2013-05-02 |
EP1799646A1 (en) | 2007-06-27 |
CN101061098A (en) | 2007-10-24 |
AU2005284098B2 (en) | 2011-06-16 |
JP5179873B2 (en) | 2013-04-10 |
EP1799646B1 (en) | 2014-12-10 |
JP2013047254A (en) | 2013-03-07 |
JP5723850B2 (en) | 2015-05-27 |
CA2581144A1 (en) | 2006-03-23 |
ZA200703088B (en) | 2008-08-27 |
AU2005284098A1 (en) | 2006-03-23 |
NO20071660L (en) | 2007-06-15 |
EA013740B1 (en) | 2010-06-30 |
JP2008513414A (en) | 2008-05-01 |
GB0420722D0 (en) | 2004-10-20 |
IL181742A0 (en) | 2007-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1799646A1 (en) | Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors | |
TWI404715B (en) | Biaryl ether urea compounds | |
US5916905A (en) | 2,3-substituted pyridines for the treatment of inflammation | |
CN103201261A (en) | Lactam derivatives useful as orexin receptor antagonists | |
TW200918536A (en) | Tetracyclic indole derivatives and methods of use thereof | |
CN103608332A (en) | Pyridin-2-amides useful as CB2 agonists | |
CN101842353A (en) | 2, 3-substituted indole derivatives for treating viral infections | |
JP7228586B2 (en) | Aminoimidazopyridazines as kinase inhibitors | |
TW200815402A (en) | 1,2-dihydropyridine compounds, process preparation of the same and use thereof | |
CN101356159A (en) | Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2H)-isoquinolones and methods of use thereof | |
CN103080104A (en) | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides as inhibitors of plasma kallikrein | |
WO2006015159A2 (en) | Potassium channel inhibitors | |
KR20090117902A (en) | Pyridine and pyrimidine derivatives as mglur2 antagonists | |
JP2009542804A (en) | Isoindoline derivatives for the treatment of arrhythmias | |
TWI833819B (en) | Compounds and compositions for treating conditions associated with apj receptor activity | |
TW201000458A (en) | Isoquinolinone derivatives as NK3 antagonists | |
CN101443334A (en) | Anti-viral compounds | |
KR20040107367A (en) | Hepatitis C virus inhibitors | |
KR101128372B1 (en) | 1H-pyridin-2-one derivatives | |
CN111303146A (en) | 3-cyanopyridine compound, pharmaceutical composition containing same, preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 181742 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/003006 Country of ref document: MX Ref document number: 2581144 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11575433 Country of ref document: US Ref document number: 2007213323 Country of ref document: US Ref document number: 12007500606 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2118/DELNP/2007 Country of ref document: IN Ref document number: 2007531759 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 554041 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005284098 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005787278 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: A200703393 Country of ref document: UA Ref document number: 1020077008762 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200700617 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 2005284098 Country of ref document: AU Date of ref document: 20050916 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005284098 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580036750.3 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005787278 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11575433 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0515412 Country of ref document: BR |